

CITATION REPORT

List of articles citing

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

DOI: 10.1093/eurheartj/ehp297

European Heart Journal, 2009, 30, 2493-537.

Source: <https://exaly.com/paper-pdf/46790646/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2325	Is ischemia implicated in chronic multifocal demyelinating neuropathy?. 1989 , 39, 106-10		27
2324	Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. 1992 , 42, 60-3		223
2323	Genome phylogenetic analysis based on extended gene contents. 2004 , 21, 1401-8		45
2322	Expression of the Stp1 LMW-PTP and inhibition of protein CK2 display a cooperative effect on immunophilin Fpr3 tyrosine phosphorylation and <i>Saccharomyces cerevisiae</i> growth. 2004 , 61, 1176-84		10
2321	Molecular characterization of Arabidopsis PHO80-like proteins, a novel class of CDKA;1-interacting cyclins. 2004 , 61, 1485-97		37
2320	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. 2009 , 18, 272-90		17
2319	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. 2009 , 62, 1467.e1-1467.e56		
2318	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. 2009 , 62, 1467.e1-1467.e56		4
2317	Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. 2010 , 16 Suppl 1, S35-41		19
2316	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. 2010 , 137, 1297-303		38
2315	Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. 2010 , 11, 719-24		22
2314	Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?. 2010 , 11, 893-905		3
2313	Endpoints in pulmonary arterial hypertension: the role of clinical worsening. 2010 , 16 Suppl 1, S1-9		19
2312	Anesthesia for patients with pulmonary hypertension. 2010 , 23, 411-6		72
2311	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. 2010 , 16 Suppl 1, S11-9		30
2310	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. 2010 , 16 Suppl 1, S27-34		16
2309	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. 2010 , 16 Suppl 1, S43-6		9

2308	Intraoperative management of pulmonary hypertension and associated right heart failure. 2010 , 23, 49-56	26
2307	The Right Heart Catheterization for the Pulmonologist. 2010 , 17, 239-243	
2306	Prosthetic valve endocarditis. 2010 , 11, 869-83	37
2305	Right ventricular adaptation to pressure overload. 2010 , 16, 237-43	17
2304	The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options. 2010 , 6, 343-55	44
2303	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. 2010 , 16 Suppl 1, S21-6	3
2302	Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis. 2010 , 49, 2309-12	8
2301	Identification of new prognostic factors of pulmonary hypertension. 2010 , 74, 1965-71	37
2300	Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. 2010 , 122, 106-8	41
2299	[Pulmonary affection in advanced liver disease - hepatepulmonary syndrome and portopulmonary hypertension]. 2010 , 105, 916-23	
2298	[Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax]. 2010 , 51 Suppl 1, 255-63	4
2297	[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society]. 2010 , 81, 444-62	12
2296	Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. 2010 , 31, 598-606	40
2295	Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG). 2010 , 99, 609-25	12
2294	CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. 2010 , 188, 191-7	21
2293	Pulmonale Hypertonie. 2010 , 7, 165-173	
2292	Diagnostik und Therapie der pulmonalen Hypertonie. 2010 , 4, 189-207	3
2291	Editorial. 2010 , 5, 1-2	

2290	Current pulmonary hypertension guidelines and remaining controversies. 2010 , 5, 3-8	2
2289	Diagnostic tools in pulmonary arterial hypertension management. 2010 , 5, 9-11	
2288	Chronic thromboembolic pulmonary hypertension (CTEPH): specific disease characteristics and similarities to idiopathic pulmonary arterial hypertension. 2010 , 5, 12-15	
2287	Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. 2010 , 12, 212-9	36
2286	A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. 2010 , 26, 509-18	50
2285	Medical therapy for pediatric pulmonary arterial hypertension. 2010 , 157, 528-32	32
2284	High-altitude exposure in patients with cardiovascular disease: risk assessment and practical recommendations. 2010 , 52, 512-24	53
2283	Management of pulmonary arterial hypertension in children. 2010 , 11, 240-5	7
2282	Pulmonary artery hypertension as an initial manifestation of Takayasu's arteritis: A case report. 2010 , 3, 211-213	1
2281	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. 2010 , 11, 73	66
2280	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. 2010 , 16, 348-56	58
2279	NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. 2010 , 43, 745-9	6
2278	Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. 2010 , 8, 21	36
2277	Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis. 2010 , 8, 25	15
2276	The value of hepatic diffusion-weighted MR imaging in demonstrating hepatic congestion secondary to pulmonary hypertension. 2010 , 8, 28	10
2275	Heart rate turbulence impairment and ventricular arrhythmias in patients with systemic sclerosis. 2010 , 33, 920-8	9
2274	Pulmonary arterial hypertension in adults with congenital heart disease. 2010 , 64, 13-24	8
2273	Highlights from the new pulmonary hypertension classification and guidelines 2009. 2010 , 64, 1-3	

2272	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. 2010 , 15, 1226-32	29
2271	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. 2010 , 6, 273-80	21
2270	Pharmacokinetic evaluation of continuous intravenous epoprostenol. 2010 , 6, 1587-98	14
2269	The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. 2010 , 36, 1294-301	32
2268	Changing demographics of pulmonary arterial hypertension in congenital heart disease. 2010 , 19, 308-13	23
2267	Pulmonary hypertension in patients with chronic myeloproliferative disorders. 2010 , 35, 1396-406	38
2266	Treatment options for paediatric pulmonary arterial hypertension. 2010 , 19, 321-30	10
2265	Management of severe pulmonary arterial hypertension. 2010 , 19, 279-87	13
2264	Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 2010 , 37, 2071-5	40
2263	Noninvasive assessment of pulmonary artery pressures: moving beyond tricuspid regurgitation velocities. 2010 , 3, 132-3	9
2262	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. 2010 , 35, 1286-93	181
2261	Pulmonary hypertension for clinicians: time to call on genetics?. 2010 , 79, 274-5	
2260	Diagnostic testing to guide the management of chronic thromboembolic pulmonary hypertension: state of the art. 2010 , 19, 55-8	11
2259	Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. 2010 , 49, 2147-53	11
2258	Heart Failure in Clinical Practice. 2010 ,	4
2257	Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?. 2010 , 19, 68-71	13
2256	Elevated pulmonary artery systolic pressure in patients with coronary artery disease and left ventricular dyssynchrony. 2010 , 12, 1067-75	5
2255	Idiopathic pulmonary arterial hypertension. 2010 , 3, 268-73	52

2254	Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. 2010 , 96, 1475-9	25
2253	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. 2010 , 19, 59-63	98
2252	Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. 2010 , 55, 1406-11	11
2251	Issues related to the management and therapy of paediatric pulmonary hypertension. 2010 , 19, 331-9	10
2250	[Prostanoids in the treatment of pulmonary arterial hypertension]. 2010 , 10 Suppl 2, 2-8	
2249	[Pulmonary hypertension related to pulmonary diseases or hypoxia and its treatment]. 2010 , 10 Suppl 2, 47-55	
2248	[Clinical end-points and surrogate markers of pulmonary arterial hypertension in the light of evidence-based treatment]. 2010 , 10 Suppl 1, 36-42	1
2247	[Diagnostic algorithms in pulmonary hypertension]. 2010 , 10 Suppl 1, 14-26	1
2246	Left ventricular underfilling and not septal bulging dominates abnormal left ventricular filling hemodynamics in chronic thromboembolic pulmonary hypertension. 2010 , 299, H1083-91	30
2245	High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. 2010 , 119, 207-13	80
2244	[Pulmonary hypertension caused by left heart disease]. 2010 , 10 Suppl 2, 42-6	1
2243	[Endothelin receptor antagonists in pulmonary arterial hypertension]. 2010 , 10 Suppl 2, 9-15	1
2242	Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. 2010 , 36, 986-90	24
2241	Emergency treatments in pulmonary arterial hypertension: a place for algorithms and for education programmes. 2010 , 19, 171-2	
2240	Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. 2010 , 19, 272-8	32
2239	Perioperative care in patients with pulmonary hypertension after cardiac surgery: clinical management, outcome and future clinical research. Results from an expert meeting. 2010 , 116, 1-2	4
2238	Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. <i>European Heart Journal</i> , 2010 , 31, 2080-6	9.5 129
2237	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2010 , 31, 1898-907	9.5 139

2236	Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. 2010 , 137, 85S-94S	19
2235	Progressive dilatation of the main pulmonary artery is a characteristic of pulmonary arterial hypertension and is not related to changes in pressure. 2010 , 138, 1395-401	84
2234	Should patients with connective tissue disease undergo exercise Doppler echocardiography?. 2010 , 138, 1523-4; author reply 1524	2
2233	New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. 2010 , 11, 516-22	62
2232	[Diagnosis and treatment of pulmonary hypertension: European guidelines 2009]. 2010 , 64, 401-14	15
2231	[Pulmonary hypertension - historical development, current therapy and perspectives]. 2010 , 64, 577-82	3
2230	[Pulmonary hypertension: hemodynamic evaluation: hemodynamic evaluation [recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S78-86	6
2229	[Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S115-24	8
2228	Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. 2010 , 135, e2-e15	0
2227	[Diseases of the lung and air passages 2010]. 2010 , 135, 1278-80	
2226	[Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S87-101	9
2225	Phosphodiesterase inhibitors for pulmonary hypertension. 2010 , 362, 559; author reply 560	9
2224	Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time!. 2010 , 181, 202-3	10
2223	[Pulmonary hypertension due to left heart disease: recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S102-14	1
2222	[Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S125-30	3
2221	[Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S67-77	7
2220	Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. 2010 , 181, 270-8	210
2219	Th2 inflammation, hypoxia-induced mitogenic factor/FIZZ1, and pulmonary hypertension and vascular remodeling in schistosomiasis. 2010 , 181, 203-5	12

2218	[Guidelines for the diagnosis and treatment of pulmonary hypertension]. 2010 , 27, 141-50	5
2217	[New international guidelines on pulmonary hypertension]. 2010 , 27, 110-1	1
2216	Timing and magnitude of regional right ventricular function: a speckle tracking-derived strain study of normal subjects and patients with right ventricular dysfunction. 2010 , 23, 823-31	161
2215	[Pulmonary hypertension of the elderly: not so infrequent]. 2010 , 27, 8-9	
2214	Accuracy of Doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. 2010 , 5, e15670	16
2213	Imaging in pulmonary hypertension. 2010 , 3, 1287-95	56
2212	Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. 2010 , 11, 182	33
2211	Tadalafil: in pulmonary arterial hypertension. 2010 , 70, 479-88	12
2210	Hypertension artfielle pulmonaire de l'enfant. 2010 , 2, 126-131	
2209	Classification de l'hypertension pulmonaire. 2010 , 2, 132-136	
2208	Nouvelle formulation p'diatrique du bosentan chez l'enfant avec hypertension artfielle pulmonaire : l'ude pharmacocintique FUTURE-1. 2010 , 2, 146-152	
2207	Traitement de l'hypertension artfielle pulmonaire de l'enfant. 2010 , 2, 153-157	
2206	The right heart and pulmonary circulation: is it really a minor circulation?. 2010 , 63, 77-80	2
2205	The right heart and pulmonary circulation (III). The pulmonary circulation in heart failure. 2010 , 63, 334-45	8
2204	Current diagnostic and prognostic assessment of pulmonary Hypertension. 2010 , 63, 583-96	3
2203	Current therapeutic approaches to pulmonary arterial hypertension. 2010 , 63, 708-24	2
2202	Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. 2010 , 63, 832-49	3
2201	Pulmonary hypertension in congenital shunts. 2010 , 63, 1179-93	5

2200	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. 2010 , 181, 851-61	209
2199	Treating pulmonary arterial hypertension: is it worth it?. 2010 , 96, 1607-8	2
2198	[Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. 2010 , 39, 134-43	8
2197	Corazñ derecho y circulaciñ pulmonar: ¿una circulaciñ menor?. 2010 , 63, 77-80	12
2196	La circulaciñ pulmonar en la insuficiencia cardiaca. 2010 , 63, 334-345	20
2195	Evaluaciñ diagnñstica y pronñstica actual de la hipertensiñ pulmonar. 2010 , 63, 583-596	13
2194	Estrategias terapñuticas actuales en la hipertensiñ arterial pulmonar. 2010 , 63, 708-724	15
2193	Enfermedad tromboembñlica pulmonar. Manejo clñico de la enfermedad aguda y crñica. 2010 , 63, 832-849	12
2192	Hipertensiñ pulmonar en los cortocircuitos congñitos. 2010 , 63, 1179-1193	20
2191	Dñister et diagnostiquer plus prñocement les hypertensions artñielles pulmonaires des connectivites : quel impact attendu sur lñvolution de la maladie ?. 2010 , 31, 3-5	
2190	Nouvelles recommandations europñennes en matiñe de traitement spñcifique prñcoce et de combinaisons thñrapeutiques : quelles implications pour la pratique ?. 2010 , 31, 8-11	1
2189	Hipertensiñ pulmonar. 2010 , 10, 4505-4512	
2188	Protocolo diagnñstico de la hipertensiñ pulmonar. 2010 , 10, 4551-4554	
2187	Protocolo terapñutico de la hipertensiñ pulmonar. 2010 , 10, 4555-4557	
2186	[Diagnosis and classification of pulmonary hypertension]. 2010 , 39 Suppl 1, 1S3-15	1
2185	[Screening and diagnosis of pulmonary arterial hypertension. Comments regarding the latest guidelines from the European Societies of Cardiology and of Pulmonology]. 2010 , 39 Suppl 1, 1S16-21	0
2184	[Treatment of pulmonary arterial hypertension]. 2010 , 39 Suppl 1, 1S22-32	4
2183	[Treatment goals in pulmonary arterial hypertension]. 2010 , 39 Suppl 1, 1S33-40	0

2182	Outcomes in pulmonary hypertension: Beyond 40 metres. 2010 , 26, 12B-16B		1
2181	Relation of myocardial T2* to right ventricular function in thalassaemia major. <i>European Heart Journal</i> , 2010 , 31, 1648-54	9.5	31
2180	Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. 2010 , 14, 1283-9		11
2179	Bosentan: in pediatric patients with pulmonary arterial hypertension. 2010 , 12, 63-73		11
2178	Riociguat for pulmonary hypertension. 2010 , 6, 155-66		24
2177	Animal models related to congenital heart disease and clinical research in pulmonary hypertension. 2010 , 116, 18-25		2
2176	Management of adult patients with perioperative pulmonary hypertension: technical aspects and therapeutic options. 2010 , 116, 3-9		21
2175	Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. 2010 , 12, 1339-44		36
2174	The authors' reply. 2010 , 8, 71-73		
2173	Pulmonary veno-occlusive disease: advances in clinical management and treatments. 2011 , 5, 217-29; quiz 230-1		33
2172	Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. 2011 , 27, 1827-34		11
2171	Ambrisentan: a guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III. 2011 , 27, 1-8		
2170	Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. 2011 , 97, 112-7		62
2169	Acute and long-term efficacy and safety of sildenafil for the treatment of chronic thromboembolic pulmonary hypertension in a heart transplant recipient. 2011 , 87, 24-7		1
2168	Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. <i>European Heart Journal</i> , 2011 , 32, 751-9	9.5	123
2167	[Hemodynamic study: indications for right- and left-sided catheterization in the diagnosis and follow-up of pulmonary hypertension]. 2011 , 47 Suppl 7, 12-4		
2166	[Role of echocardiography in suspected pulmonary hypertension]. 2011 , 47 Suppl 7, 7-11		4
2165	[Diagnostic and prognostic evaluation in patients with pulmonary hypertension]. 2011 , 47 Suppl 7, 2-6		

2164	Different patterns of adaptation of the right ventricle to pressure overload: a comparison between pulmonary hypertension and pulmonary stenosis. 2011 , 24, 1109-17	36
2163	Hypertension artfielle pulmonaire associè aux connectivites : particularitè cliniques et pronostiques. 2011 , 3, S49-S55	
2162	[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. 2011 , 47 Suppl 7, 26-31	
2161	Factors Affecting the Response to Exercise in Patients with Severe Pulmonary Arterial Hypertension. 2011 , 47, 10-16	1
2160	The year in heart failure. 2011 , 57, 1573-83	4
2159	Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. 2011 , 58, 300-9	166
2158	Right ventricular myocardial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. 2011 , 24, 886-97	65
2157	Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. <i>European Heart Journal</i> , 2011 , 32, 3137-46	9.5 74
2156	Phosphodiesterases as Drug Targets. 2011 ,	20
2155	Molecular Basis of Pulmonary Hypertension in Left Heart Failure. 2011 , 259-271	
2154	Riociguat for the treatment of pulmonary hypertension. 2011 , 20, 567-76	69
2153	Hypertension pulmonaire (HTP). 2011 , 3, 25-33	
2152	High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension. 2011 , 412, 1582-8	19
2151	Accuracy of Doppler echocardiography to estimate key hemodynamic variables in subjects with normal left ventricular ejection fraction. 2011 , 17, 405-12	26
2150	Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. 2011 , 17, 813-8	10
2149	Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. 2011 , 17, 1012-7	32
2148	Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease. 2011 , 22, 518-21	18
2147	Portopulmonary hypertension: from diagnosis to treatment. 2011 , 22, 441-7	13

2146	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. 2011 , 30, 632-43	79
2145	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. 2011 , 30, 1327-33	69
2144	Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. 2011 , 146, 105-6	38
2143	Lipid profile and plasma antioxidant status in sweet carbonated beverage-induced metabolic syndrome in rat. 2011 , 146, 106-9	17
2142	Acute hemodynamic effects of adaptive servo ventilation in patients with pulmonary hypertension. 2011 , 148, 125-7	1
2141	Transcardiac gradients of B-type natriuretic peptides are increased in human pulmonary arterial hypertension. 2011 , 151, 117-9	3
2140	Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. 2011 , 40, e65-78	21
2139	Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension. 2011 , 64, 667-73	12
2138	Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. 2011 , 105, 818-27	44
2137	Treatment of pulmonary hypertension: bench to bedside. 2011 , 105 Suppl 1, S7-11	1
2136	[Resting and exercise hemodynamics in pulmonary arterial hypertension]. 2011 , 40 Suppl 1, 1S28-38	0
2135	[Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls]. 2011 , 40 Suppl 1, 1S46-53	0
2134	[Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]. 2011 , 40 Suppl 1, 1S54-60	1
2133	ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011 , 32, 3147-97	9.5 1167
2132	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. 2011 , 279-305	6
2131	Inhaled iloprost for therapy in pulmonary arterial hypertension. 2011 , 5, 145-52	8
2130	Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. 2011 , 25, 687-704	49
2129	Long-Term (5 Years) Effects of Bosentan in Patients With Pulmonary Arterial Hypertension. 2011 , 64, 667-673	

2128	Cologne Consensus Conference on pulmonary hypertension. 2011 , 154 Suppl 1, S1-2	4
2127	Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S3-12	57
2126	Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S13-9	9
2125	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S20-33	38
2124	Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S34-44	21
2123	Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S45-53	48
2122	Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S54-60	79
2121	[Heart failure and heart transplant]. 2011 , 64 Suppl 1, 42-9	5
2120	Non-parenteral Therapy for Pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence. 2011 , 3, CMT.S2689	
2119	RESPIRATORY FUNCTION IN PATIENTS WITH RHEUMATIC HEART DISEASE COMPLICATED WITH PULMONARY HYPERTENSION. 2011 , 7, 26-30	
2118	Emerging pathogenetic mechanisms of pulmonary arterial hypertension: nitric oxide and more. 2011 , 41, 58-60	1
2117	Pulmonary thromboendarterectomy after treatment with treprostenil in a chronic thromboembolic pulmonary hypertension patient: a case report. 2011 , 4, 767-72	2
2116	Eisenmenger Syndrome. 2011 , 358-370	1
2115	Pulmonary Hypertension in the Critically Ill. 2011 ,	
2114	DIHYDROPYRIDINE CALCIUM ANTAGONISTS. POSITION OF NIFEDIPINE IN MODERN CARDIOLOGY PRACTICE. 2011 , 7, 356-364	
2113	PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. 2011 , 7, 199-203	
2112	Histopathological multiple recanalized lesion is critical element of outcome after pulmonary thromboendarterectomy. 2011 , 52, 377-81	13
2111	Noninvasive Positive Pressure Ventilation against Reperfusion Pulmonary Edema following Percutaneous Transluminal Pulmonary Angioplasty. 2011 , 2011, 204538	5

2110	Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of Canadian pulmonary hypertension physicians. 2011 , 18, 230-4	6
2109	Pulmonary hypertension related to left-sided cardiac pathology. 2011 , 2011, 381787	30
2108	Therapeutic strategies in pulmonary hypertension. 2011 , 2, 21	10
2107	The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. 2011 , 17, 392-7	18
2106	Pulmonary hypertension in critical care. 2011 , 17, 439-48	20
2105	Pulmonary hypertension: screening and evaluation in scleroderma. 2011 , 23, 536-44	14
2104	Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. 2011 , 12, 501-13	30
2103	Complication vasculaire pulmonaire des cardiopathies congénitales. 2011 , 8, 1-13	
2102	Pulmonary arterial hypertension: an early diagnosis makes a difference. 2011 , 24, 30-4	1
2101	Echocardiographic evaluation of systolic and mean pulmonary artery pressure in patients with pulmonary hypertension: reply. 2011 , 12, 968-969	
2100	The use of pocket size imaging devices: a position statement by the European Association of Echocardiography. <i>European Heart Journal</i> , 2011 , 32, 385-6	9.5 8
2099	Pulmonary hypertension in patients with neurofibromatosis type I. 2011 , 90, 201-211	42
2098	Right ventricular load at exercise is a cause of persistent exercise limitation in patients with normal resting pulmonary vascular resistance after pulmonary endarterectomy. 2011 , 139, 122-7	73
2097	Relationship between aortic valve stenosis, its replacement, and aortic function. 2011 , 12, 967-8; author reply 968	
2096	Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. 2011 , 75, 2668-74	55
2095	Recent progress in the management of pulmonary hypertension. 2011 , 75, 1801-10	65
2094	Pulmonary arterial hypertension: An overview. 2011 , 6, 268-277	1
2093	Fit for high altitude: are hypoxic challenge tests useful?. 2011 , 6, 38-46	9

2092	Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. 2011 , 50, 2341-6	8
2091	Kidney pulmonary hypertension: another road on the map?. 2011 , 6, 150-2	1
2090	2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. 2011 , 60, 419-24	17
2089	Hyperthyroidism and pulmonary hypertension: an important association. 2011 , 342, 507-12	30
2088	Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. 2011 , 25 Suppl 3, 1-13	35
2087	Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. 2011 , 17, 25-33	23
2086	Clinical perspective: biomarkers in pulmonary arterial hypertension. 2011 , 65, 5-7	12
2085	The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. 2011 , 65, 6-14	33
2084	Management of pulmonary hypertension and Down syndrome. 2011 , 65, 8-13	25
2083	Quality initiatives and models of care in patients with pulmonary arterial hypertension: the time has come!. 2011 , 65, 1-3	
2082	Right atrial speckle tracking analysis as a novel noninvasive method for pulmonary hemodynamics assessment in patients with chronic systolic heart failure. 2011 , 28, 658-64	44
2081	Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. 2011 , 28, 860-9	13
2080	Pulmonary hypertension and right ventricular function in advanced heart failure. 2011 , 17, 189-98	24
2079	Evaluation and Management of the Adult Patient With Pulmonary Hypertension. 2011 , 7, 409-416	2
2078	Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. 2011 , 158, 584-8	66
2077	The impact of micro-embolism size on haemodynamic changes in the pulmonary micro-circulation. 2011 , 175, 365-74	16
2076	Chronic thromboembolic disease and necrotizing granulomatous vasculitis [A case report]. 2011 , 4, 149-150	
2075	Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. 2011 , 142, 1439-52	96

2074	Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. 2011 , 33, 993-1004	27
2073	Pulmonary arterial hypertension. 2011 , 36, 461-517	40
2072	Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. 2011 , 107, 628-32	78
2071	Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension. 2011 , 108, 460-4	20
2070	Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. 2011 , 108, 1483-8	23
2069	Factors affecting the response to exercise in patients with severe pulmonary arterial hypertension. 2011 , 47, 10-6	3
2068	Systemic sclerosis refractory disease: from the skin to the heart. 2011 , 10, 693-701	30
2067	The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. 2011 , 34, 513-8	27
2066	Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. 2011 , 19, 509-13	9
2065	Pregnancy in women with pulmonary hypertension. 2011 , 19, 504-8	39
2064	Pulmonary hypertension, how to diagnose and who to treat?. 2011 , 19, 493-4	2
2063	Pulmonary arterial hypertension: an update. 2011 , 19, 514-22	16
2062	[Systemic lupus erythematosus]. 2011 , 70, 313-23	4
2061	Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. 2011 , 100, 879-85	21
2060	Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. 2011 , 14, 17-27	46
2059	Bewegung im Alter. 2011 , 49, 461-464	0
2058	Anorexigènes et maladies cardiovasculaires : les liaisons dangereuses. 2011 , 20, 424-435	2
2057	Evaluation of pulmonary hypertension in a child: role of computed tomography. 2011 , 78, 1417-9	3

2056	Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. 2011 , 28, 251-69	30	
2055	Pulmonale Hypertension. 2011 , 6, 78-93		
2054	High frequency of diastolic dysfunction in a population-based cohort of elderly women--but poor association with the symptom dyspnea. 2011 , 11, 71	13	
2053	Pulmonary venous occlusion and death in pulmonary arterial hypertension: survival analyses using radiographic surrogates. 2011 , 11, 47	2	
2052	Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. 2011 , 33, 225-31	25	
2051	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. 2011 , 63, 2790-6	40	
2050	Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. 2011 , 183, 1723-9	125	
2049	Varespladib: targeting the inflammatory face of atherosclerosis. <i>European Heart Journal</i> , 2011 , 32, 923-69.5	7	
2048	Treatment of pulmonary arterial hypertension: great expectations!. 2011 , 38, 403-5	1	
2047	[Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010]. 2011 , 65, 208-18	5	
2046	Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience. 2011 , 123, 32-45	2	
2045	Pulmonary arterial hypertension in connective tissue diseases. 2011 , 60, 405-9	7	
2044	Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. 2011 , 11, 253-63	5	
2043	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation	9.5	3
2042	Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. 2011 , 49, 1258-62	32	
2041	Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. 2011 , 5, 163-71	15	
2040	Use of non-invasive haemodynamic measurements to detect treatment response in precapillary pulmonary hypertension. 2011 , 66, 810-4	9	
2039	A decade of achievement in pulmonary hypertension. 2011 , 20, 215-7	9	

2038	Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. 2011 , 4, 644-50	112
2037	A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. 2011 , 37, 1096-103	63
2036	The management of Eisenmenger syndrome in the modern treatment era: a case report. 2011 , 20, 293-6	7
2035	Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion. 2011 , 1, 365-76	54
2034	Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. 2011 , 20, 270-6	20
2033	Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. 2011 , 123, 1227-32	71
2032	HIV infection and pulmonary arterial hypertension. 2011 , 5, 257-66	11
2031	Apical right ventricular dysfunction in patients with pulmonary hypertension demonstrated with magnetic resonance. 2011 , 97, 1250-6	21
2030	A hemodynamic study of pulmonary hypertension in sickle cell disease. 2011 , 365, 44-53	354
2029	Bosentan for the treatment of adult pulmonary hypertension. 2011 , 7, 19-37	9
2028	Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension. 2011 , 139, 115-21	26
2027	Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. 2011 , 139, 988-993	260
2026	Sildenafil therapy for interferon- α -induced pulmonary arterial hypertension: a case report. 2011 , 120, 187-9	33
2025	Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. 2011 , 12, 696-701	22
2024	Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. 2011 , 12, 961-6	44
2023	Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. 2011 , 140, 1016-1024	73
2022	Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. 2011 , 139, 690-693	27
2021	Pulmonary embolism: predicting disease severity. 2011 , 369, 4255-77	19

2020	Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. 2011 , 20, 236-42	52
2019	Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. 2011 , 5, 153-61	5
2018	Atrial septostomy in patients with pulmonary hypertension: should it be recommended?. 2011 , 5, 363-76	16
2017	Assessment of right ventricular functions during cancer chemotherapy. 2011 , 12, 834-40	50
2016	The value of tools to assess pulmonary arterial hypertension. 2011 , 20, 222-35	23
2015	Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. 2011 , 124, 1755-64	196
2014	In defence of exercise stress tests for the diagnosis of pulmonary hypertension. 2011 , 97, 94-5	16
2013	Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. 2011 , 184, 1114-24	199
2012	Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. 2011 , 1, 239-43	17
2011	Pulmonary hypertension in patients with treated pulmonary tuberculosis: analysis of 14 consecutive cases. 2011 , 5, 1-5	23
2010	Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. 2011 , 70, 1963-7	20
2009	A Rare Case of Prosthetic Valve Endocarditis Caused by Extended-spectrum β -Lactamase Producing <i>Escherichia coli</i> . 2011 , 3, 99-101	8
2008	Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension. 2011 , 3, e14	5
2007	Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. <i>European Heart Journal</i> , 2011 , 32, 2489-98	9.5 106
2006	Optimal management of severe pulmonary arterial hypertension. 2011 , 20, 254-61	15
2005	Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. 2011 , 38, 2186-92	17
2004	Mast cells: bridging the gap between pre- and post-capillary pulmonary hypertension?. 2011 , 37, 1303-5	6
2003	Percutaneous closure of patent ductus arteriosus in children: Immediate and short-term changes in left ventricular systolic and diastolic function. 2011 , 4, 139-44	21

2002	Pulmonary hypertension: a fatal complication of neurofibromatosis type 1. 2011 , 56, 1844-8	10
2001	Surgical treatment of pulmonary hypertension: Lung transplantation. 2011 , 1, 327-33	22
2000	The association between resting and mild-to-moderate exercise pulmonary artery pressure. 2012 , 39, 313-8	17
1999	Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders. 2012 , 2012, 273591	23
1998	Pulmonary artery hypertension in heart transplant recipients: how much is too much?. 2012 , 42, 864-9; discussion 869-70	20
1997	Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. 2012 , 60, 26-34	22
1996	Atrial septostomy benefits severe pulmonary hypertension patients by increase of left ventricular preload reserve. 2012 , 302, H2654-62	20
1995	Transforming growth factor- β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension. 2012 , 2, 461-9	5
1994	Clinical review: management of weaning from cardiopulmonary bypass after cardiac surgery. 2012 , 15, 206-23	44
1993	Abstracts of the 34th Scandinavian Congress of Rheumatology. Copenhagen, Denmark. September 2-5, 2012. 2012 , 126, 1-68	
1992	Evolution of Pulmonary Hypertension in Hyperthyroid Patients. 2012 , 8, 443-452	
1991	Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. 2012 , 2, 21-7	20
1990	Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. 2012 , 11, 51-61	41
1989	Pulmonary hypertension: chapters of innovation and tribulation. <i>European Heart Journal</i> , 2012 , 33, 961-89.5	6
1988	Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. 2012 , 39, 939-44	47
1987	The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography. 2012 , 13, 666-72	71
1986	The challenge of breathlessness in the detection of pulmonary hypertension. 2012 , 21, 1-3	2
1985	Pulmonary vascular resistances during exercise in normal subjects: a systematic review. 2012 , 39, 319-28	125

1984	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. 2012 , 71, 596-605		32
1983	Pulmonary hypertension associated with benfluorex exposure. 2012 , 40, 1164-72		60
1982	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1787-847	9.5	3691
1981	An update on the use of ambrisentan in pulmonary arterial hypertension. 2012 , 6, 331-43		11
1980	Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors. 2012 , 18, 281-8		69
1979	Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics. 2012 , 5, 47-53		29
1978	Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction: pathophysiology and natural history. 2012 , 27, 273-80		34
1977	Clinical context and mechanism of functional tricuspid regurgitation in patients with and without pulmonary hypertension. 2012 , 5, 314-23		139
1976	A review of the management of pulmonary arterial hypertension associated with congenital heart disease. 2012 , 11, 239-47		7
1975	Pulmonary arterial hypertension: bridging the present to the future. 2012 , 21, 267-70		8
1974	Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology. 2012 , 19, 1217-26		4
1973	Advances in pediatric pulmonary arterial hypertension. 2012 , 27, 70-81		25
1972	A septal angle measured on computed tomographic pulmonary angiography can noninvasively estimate pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. 2012 , 27, 325-30		13
1971	Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension. 2012 , 5, 628-36		170
1970	Pulmonary arterial hypertension associated with congenital heart disease. 2012 , 21, 328-37		95
1969	The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study. 2012 , 2, e000806		29
1968	Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. 2012 , 19, 960-71		48
1967	Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. 2012 , 21, 223-33		74

1966	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. 2012 , 40, 75-83	39
1965	Update on lung transplantation: programmes, patients and prospects. 2012 , 21, 271-305	28
1964	Current role of imaging in the diagnosis and management of pulmonary hypertension. 2012 , 198, 1320-31	20
1963	Airway bypass stents for emphysema, algorithm to exclude precapillary pulmonary hypertension, and sildenafil for pulmonary hypertension in heart failure with preserved ejection fraction. 2012 , 185, 1323-4	
1962	Systemische Sklerodermie. 2012 , 38, 44-52	1
1961	Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. 2012 , 39, 276-85	57
1960	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. 2012 , 6, 255-65	7
1959	Pulmonale Hypertonie - radiologische Diagnostik im klinischen Kontext. 2012 , 12, 143-159	
1958	Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. 2012 , 15, 947-55	38
1957	Chronic thromboembolic pulmonary hypertension: an underdiagnosed entity?. 2012 , 40, 71-9	9
1956	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. 2012 , 71, 1355-60	199
1955	Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. 2012 , 14, 1067-74	55
1954	Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis. 2012 , 39, 106-11	12
1953	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. 2012 , 14, 946-53	22
1952	The European Heart Journal and the European Journal of Heart Failure: partners in scientific publishing. 2012 , 14, 1075-82	3
1951	Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension. 2012 , 65-75	
1950	Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. 2012 , 85-93	10
1949	Pulmonary Arterial Hypertension and HIV and Other Viral Infections. 2012 , 105-112	1

1948	Pulmonary Hypertension and Left Heart Disease. 2012 , 161-168	
1947	Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease. 2012 , 51, 1765-74	26
1946	Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. 2012 , 125, 113-22	237
1945	ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. 2012 , 39, 945-55	260
1944	Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. 2012 , 21, 259-62	2
1943	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. 2012 , 40, 596-603	258
1942	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. 2012 , 71, 1335-42	67
1941	Pulmonary hypertension in left heart disease. 2012 , 21, 338-46	50
1940	Determinants of pulmonary hypertension in patients with Beta-thalassemia major and normal ventricular function. 2012 , 128, 124-9	15
1939	A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. 2012 , 5, 765-75	92
1938	Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. 2012 , 5, 748-55	355
1937	Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. 2012 , 71, 1966-72	69
1936	Letter by Farmakis and Aessopos regarding article, "echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United kingdom". 2012 , 125, e930	1
1935	Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. 2012 , 6, 41-50	5
1934	Heart failure with preserved ejection fraction. 2012 , 2012, 10	11
1933	The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension. 2012 , 2012, 106576	11
1932	Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. 2012 , 2, 139-47	30
1931	Pulmonary hypertension in parenchymal lung disease. 2012 , 2012, 684781	4

1930	Long-term inhaled iloprost use in children with pulmonary arterial hypertension. 2012 , 22, 396-403	6
1929	Differences in hemodynamic parameters and exercise capacity between patients with pulmonary arterial hypertension and chronic heart failure. 2012 , 32, 379-85	14
1928	Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: "it is a matter of the heart". 2012 , 39, 206-9	19
1927	Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance. 2012 , 121, 76-82	25
1926	Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. 2012 , 98, 1805-11	177
1925	Early-diastolic left ventricular lengthening implies pulmonary hypertension-induced right ventricular decompensation. 2012 , 96, 286-95	19
1924	Shape of the right ventricular outflow Doppler envelope and severity of pulmonary hypertension. 2012 , 13, 309-16	17
1923	The best of the European Heart Journal: look back with pride. <i>European Heart Journal</i> , 2012 , 33, 1161-719.5	4
1922	Moving from impact to influence: measurement and the changing role of medical journals. <i>European Heart Journal</i> , 2012 , 33, 2892-6	9.5 25
1921	Pulmonary hypertension in dialysis patients: a prevalent, risky but still uncharacterized disorder. 2012 , 27, 3674-7	2
1920	A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. 2012 , 17, 1327-34	26
1919	Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. 2012 , 25, 681-9	24
1918	Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. 2012 , 10, 162-4	20
1917	Gh̃tique de l'hypertension artfielle pulmonaire : du fundamental au conseil gh̃tique. 2012 , 9, 1-9	
1916	Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. 2012 , 26, 1967-9	27
1915	Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. 2012 , 142, 869-876	40
1914	Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review. 2012 , 13, 472-80	25
1913	Multidetector computed tomography for detection and characterization of pulmonary hypertension in consideration of WHO classification. 2012 , 36, 175-80	23

1912	Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension. 2012 , 47, 571-7	70
1911	Predictors of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Arterial Hypertension. 2012 , 14, 283-292	11
1910	A feasibility analysis of implementing interventions for discordant couples in 14 African countries: implications for epidemic control. 2012 , 26, 1969-71	5
1909	Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. 2012 , 60, 342-6	21
1908	Non-invasive algorithms for the diagnosis of pulmonary hypertension. 2012 , 108, 1037-41	5
1907	Pulmonary Veno-Occlusive Disease. 2012 , 149-160	
1906	Comparison of acute hemodynamic effects of aerosolized iloprost and inhaled nitric oxide in adult congenital heart disease with severe pulmonary arterial hypertension. 2012 , 51, 2857-62	4
1905	Diagnosis of cardiac disease. 75-80	
1904	Invasive diagnosis techniques. 95-102	
1903	Aortic valve disease. 193-199	
1902	Pulmonary vascular disease. 282-287	
1901	De Gruyter. 2012 , 18, 1-8	
1900	Portopulmonary hypertension: light at the end of the tunnel?. 2012 , 141, 840-842	3
1899	Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. 2012 , 142, 1150-1157	79
1898	Right ventricular function in pulmonary hypertension. 2012 , 4, 657-665	2
1897	New developments in the treatment of chronic thromboembolic pulmonary hypertension. 2012 , 2, 397-402	
1896	Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. 2012 , 76, 1235-44	37
1895	Electrocardiogram for the diagnosis of right ventricular hypertrophy and dilation in idiopathic pulmonary arterial hypertension. 2012 , 76, 1744-9	27

1894	Percutaneous transluminal pulmonary angioplasty for distal-type chronic thromboembolic pulmonary hypertension. 2012 , 76, 307-8	3
1893	Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. 2012 , 76, 2249-54	61
1892	Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. 2012 , 51, 2337-40	30
1891	Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension. 2012 , 120, 206-12	3
1890	Clinical features of paediatric pulmonary hypertension: a registry study. 2012 , 379, 537-46	346
1889	Pulmonary hypertension in early life. 2012 , 379, 500-1	2
1888	WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. 2012 , 55, 89-103	18
1887	Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension). 2012 , 55, 104-18	14
1886	Pulmonary hypertension due to left heart disease. 2012 , 126, 975-90	294
1885	Imatinib mesylate for the treatment of pulmonary arterial hypertension. 2012 , 21, 119-34	50
1884	Heritable pulmonary arterial hypertension with elevated pulmonary wedge pressure. 2012 , 126, e124-7	
1883	The pharmacological treatment of pulmonary arterial hypertension. 2012 , 64, 583-620	88
1882	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. 2012 , 60, 768-74	101
1881	Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats. 2012 , 46, 374-80	4
1880	Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. 2012 , 17, 1269-74	49
1879	The management of neonatal pulmonary hypertension. 2012 , 97, F223-8	54
1878	Potential of right to left ventricular volume ratio measured on chest CT for the prediction of pulmonary hypertension: correlation with pulmonary arterial systolic pressure estimated by echocardiography. 2012 , 22, 1929-36	10
1877	Effect of simulated diving trips on pulmonary artery pressure in healthy men. 2012 , 101, 947-53	1

1876	Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival. 2012 , 190, 645-9	18
1875	Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. 2012 , 109, 1801-6	12
1874	Polymorphisms in the Serotonin Transporter Protein (SERT) Gene in Patients With Pulmonary Arterial Hypertension. 2012 , 48, 77-80	
1873	Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. 2012 , 94, 817-24	93
1872	Iron chelation inhibits the development of pulmonary vascular remodeling. 2012 , 53, 1738-47	29
1871	Biomarkers of functional class in systolic heart failure: The relevance of copeptin. 2012 , 31, 701-710	3
1870	Pulmonary hypertension-"state of the art" management in 2012. 2012 , 64, 60-73	2
1869	Hipertensi3 pulmonar y embarazo. 2012 , 47, 154-160	1
1868	Prise en charge de l'hypertension artfielle pulmonaire. 2012 , 4, 61-66	
1867	Congenital heart disease and pulmonary hypertension. 2012 , 8, 427-45	11
1866	Right ventricular longitudinal peak systolic strain measurements from the subcostal view in patients with suspected pulmonary hypertension: a feasibility study. 2012 , 25, 674-81	19
1865	Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. 2012 , 25, 274-9	4
1864	Value of tissue Doppler echocardiography in children with pulmonary hypertension. 2012 , 25, 504-10	43
1863	[Biomarkers of functional class in systolic heart failure: the relevance of copeptin]. 2012 , 31, 701-10	2
1862	Comparison of the 2007 and 2011 appropriate use criteria for transthoracic echocardiography in various clinical settings. 2012 , 25, 1162-9	53
1861	[Pulmonary hypertension: from molecular pathophysiology to haemodynamic abnormalities]. 2012 , 29, 956-70	4
1860	Comparison of the 2007 and 2011 appropriate use criteria for transesophageal echocardiography. 2012 , 25, 1170-5	14
1859	Hypertension pulmonaire. 2012 , 4, 15-22	

1858	Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. 2012 , 17, 303-7	12
1857	Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. 2012 , 8, 203-13	26
1856	Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection. 2012 , 117, 979-91	11
1855	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. 2012 , 14, 803-69	1892
1854	Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. 2012 , 55, 145-52	72
1853	The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. 2012 , 71, 249-52	52
1852	Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. 2012 , 98, 238-43	206
1851	Funci3n longitudinal del ventr3culo derecho estimada por el desplazamiento sist3lico del anillo tric3spide (TAPSE) en 557 pacientes sanos. 2012 , 19, 281-286	1
1850	Echocardiographic predictors of outcome in eisenmenger syndrome. 2012 , 126, 1461-8	92
1849	Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. 2012 , 25, 33-9	24
1848	Gu3a de pr3ctica cl3nica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. 2012 , 65, 171.e1-171.e44	6
1847	Hypertension pulmonaire au cours du syndrome des antisynt3tases. 2012 , 33, S41-S42	
1846	An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin3), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. 2012 , 64, 95-103	21
1845	BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. 2012 , 5, 511-8	26
1844	Echocardiography in Respiratory Medicine. 2012 , 193-201	
1843	Pulmonary hypertension. 2012 , 308, 1366-74	57
1842	Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. 2012 , 163, 580-8	59
1841	Introduction: devising a prognostic score for pulmonary arterial hypertension. 2012 , 110, 1S-2S	2

1840	Hemodynamics in pulmonary arterial hypertension: current and future perspectives. 2012 , 110, 9S-15S	33
1839	The potential of biomarkers in pulmonary arterial hypertension. 2012 , 110, 32S-38S	28
1838	[Interventional cardiac catheterization in children]. 2012 , 19, 96-102	6
1837	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. 2012 , 31, 150-8	73
1836	Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. 2012 , 31, 373-80	147
1835	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. 2012 , 31, 364-72	38
1834	Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. 2012 , 31, 735-43	37
1833	Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. 2012 , 155, 378-82	84
1832	Pulmonary hypertension in left heart disease: a review. 2012 , 156, 253-8	7
1831	Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). 2012 , 158, 6-11	37
1830	Patch valvuloplasty in patients with posterior chordae rupture. 2012 , 154, 206-7	6
1829	Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. 2012 , 154, 205-6	20
1828	Glycemic improvement normalizes myocardial microvascular reserve in type 2 diabetes. 2012 , 156, 245-7	6
1827	Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics. 2012 , 156, 244-5	7
1826	Prevalence of bicuspid aortic valve in patients presenting with subarachnoid hemorrhage related to an intracerebral aneurysm. 2012 , 157, 142-3	9
1825	Serial phase-contrast MRI for prediction of pulmonary hemodynamic changes in patients with pulmonary arterial hypertension. 2012 , 157, 140-2	8
1824	Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: could this evaluation replace lung perfusion scintigraphy?. 2012 , 81, e1-6	9
1823	Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. 2012 , 32, 838-55	11

1822	Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. 2012 , 13, 21	77
1821	Pulmonary hypertension in patients with Martorell hypertensive leg ulcer: a case control study. 2012 , 13, 45	
1820	A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study. 2012 , 13, 76	15
1819	Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. 2012 , 14, 40	89
1818	Cardiovascular magnetic resonance in pulmonary hypertension. 2012 , 14, 6	51
1817	Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. 2012 , 42, 1351-4	13
1816	The effects of siRNA against RPL22 on ET-1-induced proliferation of human pulmonary arterial smooth muscle cells. 2012 , 30, 351-7	6
1815	Severe portopulmonary hypertension associated with an unusual pattern of abernethy malformation: three-dimensional computed tomography view. 2012 , 29, E275-7	1
1814	Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. 2012 , 66, 1117-24	
1813	Prognostic value of pulmonary hypertension in patients undergoing surgery for degenerative mitral valve disease with leaflet prolapse. 2012 , 27, 668-75	9
1812	Treatment of pulmonary arterial hypertension in connective tissue disease. 2012 , 72, 1039-56	2
1811	The right ventricle in health and disease: insights into physiology, pathophysiology and diagnostic management. 2012 , 121, 263-73	42
1810	Complex Challenges of Pulmonary Hypertension. 2012 , 447-460	1
1809	Clinical Assessment of Pulmonary Hypertension. 2012 , 429-435	
1808	Pulmonary pressures and death in heart failure: a community study. 2012 , 59, 222-31	200
1807	Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. 2012 , 60, 1192-201	178
1806	Echocardiographic evaluation of pulmonary artery pressure in patients with heart failure. 2012 , 60, 83; author reply 83-4	1
1805	Reply. 2012 , 60, 82-83	1

1804	Reply. 2012 , 60, 83-84	1
1803	Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension. 2012 , 60, 157-64	25
1802	Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy. 2012 , 24, 487-9	3
1801	Obstructive sleep apnea syndrome. 2012 , 23, 586-93	172
1800	The ratio of right ventricular volume to left ventricular volume reflects the impact of pulmonary regurgitation independently of the method of pulmonary regurgitation quantification. 2012 , 81, e977-81	9
1799	Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension. 2012 , 31, 865-73	38
1798	Ablation of typical right atrial flutter in patients with pulmonary hypertension. 2012 , 21, 695-9	16
1797	Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist. 2012 , 21, 671-8	5
1796	Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension. 2012 , 41, 599-605	11
1795	World Health Organization Group III pulmonary hypertension. 2012 , 55, 119-27	21
1794	What we need to know about drug interactions in patients with pulmonary arterial hypertension. 2012 , 34, 119-122	1
1793	Can We Predict the Severity of Pulmonary Hypertension in Patients With Scleroderma?. 2012 , 8, 259-262	
1792	Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease. 2012 , 106, 1749-55	21
1791	Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY ¹ . 2012 , 87, 825-34	50
1790	Imaging of Pulmonary Hypertension. 2012 , 139-160	
1789	Right ventricular remodeling in pulmonary hypertension. 2012 , 8, 403-12	16
1788	Chronic thromboembolic pulmonary hypertension. 2012 , 8, 475-83	4
1787	The effect of endogenous estrogen on Doppler-estimated right ventricular systolic pressure during exercise. 2012 , 90, 1364-71	

1786	Predicting survival in pulmonary arterial hypertension in the UK. 2012 , 40, 604-11	84
1785	Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. 2012 , 7, 425-30	22
1784	Right ventricular pulmonary hypertension. 2012 , 9, 303-8	4
1783	Exercise tests in heart failure patients: is simple better?. 2012 , 60, 2662-3	2
1782	Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. 2012 , 60, 344-9	21
1781	Can we predict the severity of pulmonary hypertension in patients with scleroderma?. 2012 , 8, 259-62	4
1780	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. 2012 , 65, 938.e1-938.e59	27
1779	Validation study on the accuracy of echocardiographic measurements of right ventricular systolic function in pulmonary hypertension. 2012 , 25, 280-6	106
1778	Tadalafil for the treatment of pulmonary arterial hypertension. 2012 , 13, 747-55	13
1777	Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. 2012 , 21, 386-401	51
1776	Diagnostic dilemmas in pulmonary hypertension. 2012 , 8, 331-52	1
1775	Hydroxysafflor yellow A (HSYA) from flowers of <i>Carthamus tinctorius</i> L. and its vasodilatation effects on pulmonary artery. 2012 , 17, 14918-27	32
1774	Pediatric Pulmonary Hypertension. 2012 , 730-752	
1773	Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease. 2012 , 33, 1323-31	26
1772	Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. 2012 , 12, 75	19
1771	Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. 2012 , 12, 23	68
1770	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. 2012 , 14, R143	65
1769	Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. 2012 , 14, R148	79

1768	Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. 2012 , 7, e36302	4
1767	Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. 2012 , 7, e45834	33
1766	Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. 2012 , 7, e47662	119
1765	Treatment of pulmonary hypertension. 2012 , 18, RA31-9	10
1764	Perioperative anesthesiological management of patients with pulmonary hypertension. 2012 , 2012, 356982	30
1763	Atrial Septostomy. 2012 , 254-261	
1762	Pulmonary Hypertension in Hemodialysis Patients. 2012 , 4, 148-152	0
1761	Pulmonary hypertension: an emerging risk in hemoglobin disorders. 2012 , 1,	
1760	Inhaled treprostinil: a therapeutic review. 2012 , 6, 19-28	32
1759	Long-term treatment with high-dose of sildenafil in a thalassemic patient with pulmonary hypertension. 2012 , 78, 105-6	8
1758	Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. 2012 , 108, 1049-60	11
1757	Invasive Rest and Exercise Hemodynamics in the Modern Management of Pulmonary Vascular Disease: An Expanding Role in the Future. 2012 , 23-36	
1756	Lung Transplantation and Role for Novel Extracorporeal Support in Pulmonary Hypertension. 2012 , 246-253	
1755	Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. 2012 , 78, 205-9	5
1754	Aortic pulse wave velocity measurement in systemic sclerosis patients. 2012 , 64, 360-7	13
1753	Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. 2012 , 141, 661-673	42
1752	Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. 2012 , 69, 2805-31	15
1751	Cardiac sympathetic activation in patients with pulmonary arterial hypertension. 2012 , 302, R1153-7	39

1750	Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. 2012 , 64, 1257-62	47
1749	Detection of exercise-induced pulmonary arterial hypertension by cardiopulmonary exercise testing. 2012 , 35, 548-53	11
1748	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. 2012 , 40, 874-80	203
1747	Current status of lung transplantation. 2012 , 9, 131-45	12
1746	[Management of patients with pulmonary hypertension]. 2012 , 61, 574-77, 580-7	4
1745	[Blind in the right eye? : Perioperative management of high risk cardiac patients]. 2012 , 61, 572-3	
1744	Three-dimensional analysis of interventricular septal curvature from cardiac magnetic resonance images for the evaluation of patients with pulmonary hypertension. 2012 , 28, 1073-85	20
1743	Treatment for pulmonary hypertension of left heart disease. 2012 , 14, 319-27	12
1742	Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients. 2012 , 22, 1059-66	5
1741	Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. 2012 , 22, 1672-9	114
1740	Pulmonary hypertension and pregnancy--a review of 12 pregnancies in nine women. 2012 , 119, 752-61	41
1739	Atrial electrical and structural remodeling associated with longstanding pulmonary hypertension and right ventricular hypertrophy in humans. 2012 , 23, 614-20	55
1738	Family caregiving in pulmonary arterial hypertension. 2012 , 41, 26-34	18
1737	Morphologic and functional remodeling of the right ventricle in pulmonary hypertension by real time three dimensional echocardiography. 2012 , 109, 906-13	41
1736	Right ventricular function in patients with Eisenmenger syndrome. 2012 , 109, 1206-11	24
1735	Polymorphisms in the serotonin transporter protein (SERT) gene in patients with pulmonary arterial hypertension. 2012 , 48, 77-80	9
1734	Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeronex Pro: formulation aspects and nanoparticle stability to nebulization. 2012 , 422, 398-408	53
1733	Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 2012 , 26, 79-90	16

1732	Catheter ablation of typical atrial flutter in severe pulmonary hypertension. 2012 , 23, 1185-90	17
1731	Ablation of atrial flutter in severe pulmonary hypertension: pushing the outside of the envelope. 2012 , 23, 1191-2	2
1730	sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model. 2012 , 206, 178-94	13
1729	Predictors of pulmonary hypertension in patients with end-stage heart failure. 2012 , 18, 212-6	3
1728	Evolving surgical techniques for pulmonary endarterectomy according to the changing features of chronic thromboembolic pulmonary hypertension patients during 17-year single-center experience. 2012 , 144, 100-7	35
1727	Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. 2012 , 42, 933-42	24
1726	Pulmonary hypertension before first and second lung transplantation. 2012 , 26, 672-8	
1725	Differences of cardiac output measurements by open-circuit acetylene uptake in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a cohort study. 2012 , 13, 18	6
1724	Percutaneous transcatheter closure of interatrial septal defect in adults: procedural outcome and long-term results. 2012 , 79, 322-30	21
1723	Value of oxygen-enhanced MRI of the lungs in patients with pulmonary hypertension: a qualitative and quantitative approach. 2012 , 35, 86-94	7
1722	An update on the evaluation and management of pulmonary hypertension in scleroderma. 2012 , 14, 1-10	5
1721	Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: Is it safe?. 2012 , 29, 271-5	7
1720	Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?. 2012 , 31, 357-61	4
1719	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. 2012 , 31, 557-61	12
1718	Right atrial to left atrial area ratio on early echocardiography predicts long-term survival after acute pulmonary embolism. 2013 , 11, 17	25
1717	Use of echocardiographic pulmonary acceleration time and estimated vascular resistance for the evaluation of possible pulmonary hypertension. 2013 , 11, 7	50
1716	Vascular remodeling in pulmonary hypertension. 2013 , 91, 297-309	142
1715	Mise au point sur les traitements de l'hypertension artérielle pulmonaire de l'enfant. 2013 , 22, 359-364	

1714	Assessment of pulmonary arterial hypertension and vascular resistance by measurements of the pulmonary arterial flow velocity curve in the absence of a measurable tricuspid regurgitant velocity in childhood congenital heart disease. 2013 , 34, 646-55	20
1713	Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. 2013 , 26, 1-14	316
1712	Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. 2013 , 168, 3797-801	49
1711	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. 2013 , 369, 319-29	852
1710	Riociguat for the treatment of pulmonary arterial hypertension. 2013 , 369, 330-40	861
1709	Dispersion durations of P-wave and QT interval in children with congenital heart disease and pulmonary arterial hypertension. 2013 , 34, 591-6	10
1708	Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. 2013 , 62, 1103-1111	138
1707	Portopulmonary hypertension, tuberculosis and previous dirofilariasis: case report and review of literature. 2013 , 11, 101-107	1
1706	Microvolt T wave alternans in adults with congenital heart diseases characterized by right ventricle pathology or single ventricle physiology: a case control study. 2013 , 13, 26	3
1705	QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. 2013 , 167, 669-76	61
1704	The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. 2013 , 7, 43-55	12
1703	Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India. 2013 , 288, 305-9	24
1702	Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). 2013 , 30, 459-71	11
1701	New treatment strategies for pulmonary arterial hypertension: hopes or hypes?. 2013 , 62, 1101-1102	33
1700	Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). 2013 , 62, 1092-1100	135
1699	Exaggerated increase of exercise-induced pulmonary artery pressure in systemic sclerosis patients predominantly results from left ventricular diastolic dysfunction. 2013 , 102, 813-20	9
1698	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. 2013 , 1, 92-101	2
1697	Assessment of the right ventricle with cardiovascular magnetic resonance at 7 Tesla. 2013 , 15, 23	36

1696	Macitentan and morbidity and mortality in pulmonary arterial hypertension. 2013 , 369, 809-18	878
1695	Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. 2013 , 8, 689-94	3
1694	Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension. 2013 , 8, 307-16	4
1693	Pulmonary artery pressure and PaO ₂ in chronic obstructive pulmonary disease. 2013 , 107, 1271-9	17
1692	Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. 2013 , 51, 134-46	48
1691	¿Cuáles la mejor forma de medir el impacto de la hipertensión pulmonar en el ventrículo derecho? ¿Es esto realmente importante?. 2013 , 48, 47-50	1
1690	Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. 2013 , 34, 825-40	34
1689	Extension of the survival dimensionality reduction algorithm to detect epistasis in competing risks models (SDR-CR). 2013 , 46, 174-80	
1688	Chronic thromboembolic pulmonary hypertension. 2013 , 34, 779-97	10
1687	Utilidad del estudio hemodinámico invasivo en la hipertensión pulmonar. 2013 , 48, 51-54	1
1686	Evaluation of left ventricular function in patients with chronic obstructive pulmonary disease with or without pulmonary hypertension. 2013 , 62, 575-582	2
1685	Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure. 2013 , 112, 1471-6	24
1684	Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. 2013 , 9, 4-7	4
1683	Pulmonary hypertension due to left heart diseases. 2013 , 62, D100-8	437
1682	Predictors of pulmonary hypertension after intermediate-to-high risk pulmonary embolism. 2013 , 32, 857-864	7
1681	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. 2013 , 167, 2630-7	29
1680	Management of pulmonary hypertension in left heart disease. 2013 , 7, 131-51	9
1679	Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. 2013 , 19, 202-7	59

1678	[Pulmonary arterial hypertension and sickle cell disease]. 2013 , 42, 338-46	2
1677	[Echocardiography and scintigraphy in chronic thromboembolic pulmonary hypertension]. 2013 , 140, 380	
1676	Pulmonary hypertension in obesity-hypoventilation syndrome. 2013 , 107, 2061-70	60
1675	Exercise-induced pulmonary hypertension in scleroderma patients: a common finding but with elusive pathophysiology. 2013 , 30, 378-84	10
1674	Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension. 2014 , 50, 74-86	75
1673	Connective tissue diseases: To screen or not to screen for PAH in connective tissue diseases?. 2013 , 9, 699-700	
1672	Geometry of the right heart and tricuspid regurgitation to exclude elevated pulmonary artery pressure: new insights. 2013 , 168, 3866-71	9
1671	Simple exercise echocardiography using a Master's two-step test for early detection of pulmonary arterial hypertension. 2013 , 62, 176-82	16
1670	Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. 2013 , 12, 410-5	54
1669	Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. 2013 , 168, 375-81	99
1668	The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. 2013 , 139, 1971-84	38
1667	Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. 2013 , 112, 1635-40	46
1666	An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. 2013 , 188, e13-64	1863
1665	Pharmacotherapy of Pulmonary Hypertension. 2013 ,	2
1664	Pulmonary arterial hypertension in SLE: what do we know?. 2013 , 22, 1274-85	21
1663	Pulmonary hypertension after hematopoietic stem cell transplantation. 2013 , 19, 1546-56	57
1662	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. 2013 , 32, 1179-86	33
1661	Pulmonary hypertension in systemic lupus erythematosus. 2013 , 27, 425-34	12

1660	Left ventricular dysfunction with pulmonary hypertension: Part 1: epidemiology, pathophysiology, and definitions. 2013 , 6, 344-54		35
1659	Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. 2013 , 165, 200-7		47
1658	Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. 2013 , 99, 35-43		66
1657	Pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension: an institutional experience. 2013 , 44, e219-27; discussion e227		26
1656	Updated treatment algorithm of pulmonary arterial hypertension. 2013 , 62, D60-72		495
1655	Definitions and diagnosis of pulmonary hypertension. 2013 , 62, D42-50		1163
1654	Chronic thromboembolic pulmonary hypertension. 2013 , 62, D92-9		404
1653	Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation. 2013 , 16, 389-92		8
1652	Pulmonary hypertension, heart failure and hyperthyroidism: A case report. 2013 , 32, 253-256		1
1651	Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription. <i>European Heart Journal</i> , 2013 , 34, 3669-74	9.5	106
1650	Echocardiography in pediatric pulmonary hypertension. 2013 , 14, 157-64		13
1649	Drugs induced pulmonary arterial hypertension. 2013 , 42, e303-10		22
1648	Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers. 2013 , 455, 248-58		23
1647	Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease. 2013 , 13, 74		26
1646	Pulmonary arterial hypertension. 2013 , 8, 97		168
1645	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. 2013 , 15, R193		37
1644	Obituary: pulmonary artery catheter 1970 to 2013. 2013 , 3, 38		107
1643	Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension. 2013 , 14, 130		26

1642	Epidemiology of pulmonary arterial hypertension. 2013 , 15, 638-49	15
1641	Pediatric pulmonary arterial hypertension. 2013 , 15, 606-13	4
1640	A GPS map for pulmonary hypertension: a review of imaging modalities. 2013 , 15, 650-8	1
1639	Simple prediction of right ventricular ejection fraction using tricuspid annular plane systolic excursion in pulmonary hypertension. 2013 , 29, 1799-805	30
1638	New Aspects of Echocardiographic Assessment of Pulmonary Hypertension. 2013 , 6, 507-516	
1637	Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome. 2013 , 168, 4784-9	42
1636	Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. 2013 , 280, 2042-55	36
1635	Pulmonary hypertension update from CHEST 2012. 2013 , 67, 2-4	
1634	The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis. 2013 , 30, 258-65	61
1633	Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension. 2013 , 43, 1016-24	16
1632	Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. 2013 , 65, 1074-84	107
1631	Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. 2013 , 52, 155-60	122
1630	Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation. 2013 , 27, 25-31	16
1629	Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension. 2013 , 23, 324-31	60
1628	Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. 2013 , 191, 61-7	30
1627	The strain-encoded (SENC) MR imaging for detection of global right ventricular dysfunction in pulmonary hypertension. 2013 , 29, 371-8	17
1626	Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. 2013 , 52, 1208-13	50
1625	New trial designs and potential therapies for pulmonary artery hypertension. 2013 , 62, D82-91	90

1624	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. 2013 , 32, 1114-22	74
1623	Patient selection and preoperative evaluation for transplant surgery. 2013 , 31, 689-704	4
1622	Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. 2013 , 168, 1370-7	29
1621	Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. 2013 , 147, 71-8	11
1620	Hipertensiñ arterial pulmonar. 2013 , 11, 2625-2633	
1619	Pulmonary hypertension in chronic obstructive and interstitial lung diseases. 2013 , 168, 1795-804	22
1618	Recommendations for long-term home oxygen therapy in children and adolescents. 2013 , 89, 6-17	
1617	Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. 2013 , 164, 64-9	49
1616	Predictors of pulmonary hypertension after intermediate-to-high risk pulmonary embolism. 2013 , 32, 857-64	12
1615	Recommendations for the management and treatment of systemic sclerosis. 2013 , 53, 258-275	1
1614	69-year-old woman with ascites, hypoxia, and weight loss. 2013 , 88, 1475-9	
1613	Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. 2013 , 32, 123-129	11
1612	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. 2013 , 168, 871-80	231
1611	Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. 2013 , 6, 1036-1047	104
1610	Pulmonary hypertension is a mild comorbidity in end-stage cystic fibrosis patients. 2013 , 32, 609-14	17
1609	Right ventricular stroke work index as a negative predictor of mortality and initial hospital stay after lung transplantation. 2013 , 32, 603-8	28
1608	An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: emerging role of CT-proET-1. 2013 , 32, 1214-21	20
1607	Lung ventilation/perfusion scintigraphy in pulmonary capillary hemangiomatosis: A pattern to consider. 2013 , 32, 98-101	

1606	Regulation of cardiovascular connexins by mechanical forces and junctions. 2013 , 99, 304-14	33
1605	The unnatural history of an atrial septal defect: longitudinal 35 year follow up after surgical closure at young age. 2013 , 99, 1346-52	56
1604	Single-lobe lung transplantation for rapidly deteriorating pulmonary venoocclusive disease. 2013 , 95, 689-91	7
1603	Lung ventilation/perfusion scintigraphy in pulmonary capillary hemangiomatosis: a pattern to consider. 2013 , 32, 98-101	2
1602	Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. 2013 , 32, 347-54	58
1601	Right isovolumic contraction velocity predicts survival in pulmonary hypertension. 2013 , 26, 297-306	47
1600	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. 2013 , 381, 1116-24	100
1599	Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. 2013 , 29, 678-82	33
1598	Pulmonary arterial hypertension associated with congenital heart disease. 2013 , 34, 707-17	9
1597	Plasma N-terminal pro-brain natriuretic peptide levels are positively correlated with pulmonary arterial pressure in atrial septal defect patients. 2013 , 183, 13-6	2
1596	Reply to letter to the Editor. 2013 , 42, 229-30	
1595	Inhaled nitric oxide versus sodium nitroprusside for preoperative evaluation of pulmonary hypertension in heart transplant candidates. 2013 , 45, 2746-9	9
1594	Common intronic D variant of ACE gene is associated with endothelial dysfunction in COPD. 2013 , 107, 1217-21	11
1593	Mujer de 66 años con disnea e inestabilidad hemodinámica. 2013 , 11, 2667.e1-2667.e4	
1592	Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine. 2013 , 167, 848-54	6
1591	Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. 2013 , 111, 278-85	47
1590	A simple echocardiographic method to estimate pulmonary vascular resistance. 2013 , 112, 873-82	50
1589	Protocolo diagnóstico y terapéutico de la hipertensión arterial pulmonar. 2013 , 11, 2649-2653	

1588	Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. 2013 , 164, 323-6	46
1587	Foudroyant right heart failure in a 25-year-old female struck by alternating current: a potential role of electric shock in the development of pulmonary arterial hypertension. 2013 , 169, e40-2	
1586	[Pulmonary hypertension in patients infected with human immunodeficiency virus: current situation]. 2013 , 31, 461-70	
1585	Recomendações de 2012 da ESC para o diagnóstico e o tratamento da insuficiência cardíaca aguda e crônica. 2013 , 32, 641.e1-641.e61	
1584	Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. 2013 , 32, 123-9	16
1583	Heart failure: not only reduced left ventricular ejection fraction but also reserved ejection fraction!. 2013 , 42, 229	2
1582	Clinical features of adult patients with Eisenmenger's syndrome in Japan and Korea. 2013 , 167, 205-9	4
1581	Long-term clinical course of acute pulmonary embolism. 2013 , 27, 185-92	21
1580	Cardiovascular parameters of computed tomographic pulmonary angiography to assess pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. 2013 , 164, 295-300	16
1579	Recomendações sobre diagnóstico e tratamento da esclerose sistêmica. 2013 , 53, 258-275	5
1578	[Pulmonary hypertension, heart failure and hyperthyroidism: a case report]. 2013 , 32, 253-6	3
1577	Determinants of clinical right ventricular failure after congenital heart surgery in adults. 2013 , 27, 723-7	26
1576	Pressure reflection in the pulmonary circulation by echocardiography in patients with left heart disease indicates reactive pulmonary hypertension. 2013 , 168, 4222-7	2
1575	Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension. 2013 , 30, 17-26	20
1574	Assessment and treatment of right ventricular failure. 2013 , 10, 204-18	61
1573	Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. 2013 , 187, 576-83	190
1572	Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. 2013 , 173, 887-93	98
1571	When to initiate intravenous therapy and/or refer. 2013 , 111, 21C-4C	1

1570	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. 2013 , 187, 294-302	126
1569	Methods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculature. 2013 , 41, 1384-98	52
1568	Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review. 2013 , 43, 751-60	9
1567	Recommendations for long-term home oxygen therapy in children and adolescents. 2013 , 89, 6-17	10
1566	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). 2013 , 125, 200-19	36
1565	Pulmonary Vascular Disease. 2013 , 603-625	1
1564	Pregnancy and Heart Disease. 2013 , 655-667	
1563	The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study. 2013 , 91, 178-84	12
1562	Haemodynamic responses to exercise in patients with COPD. 2013 , 41, 1031-41	67
1561	Human immunodeficiency virus-associated pulmonary arterial hypertension. 2013 , 34, 283-92	26
1560	Pulmonary hypertension in β -thalassaemia. 2013 , 1, 488-96	11
1559	Magnetic resonance as an alternative imaging method for the evaluation of patients with pulmonary hypertension. 2013 , 82, 195-6	2
1558	Outcomes after single lung transplantation in older patients with secondary pulmonary arterial hypertension. 2013 , 32, 134-6	4
1557	From extracorporeal membrane oxygenation to ventricular assist device oxygenation without sternotomy. 2013 , 32, 138-9	22
1556	Early versus delayed right heart catheterization in evaluation of pulmonary arterial hypertension. 2013 , 32, 137-8	1
1555	The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox". 2013 , 107, 139-46	43
1554	Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device. 2013 , 16, 101-4	13
1553	Hypertension artfielle pulmonaire de la sclfodermie systfmique. 2013 , 38, 71-72	

1552	Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension. 2013 , 112, 1505-9		11
1551	Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. 2013 , 128, 2622-703		183
1550	Reactive oxygen species and antioxidants in pulmonary hypertension. 2013 , 18, 1789-96		83
1549	Update of the echocardiography core syllabus of the European Association of Cardiovascular Imaging (EACVI). 2013 , 14, 837-9		47
1548	Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. 2013 , 48, 374-81		32
1547	Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. 2013 , 22, 535-42		85
1546	Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance. 2013 , 14, 890-7		37
1545	TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. 2013 , 50, 500-6		115
1544	ESC core curriculum for the general cardiologist (2013). <i>European Heart Journal</i> , 2013 , 34, 2381-411	9.5	56
1543	Surgical cure of central sleep apnea?. 2013 , 188, 395-6		4
1542	Cardiac magnetic resonance imaging in pulmonary arterial hypertension. 2013 , 22, 526-34		54
1541	[Early diagnosis and therapy in pulmonary hypertension--aspects of a vision]. 2013 , 67, 376-87		0
1540	[Connective tissue disease-related pulmonary arterial hypertension--a pathology beyond the precapillary vessels]. 2013 , 138, 2201-6		
1539	Clinical significance of electrocardiographic right ventricular hypertrophy in athletes: comparison with arrhythmogenic right ventricular cardiomyopathy and pulmonary hypertension. <i>European Heart Journal</i> , 2013 , 34, 3649-56	9.5	64
1538	Pulmonale Hypertonie bei Linksherzinsuffizienz [Aktuelle Studien]. 2013 , 67, S112-S113		3
1537	Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension. 2013 , 65, 2403-11		38
1536	Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension. 2013 , 3, 639-46		11
1535	Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists. 2013 , 3, 792-801		7

1534	Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. 2013 , 187, 303-10	36
1533	Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2013 , 14, 104	64
1532	Updating clinical endpoint definitions. 2013 , 3, 206-16	19
1531	From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. 2013 , 3, 507-22	5
1530	Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. 2013 , 34, 645-53	11
1529	Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. 2013 , 3, 100-7	30
1528	Pim-1: A new biomarker in pulmonary arterial hypertension. 2013 , 3, 74-81	31
1527	Non-invasive evaluation of hemodynamics in pulmonary hypertension by a Septal angle measured by computed tomography pulmonary angiography: Comparison with right-heart catheterization and association with N-terminal pro-B-type natriuretic peptide. 2013 , 6, 1350-1358	3
1526	Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients. 2013 , 6, 906-12	45
1525	Iloprost improves ventricular function in the hypertrophic and functionally impaired right heart by direct stimulation. 2013 , 3, 870-9	8
1524	European Perspectives. 2013 , 127,	
1523	Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. 2013 , 41, 872-8	44
1522	Enhancing the accuracy of echocardiography in the diagnosis of pulmonary arterial hypertension: looking at the heart to learn about the lungs. 2013 , 19, 437-45	20
1521	Management of pulmonary arterial hypertension. 2013 , 19, 44-50	7
1520	Cyber support: describing concerns of caregivers of people with pulmonary hypertension. 2013 , 31, 581-8	4
1519	Magnetic resonance and computed tomography imaging of the structural and functional changes of pulmonary arterial hypertension. 2013 , 28, 178-93	18
1518	Pulmonary Hypertension and Management of Perioperative Right Ventricular Failure. 2013 , 41, 115-124	1
1517	Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause. 2013 , 19, 421-5	9

1516	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. 2013 , 41, 224-32	78
1515	Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. 2013 , 40, 1127-33	35
1514	Right ventricular load and function during exercise in patients with open and closed atrial septal defect type secundum. 2013 , 20, 597-604	13
1513	Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. 2013 , 128, 1470-9	244
1512	BIOMECHANICAL APPROACH TO THE CLINICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION. 2013 , 13, 1340005	3
1511	A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges. 2013 , 7, 119-23	13
1510	Pathology and diagnosis of pulmonary arterial hypertension. 2013 , 24-39	
1509	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. 2013 , 22, 515-25	20
1508	Treatment of Pulmonary Arterial Hypertension. 2013 , 596-605	
1507	Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. 2013 , 42, 689-700	80
1506	Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. 2013 , 85, 471-7	19
1505	Noninvasive assessment of right heart function and hemodynamics during exercise in patients with pulmonary arterial hypertension. 2013 , 106, 141-6	4
1504	Wrist actigraphy predicts outcome in patients with pulmonary hypertension. 2013 , 86, 45-51	29
1503	Central venous catheter infections in outpatients with pulmonary hypertension treated with continuous iloprost. 2013 , 86, 402-6	11
1502	Distinguishing pulmonary hypertension in interstitial lung disease by ventilation and perfusion defects measured by cardiopulmonary exercise testing. 2013 , 86, 407-13	14
1501	ACR Appropriateness Criteria [®] pulmonary hypertension. 2013 , 28, W57-60	9
1500	Pulse pressure variation is comparable with central venous pressure to guide fluid resuscitation in experimental hemorrhagic shock with endotoxemia. 2013 , 40, 303-11	5
1499	Pressure reflection in the pulmonary circulation in patients with severe mitral regurgitation indicates adverse postoperative outcome. 2013 , 44, 1037-44	1

1498	Pulmonary hypertension in Portugal: first data from a nationwide registry. 2013 , 2013, 489574	34
1497	A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. 2013 , 3, 381-8	12
1496	A practical approach of pulmonary hypertension in the elderly. 2013 , 34, 654-64	15
1495	Prevalence, clinical characteristics and outcome of pulmonary hypertension among admitted heart failure patients. 2013 , 12, 197-204	12
1494	Pulmonary hypertension in Saudi Arabia: A single center experience. 2013 , 8, 78-85	18
1493	Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. 2013 , 3, 89-94	62
1492	Effect of bosentan on exercise capacity and clinical worsening in patients with dual down and Eisenmenger syndrome. 2013 , 7, 29-34	16
1491	A Case of Patient with Eisenmenger Syndrome Admitted to Intensive Care Unit Due to Septic Shock Complicated with Newlydiagnosed Down Syndrome and Moyamoya Disease. 2013 , 28, 204	
1490	Assesment of Right Ventricular Diastolic Function in Chronic Obstructive Lung Disease. 2013 , 13, 152-157	
1489	Pulmonary Arterial Hypertension Centre – Model for Rare Disease Management / Centrum pre pŕnu artŕiovŕhypertenziu – model v manaŕmente zriedkavŕh chorŕb. 2013 , 60, 22-25	
1488	Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. 2013 , 29, 889-99	7
1487	Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. 2013 , 18, 1271-7	24
1486	Prognostic relevance of a non-invasive evaluation of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. 2013 , 15, 408-14	89
1485	Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. 2013 , 18, 1076-82	25
1484	High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. 2013 , 8, 520-6	29
1483	Pulmonary hypertension in patients with chronic and end-stage kidney disease. 2013 , 84, 682-92	74
1482	Prostacyclin withdrawal in pulmonary hypertension #264. 2013 , 16, 204-5	1
1481	Comparison of right ventricular systolic function in patients with low risk and intermediate-to-high risk pulmonary embolism: a two-dimensional strain imaging study. 2013 , 30, 301-8	11

1480	Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of Eatenin. 2013 , 304, L103-11	28
1479	High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. 2013 , 29, 231-4	28
1478	Building a pulmonary vascular service: the 12-year experience and outcomes of the Auckland pulmonary arterial hypertension clinic. 2013 , 43, 635-42	2
1477	Echocardiographic assessment in a patient with vasoreactive pulmonary hypertension. 2013 , 30, 419-25	2
1476	Advantages of real time three-dimensional echocardiography in the assessment of right ventricular volumes and function in patients with pulmonary hypertension compared with conventional two-dimensional echocardiography. 2013 , 30, 820-8	21
1475	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. 2013 , 128, 2005-15	149
1474	Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. 2013 , 128, 2016-25, 1-10	228
1473	A virtual community: concerns of patients with pulmonary hypertension. 2013 , 22, 155-71	18
1472	Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension. 2013 , 112, 227-9	10
1471	Angiostrongylosis clinical forum: a case presenting in a Terrier. 2013 , 18, 315-321	2
1470	Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. 2013 , 18, 60-9	9
1469	Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. 2013 , 9, 1077-90	30
1468	Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. 2013 , 3, 632-8	28
1467	Does left heart disease cause most systemic sclerosis associated pulmonary hypertension?. 2013 , 42, 888-90	12
1466	Optical coherence tomography is superior to intravascular ultrasound for diagnosis of distal-type chronic thromboembolic pulmonary hypertension. 2013 , 77, 1081-3	31
1465	Noninvasive and simple assessment of cardiac output and pulmonary vascular resistance with whole-body impedance cardiography is useful for monitoring patients with pulmonary hypertension. 2013 , 77, 2383-9	12
1464	Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. 2013 , 77, 2619-25	114
1463	A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?. 2013 , 77, 2477-8	2

1462	Being mindful of pulmonary arterial hypertension. 2013 , 8, 127-133	
1461	The distance walked daily as a post-operative measure after pulmonary endarterectomy. 2013 , 20, 195-199	3
1460	Pulmonary artery occlusion pressure may overdiagnose pulmonary artery hypertension in sickle cell disease. 2013 , 36, 524-30	9
1459	Management of chronic thromboembolic pulmonary hypertension: current status and emerging options. 2013 , 10, 345-357	2
1458	Practical recommendations on the use of echocardiography to assess pulmonary arterial hypertension--a Belgian expert consensus endorsed by the Working Group on Non-Invasive Cardiac Imaging. 2013 , 68, 59-69	9
1457	Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure. 2014 , 1, 143-51	2
1456	Pulmonary Hypertension and Right Heart Failure in Chronic Kidney Disease: New Challenge for 21st-Century Cardiologists. 2013 , 3, 96-103	23
1455	Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension. 2013 , 144, 959-965	10
1454	Frequency of mediastinal lymphadenopathy in patients with idiopathic pulmonary arterial hypertension. 2013 , 143, 344-348	9
1453	Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. 2013 , 144, 160-168	70
1452	Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2013 , 144, 522-530	37
1451	Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. 2013 , 143, 758-766	266
1450	Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. 2013 , 143, 324-332	102
1449	Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. 2013 , 144, 1521-1529	58
1448	WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension. 2013 , 144, 638-650	36
1447	A pathophysiological approach towards right ventricular function and failure. 2013 , 30, 386-94	9
1446	Imaging techniques in chronic thromboembolic pulmonary hypertension. 2013 , 19, 562-74	11
1445	Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. 2013 , 52, 1061-5	7

1444	Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease. 2013 , 28, 1200-6	14
1443	Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia. 2013 ,	1
1442	Chronic Thromboembolic Pulmonary Hypertension. 2013 ,	
1441	Endogenous estrogen attenuates hypoxia-induced pulmonary hypertension by inhibiting pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cells proliferation. 2013 , 10, 771-81	15
1440	A Case of Pulmonary Hypertension Recurred by Graves' Disease. 2013 , 28, 171	
1439	Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. 2013 , 7, 401-9	7
1438	Pulmonary arterial hypertension: diagnosis and treatment. 2013 , 3, 273-279	
1437	Cardiopulmonary Disease in SLE. 2013 , 352-362	
1436	Paradoxical interventricular septal motion as a major determinant of late gadolinium enhancement in ventricular insertion points in pulmonary hypertension. 2013 , 8, e66724	26
1435	Echocardiographic parameters in patients with pulmonary arterial hypertension: correlations with right ventricular ejection fraction derived from cardiac magnetic resonance and hemodynamics. 2013 , 8, e71276	24
1434	Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. 2013 , 8, e73502	14
1433	The E-wave deceleration rate E/DT outperforms the tissue Doppler-derived index E/e' in characterizing lung remodeling in heart failure with preserved ejection fraction. 2013 , 8, e82077	7
1432	[Pulmonary hypertension associated with connective tissue diseases]. 2013 , 141, 58-62	1
1431	Pulmonary Arterial Hypertension: An Overview. 2013 ,	
1430	Right Chambers Quantification in Clinical Practice: Echocardiography Compared with Cardiac Magnetic Resonance Imaging. 2013 ,	2
1429	20.4 Extrapulmonale, nicht kardial bedingte Dyspnoe. 2013 ,	
1428	Perioperative Considerations of Patients with Pulmonary Hypertension. 2013 ,	2
1427	Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. 2013 , 9, 593-601	87

1426	Physiological Manifestation in Pulmonary Sarcoidosis. 2013 ,	
1425	Echocardiographic assessment of right heart indices in dogs with elevated pulmonary artery pressure associated with chronic respiratory disorders, heartworm disease, and chronic degenerative mitral valvular disease. 2013 , 58, 613-620	7
1424	REMODELING OF THE RIGHT HEART AND THE LEVEL OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A COMPARATIVE CROSS-SECTIONAL OBSERVATIONAL STUDY. 2013 , 9, 258-264	1
1423	Macitentan: A new option in the treatment of pulmonary arterial hypertension. 2014 , 9, 198-199	
1422	Flow characteristics of the proximal pulmonary arteries and vena cava in patients with chronic thromboembolic pulmonary hypertension: correlation between 3.0 T phase-contrast MRI and right heart catheterization. 2014 , 20, 414-20	2
1421	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. 2014 , 9, 71-80	9
1420	Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension. 2014 , 55, 1526-32	10
1419	Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease. 2014 , 9, e106163	39
1418	Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. 2014 , 9, e107809	14
1417	Identification of a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension in a large family with mean clinical follow-up of 12 years. 2014 , 9, e91374	15
1416	Supplementing exposure to hypoxia with a copper depleted diet does not exacerbate right ventricular remodeling in mice. 2014 , 9, e92983	7
1415	Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. 2014 , 9, e100261	36
1414	Key role of the endothelial TGF- β /ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. 2014 , 9, e100310	67
1413	Hypoxia and exercise increase the transpulmonary passage of 99mTc-labeled albumin particles in humans. 2014 , 9, e101146	16
1412	Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. 2014 , 9, e104890	31
1411	Utility of the physical examination in detecting pulmonary hypertension. A mixed methods study. 2014 , 9, e108499	18
1410	Two-dimensional echocardiography in the assessment of long-term prognosis in patients with pulmonary arterial hypertension. 2014 , 9, e114443	1
1409	Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension. 2014 , 10, 1055-6	

1408	Heart diastolic dysfunction in patients with systemic sclerosis. 2014 , 10, 445-54	11
1407	The Significance of Pulmonary Artery Size in Pulmonary Hypertension. 2014 , 2, 243-259	17
1406	Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate. 2014 , 2, 7	25
1405	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. 2015 , 66, 270-6	11
1404	The Role of Extracellular Matrix in Lung Diseases. 2014 , 06,	6
1403	Right Ventricular Geometry and Function in Pulmonary Hypertension: Non-Invasive Evaluation. 2014 , 2, 274-295	3
1402	[Spontaneous rupture of tricuspid valve papillary muscle in pulmonary hypertension secondary to HIV infection. Report of one case]. 2014 , 142, 246-9	1
1401	A 53-year-old woman with thrombocytosis and pulmonary embolism. 2014 , 10, 191-4	1
1400	Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. 2014 , 10, 825-39	21
1399	Clinical characteristics and survival of Korean idiopathic pulmonary arterial hypertension patients based on vasoreactivity. 2014 , 29, 1665-71	2
1398	Pulmonary Rehabilitation. 2014 , 411-422	
1397	CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND PROBLEMS OF RARE AND INTERDISCIPLINARY DISEASE. 2014 , 10, 73-78	1
1396	Large serpiginous thrombus straddling the patent foramen ovale and traversing through mitral and tricuspid valves into both ventricles: a therapeutic dilemma of impending paradoxical embolism and recurrent pulmonary embolism. 2014 , 8, 1-13	2
1395	Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. 2014 , 40, 609-16	13
1394	Fatal haemolytic crisis with microvascular pulmonary obstruction mimicking a pulmonary embolism in a young African man with glucose-6-phosphate dehydrogenase deficiency. 2014 , 2014,	4
1393	Treatment of trivalvular rheumatic heart disease: why it matters where we live. 2014 , 2014,	
1392	Genetic susceptibility to hepatotoxicity due to bosentan treatment in pulmonary hypertension. 2014 , 13, 803-809	11
1391	14.4 Pulmonale venookklusive Erkrankung (PVOD). 2014 ,	

1390	Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. 2014 , 43, 912-4	45
1389	Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. 2014 , 100, 224-30	30
1388	Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. 2014 , 44, 963-72	72
1387	Management of pulmonary hypertension due to heart failure with preserved ejection fraction. 2014 , 16, 501	3
1386	The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. 2014 , 14, 676	53
1385	Predicting prognosis of children with pulmonary arterial hypertension: the importance of multimodal expert assessment. 2014 , 100, 1305-7	5
1384	Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. 2014 , 8, 71-77	11
1383	Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension. 2014 , 12, 1391-9	2
1382	Novel serum biomarkers in pulmonary arterial hypertension. 2014 , 8, 1001-11	4
1381	Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort. 2014 , 43, 314-23	11
1380	Selexipag for the treatment of pulmonary arterial hypertension. 2014 , 15, 429-36	23
1379	Sildenafil for the treatment of pulmonary hypertension in children. 2014 , 12, 1157-84	12
1378	Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. 2014 , 2014, 704094	12
1377	Predicting mortality after congenital heart surgeries: evaluation of the Aristotle and Risk Adjustment in Congenital Heart Surgery-1 risk prediction scoring systems: a retrospective single center analysis of 1150 patients. 2014 , 17, 266-70	13
1376	Presurgical pulmonary evaluation in renal transplant patients. 2014 , 6, 605-12	3
1375	Macitentan in pulmonary arterial hypertension: The SERAPHIN trial. 2014 , 2014, 26-30	2
1374	Noninvasive imaging of pulmonary hypertension. 2014 , 35, 99-111	10
1373	Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model. 2014 , 177, 423-8	20

1372	Systems approach to the study of stretch and arrhythmias in right ventricular failure induced in rats by monocrotaline. 2014 , 115, 162-72		20
1371	State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series). 2014 , 4, 158-68		18
1370	Pulmonary hypertension caused by pulmonary venous hypertension. 2014 , 4, 581-95		13
1369	Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. 2014 , 2014, 147040		27
1368	Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. 2014 , 2014, 617565		9
1367	Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension. 2014 , 41, 159-64		10
1366	Right heart functional changes in the acute, hypercapnic exacerbations of COPD. 2014 , 2014, 596051		9
1365	Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis. 2014 , 35, 362-71		31
1364	Depression in pulmonary arterial hypertension and interstitial lung diseases. 2014 , 6, 240-9		10
1363	Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. 2014 , 2014, 743868		8
1362	State of the art: pulmonary hypertension. 2014 , 10, 188-197		1
1361	Rescue balloon pulmonary angioplasty in a rapidly deteriorating chronic thromboembolic pulmonary hypertension patient with liver failure and refractory infection. 2014 , 4, 142-7		17
1360	Pulmonary Manifestations of Systemic Lupus Erythematosus (SLE). 2014 , 61-72		2
1359	Clinical value of echocardiographic Doppler-derived right ventricular dp/dt in patients with pulmonary arterial hypertension. 2014 , 15, 1411-9		24
1358	Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. <i>European Heart Journal</i> , 2014 , 35, 725-32	9.5	156
1357	Living with pulmonary hypertension: unique insights from an international ethnographic study. 2014 , 4, e004735		24
1356	Measuring health in pulmonary hypertension: emphasising the right end-point?. 2014 , 43, 960-2		1
1355	emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. 2014 , 43, 1106-13		82

1354	Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. 2014 , 145, 1055-1063	32
1353	Anticoagulation therapy versus placebo for pulmonary hypertension. 2014 , CD010695	6
1352	Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. 2014 , 4, 311-8	40
1351	[Chronic thromboembolic pulmonary hypertension: Time delay from onset of symptoms to diagnosis and clinical condition at diagnosis]. 2014 , 139, 1647-52	14
1350	[Chronic thromboembolic pulmonary hypertension--a position paper]. 2014 , 139 Suppl 4, S155-65	1
1349	[Cardiac sarcoidosis: diagnostic and therapeutic algorithms]. 2014 , 68, 124-32	10
1348	[Supportive therapy in pulmonary arterial hypertension]. 2014 , 139 Suppl 4, S136-41	4
1347	[Echocardiography and right heart catheterization in pulmonal hypertension]. 2014 , 139, 1511-7	4
1346	Pulmonary hypertension in patients with advanced heart failure is associated with increased levels of interleukin-6. 2014 , 19, 385-90	9
1345	Cardiac MRI as a diagnostic tool in pulmonary hypertension. 2014 , 10, 117-30	8
1344	Chronic thromboembolic pulmonary hypertension (CTEPH) - potential role of multidetector-row CT (MD-CT) and MR imaging in the diagnosis and differential diagnosis of the disease. 2014 , 186, 751-61	14
1343	[Vulnerando sanamus]. 2014 , 139, 1645-6	
1342	Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation. 2014 , 19, 675-82	22
1341	Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. 2014 , 271, 373-80	39
1340	Preoperative pulmonary hypertension and its impact on survival after heart transplantation. 2014 , 48, 47-58	8
1339	Improving patient care in pulmonary arterial hypertension: addressing psychosocial issues. 2014 , 16, 159-61	5
1338	Managing cardiovascular disease during pregnancy: best practice to optimize outcomes. 2014 , 10, 421-33	4
1337	Adiponectin levels are elevated in patients with pulmonary arterial hypertension. 2014 , 37, 21-5	21

1336	Mutations of NOTCH3 in childhood pulmonary arterial hypertension. 2014 , 2, 229-39		37
1335	Global and regional right ventricular dysfunction in pulmonary hypertension. 2014 , 31, 164-71		14
1334	Prevalence and spectrum of conditions associated with severe tricuspid regurgitation. 2014 , 31, 558-62		27
1333	Identification of treatment goals in paediatric pulmonary arterial hypertension. 2014 , 44, 1616-26		63
1332	Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity. 2014 , 8, 404-9		6
1331	Medical and Surgical Management for Chronic Thromboembolic Pulmonary Hypertension: A Single Center Experience. 2014 , 50, 521-527		1
1330	Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. 2014 , 171, 567-79		62
1329	Grupo de Trabajo Conjunto sobre cirugía no cardíaca: Evaluación y manejo cardiovascular de la Sociedad Europea de Cardiología (ESC) y la European Society of Anesthesiology (ESA). 2014 , 67, 1052.e1-1052.e43		3
1328	Chronic Thromboembolic Pulmonary Hypertension: Experience Improves Outcomes. 2014 , 50, 507-508		
1327	Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study. 2014 , 52, 357-64		37
1326	Pulmonary venous hypertension vs. pulmonary arterial hypertension: usefulness of echocardiography in the case of misleading heart catheterization data. 2014 , 177, e102-4		
1325	A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology. 2014 , 2, e12133		14
1324	Echocardiographic evolution of pulmonary artery pressure after acute pulmonary embolism. Results from IPER registry. 2014 , 134, 1224-8		6
1323	Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials. 2014 , 68, 568-77		6
1322	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , 35, 2383-431	9.5	849
1321	Pattern of resolution of pulmonary hypertension, long-term allograft right ventricular function, and exercise capacity in high-risk heart transplant recipients listed under oral sildenafil. 2014 , 28, 837-43		7
1320	Clinical outcome of isolated tricuspid regurgitation. 2014 , 7, 1185-94		269
1319	LGE patterns in pulmonary hypertension do not impact overall mortality. 2014 , 7, 1209-17		62

1318	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. 2014 , 43, 1691-7	214
1317	Characterization of echocardiographic measures of cardiac structure and function in healthy octogenarians. 2014 , 31, 1062-70	5
1316	Fontan-like circulation as a criterion for heart transplantation in arrhythmogenic right ventricular dysplasia. 2014 , 126, 705-9	2
1315	Six-minute walk distance target in elderly patients with idiopathic pulmonary arterial hypertension - consideration of predicted values. 2014 , 68, 543-50	2
1314	Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells. 2014 , 57, 442-50	61
1313	Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. 2014 , 37, 365-70	31
1312	Riociguat for pulmonary hypertension. 2014 , 7, 259-70	6
1311	Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. 2014 , 16, 444-53	19
1310	Pulmonary hypertension in mitral regurgitation. 2014 , 3,	39
1309	Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. 2014 , 87, 379-87	62
1308	Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?. 2014 , 44, 1404-7	3
1307	Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. 2014 , 100, 960-8	95
1306	A retrospective study on the effects of pulmonary rehabilitation in patients with pulmonary hypertension. 2014 , 11, 153-162	11
1305	Chronic thromboembolic pulmonary hypertension. 2014 , 22, 533-41	10
1304	Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. 2014 , 7, 100-6	67
1303	Therapeutic options in pulmonary hepatic vascular diseases. 2014 , 7, 31-42	9
1302	A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. 2014 , 44, 415-24	33
1301	Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. 2014 , 14, 45	43

1300	Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. 2014 , 3,	92
1299	Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing. 2014 , 3, e000520	28
1298	High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. 2014 , 7, 116-22	123
1297	Improving outcomes for pulmonary hypertension. 2014 , 9, 32-40	
1296	Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension. 2014 , 44, 704-13	41
1295	Pulmonary hypertension and pregnancy: an overview. 2014 , 57, 806-26	14
1294	Acute pulmonary hypertension after transjugular intrahepatic portosystemic shunt: a potentially deadly but commonly forgotten complication. 2014 , 37, 33-8; quiz 39-40	3
1293	Goal-oriented treatment of pulmonary arterial hypertension. 2014 , 20, 409-13	3
1292	Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the art. 2014 , 29, 68-79	49
1291	Translational research in pulmonary hypertension: challenge and opportunity. 2014 , 43, 325-8	
1290	The changing landscape of pulmonary arterial hypertension and implications for patient care. 2014 , 23, 450-7	81
1289	The role of combination therapy in managing pulmonary arterial hypertension. 2014 , 23, 469-75	35
1288	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). 2014 , 31, 517-73	242
1287	Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. 2014 , 29, 178-84	36
1286	The ratio of (18)F-FDG activity uptake between the right and left ventricle in patients with pulmonary hypertension correlates with the right ventricular function. 2014 , 39, 426-30	25
1285	Measuring microangiopathy abnormalities in systemic sclerosis patients: the role of capillaroscopy-based scoring models. 2014 , 348, 331-6	15
1284	Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. 2014 , 7, 107-14	111
1283	Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. 2014 , 55, 223-5	17

1282	Insulin resistance in pulmonary arterial hypertension, is it a novel disease modifier?. 2014 , 3, e19710	16
1281	Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. 2014 , 44, 425-34	48
1280	The assessment of breathlessness in pulmonary arterial hypertension: reliability and validity of the Dyspnoea-12. 2014 , 13, 506-14	25
1279	Incidence, predictors, and clinical course of atrial tachyarrhythmias in patients with pulmonary hypertension. 2014 , 41, 9-14	6
1278	Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. 2014 , 44, 1635-45	140
1277	High-Flow Nasal Cannula Therapy in a Patient with Reperfusion Pulmonary Edema following Percutaneous Transluminal Pulmonary Angioplasty. 2014 , 2014, 837612	4
1276	Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience. 2014 , 31, 354-60	14
1275	"Pulmonary hypertension in Saudi Arabia: A single center experience," which was published in the previous issue of Annals of Thoracic Medicine. 2014 , 9, 49	
1274	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. 2014 , 9, S1-S15	7
1273	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease. 2014 , 9, S47-55	6
1272	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia. 2014 , 9, S56-61	6
1271	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pregnancy in pulmonary hypertension. 2014 , 9, S108-12	6
1270	Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. 2014 , 9, 209-15	17
1269	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
1268	Transplantation in end-stage pulmonary hypertension (Third International Right Heart Failure Summit, part 3). 2014 , 4, 717-27	5
1267	Saudi guidelines on the treatment and management of pulmonary hypertension 2014: Updates a fresh understanding of pulmonary vascular diseases in the developing world. 2014 , 9, 131-3	
1266	Pulmonary hypertension and right heart dysfunction in chronic lung disease. 2014 , 2014, 739674	50
1265	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. 2014 , 4, 669-78	14

1264	Red blood cell distribution width predicts survival in patients with Eisenmenger syndrome. 2014 , 52, 743-50	8
1263	Noninvasive imaging for the diagnosis and prognosis of pulmonary hypertension. 2014 , 12, 71-86	7
1262	Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension. 2014 , 21, 1481-3	5
1261	Quantitative Doppler-echocardiographic imaging and clinical outcomes with left ventricular systolic dysfunction: independent effect of pulmonary hypertension. 2014 , 7, 330-6	18
1260	Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease. 2014 , 15, 476-80	3
1259	Prevalence of undiagnosed chronic thromboembolic pulmonary hypertension after pulmonary embolism. 2014 , 25, 649-53	15
1258	Dual-energy computed tomography in the assessment of vascular and parenchymal enhancement in suspected pulmonary hypertension. 2014 , 29, 98-106	30
1257	Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley--a high altitude region in Himachal Pradesh, India. 2014 , 15, 504-10	11
1256	Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. 2014 , 33, 800-8	38
1255	Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. 2014 , 30, 879-87	21
1254	Survey of the current status and management of Eisenmenger syndrome: a Japanese nationwide survey. 2014 , 63, 286-90	2
1253	Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. 2014 , 18, 487-90	2
1252	Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. 2014 , 175, 233-9	52
1251	Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views. 2014 , 27, 657-665.e3 ⁶⁵	
1250	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. 2014 , 167, 218-225.e1	21
1249	Clinical aspects of portopulmonary hypertension. 2014 , 108, 943-54	10
1248	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. 2014 , 172, 332-9	34
1247	Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. 2014 , 28, 87-89	6

1246	The genetic basis of pulmonary arterial hypertension. 2014 , 133, 471-9	62
1245	Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. 2014 , 33, 83-9	16
1244	Dual-energy CT perfusion and angiography in chronic thromboembolic pulmonary hypertension: diagnostic accuracy and concordance with radionuclide scintigraphy. 2014 , 24, 42-51	102
1243	Pulmonary veno-occlusive disease: the role of CT. 2014 , 119, 667-73	20
1242	Recovery from mitomycin-induced pulmonary arterial hypertension. 2014 , 11, 468-70	10
1241	Pulmonary hypertension in systemic lupus erythematosus: echocardiography-based definitions predict 6-year survival. 2014 , 53, 1256-63	19
1240	Macitentan for the treatment of pulmonary arterial hypertension. 2014 , 48, 538-47	15
1239	Cellular interplay in pulmonary arterial hypertension: implications for new therapies. 2014 , 1843, 885-93	21
1238	Red cell distribution width: a new predictor for chronic thromboembolic pulmonary hypertension after pulmonary embolism. 2014 , 11, 73-81	18
1237	Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort. 2014 , 33, 197-205	10
1236	Percutaneous interventional therapies for the treatment of patients with severe pulmonary hypertension. 2014 , 63, 611-618	30
1235	Management of cardiovascular diseases during pregnancy. 2014 , 39, 85-151	21
1234	Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. 2014 , 19, 743-58	6
1233	Empfehlungen zur Notfallechokardiographie. 2014 , 8, 45-64	7
1232	Konsensuspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung (DGK) zur Diagnostik und Therapie der kardialen Sarkoidose. 2014 , 8, 13-25	4
1231	Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. 2014 , 31, 168-79	9
1230	Pulmonary Hypertension and Thoracic Surgery: Diagnostics and Advances in Therapy and Intraoperative Management. 2014 , 4, 135-141	4
1229	Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature. 2014 , 119, 41-53	4

1228	Influence of percutaneous atrial septal defect closure on inter- and intra-ventricular mechanical dyssynchrony in adults: evaluation of strain pattern. 2014 , 30, 721-7		3
1227	Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. 2014 , 28, 45-51		4
1226	Impact of right ventricular dyssynchrony on left ventricular performance in patients with pulmonary hypertension. 2014 , 30, 713-20		12
1225	Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. 2014 , 34, 221-5		12
1224	Studies on Respiratory Disorders. 2014 ,		1
1223	Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. 2014 , 108, 531-7		29
1222	Pulmonary manifestations of systemic lupus erythematosus. 2014 , 35, 249-54		49
1221	Pulmonary hypertension and noncardiac surgery: implications for the anesthesiologist. 2014 , 28, 1064-74		16
1220	Pulmonary hypertension related to congenital heart disease: a call for action. <i>European Heart Journal</i> , 2014 , 35, 691-700	9.5	107
1219	STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. 2014 , 129, 1914-23		129
1218	Pulmonary hypertension and breathlessness: is it a combination we can ignore?. 2014 , 44, 114-23		4
1217	Biomarkers for the prognosis of pulmonary arterial hypertension: Holy Grail or flying circus?. 2014 , 33, 341-3		7
1216	Molecular characterization of reactive oxygen species in systemic and pulmonary hypertension. 2014 , 27, 643-50		37
1215	The patient with dyspnea. Rational diagnostic evaluation. 2014 , 39, 8-14		7
1214	Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. 2014 , 70, 13-21		10
1213	Echocardiographic assessment of right ventricular contractile reserve in patients with pulmonary hypertension. 2014 , 33, 155-63		18
1212	Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. 2014 , 66, 40-5		22
1211	Small Molecules in Oncology. 2014 ,		3

1210	Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension. 2014 , 118, 410-3	6
1209	Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation. 2014 , 20, 1081-8	28
1208	Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. 2014 , 63, 2159-2169	90
1207	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. 2014 , 211, 314-33	12
1206	[Pulmonary complications in liver diseases]. 2014 , 109, 235-9	1
1205	The Right Heart. 2014 ,	1
1204	[Endothelin: From discovery to pharmacotherapeutic innovations]. 2014 , 43, 742-55	0
1203	Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. 2014 , 144, 12-27	89
1202	Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. 2014 , 52, 167-72	4
1201	Reactive Oxygen Species and Antioxidants in Pulmonary Hypertension and Right Heart Failure. 2014 , 1671-1687	
1200	Pulmonary complications of cystic fibrosis. 2014 , 69, e153-62	12
1199	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. 2014 , 43, 526-35	91
1198	Acute decompensated heart failure and pulmonary hypertension. 2014 , 20, 63	1
1197	Targeted therapies in pulmonary arterial hypertension. 2014 , 141, 172-91	128
1196	Accelerated thrombolysis for pulmonary embolism: will clinical benefit be ULTIMATEly realized?. 2014 , 129, 420-1	17
1195	Prevalence and risk factors for pulmonary arterial hypertension in a large group of β -thalassemia patients using right heart catheterization: a Webthal study. 2014 , 129, 338-45	79
1194	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). 2014 , 123, 494-500	309
1193	Clinical diagnosis of pulmonary hypertension. 2014 , 130, 1820-30	79

1192	Right ventricular ejection efficiency: a new echocardiographic measure of mechanical performance in chronic pulmonary hypertension. 2014 , 31, 516-23	24
1191	Medical and surgical management for chronic thromboembolic pulmonary hypertension: a single center experience. 2014 , 50, 521-7	14
1190	Chronic thromboembolic pulmonary hypertension: experience improves outcomes. 2014 , 50, 507-8	
1189	Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. 2014 , 74, 2065-78	8
1188	Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. 2014 , 13, 391-405	51
1187	[Pulmonary hypertension--diagnostic and current concepts]. 2014 , 156, 49-52; quiz 53	
1186	Macitentan: a review of its use in patients with pulmonary arterial hypertension. 2014 , 74, 1495-507	7
1185	Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. 2014 , 29, 241-9	13
1184	Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. 2014 , 10, 481-501	27
1183	Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. 2014 , 43, 569-73	12
1182	Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. 2014 , 43, 534-40	18
1181	Improved survival of Korean patients with idiopathic pulmonary arterial hypertension after the introduction of targeted therapies. 2014 , 43, 561-8	4
1180	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. 2014 , 73, 420-7	28
1179	Prognostic impact of pulmonary artery systolic pressure in patients undergoing transcatheter aortic valve replacement for aortic stenosis. 2014 , 114, 1562-7	24
1178	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. 2014 , 73, 1340-9	444
1177	The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. 2014 , 51, 721-9	30
1176	Dual-energy CT for imaging of pulmonary hypertension: challenges and opportunities. 2014 , 34, 1769-90	60
1175	Transgelin as a therapeutic target to prevent hypoxic pulmonary hypertension. 2014 , 306, L574-83	23

1174	Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. 2014 , 115, 738-50	68
1173	Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. 2014 , 130, 496-507	42
1172	Complications cardiovasculaires du dopage. 2014 , 29, 220-226	
1171	Current and advancing treatments for pulmonary arterial hypertension in childhood. 2014 , 8, 615-28	2
1170	Exercise ventilatory parameters for the diagnosis of reactive pulmonary hypertension in patients with heart failure. 2014 , 20, 650-7	25
1169	Pulmonary endarterectomy: part I. Pathophysiology, clinical manifestations, and diagnostic evaluation of chronic thromboembolic pulmonary hypertension. 2014 , 18, 319-30	33
1168	Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. 2014 , 307, H1204-15	74
1167	Molecular imaging of the pulmonary circulation in health and disease. 2014 , 2, 415-426	8
1166	Impaired 6-min walk test, heart rate recovery and cardiac function post pulmonary embolism in long-term survivors. 2014 , 108, 1556-65	25
1165	Structural and mechanical adaptations of right ventricle free wall myocardium to pressure overload. 2014 , 42, 2451-65	61
1164	[Treatment of pulmonary arterial hypertension]. 2014 , 43, 981-93	0
1163	Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study. 2014 , 15, 666-72	47
1162	Prevalence and associated factors of pulmonary hypertension in Kenyan children with adenoid or adenotonsillar hypertrophy. 2014 , 78, 1381-6	6
1161	Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. 2014 , 64, 41-51	143
1160	Diagnosis of heart failure with preserved ejection fraction. 2014 , 10, 399-406	18
1159	Pulmonary vascular dysfunction in ARDS. 2014 , 4, 28	49
1158	Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014 , 35, 2032-9	9.5 25
1157	Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. 2014 , 43, 156-65	62

1156	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231
1155	Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. 2014 , 148, 1005-11; 1012.e1-2; discussion 1011-2		65
1154	Longitudinal strain of right ventricular free wall by 2-dimensional speckle-tracking echocardiography is useful for detecting pulmonary hypertension. 2014 , 111, 12-7		12
1153	Update on chronic thromboembolic pulmonary hypertension. 2014 , 130, 508-18		194
1152	Update in systemic sclerosis-associated pulmonary arterial hypertension. 2014 , 43, e293-304		20
1151	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. 2014 , 73, 191-7		35
1150	Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery. 2014 , 4, 10-24		19
1149	A symptom-related monitoring program following pulmonary embolism for the early detection of CTEPH: a prospective observational registry study. 2014 , 14, 141		34
1148	Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. 2014 , 14, 246		12
1147	Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents. 2014 , 7, 359		3
1146	Right ventricle free wall mechanics in metabolic syndrome without type-2 diabetes: effects of a 3-month lifestyle intervention program. 2014 , 13, 116		14
1145	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. 2014 , 108, 1626-32		55
1144	Portopulmonary hypertension: improved detection using CT and echocardiography in combination. 2014 , 24, 2385-93		13
1143	Development and pathologies of the arterial wall. 2014 , 71, 1977-99		20
1142	[Cor pulmonale and pulmonary hypertension. Update after the world conference in Nice]. 2014 , 39, 58-65		1
1141	Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension. 2014 , 41, 173-80		3
1140	Utility of combining assessment of right ventricular function and right atrial remodeling as a prognostic factor for patients with pulmonary hypertension. 2014 , 30, 1269-77		29
1139	Assessment of right ventricular geometry and mechanics in chronic obstructive pulmonary disease patients living at high altitude. 2014 , 30, 1305-13		2

1138	Influence on ICU course, outcome and costs for lung transplantation after implementation of the new Swiss transplantation law. 2014 , 3, 9		2
1137	Stress echo applications beyond coronary artery disease. <i>European Heart Journal</i> , 2014 , 35, 1033-40	9.5	69
1136	The exceptional and far-flung manifestations of heart failure in Eisenmenger syndrome. 2014 , 10, 91-104		12
1135	Pulmonary arterial hypertension in HIV infection: a concise review. 2014 , 23, 299-302		7
1134	Direct haemodynamic effects of pulmonary arteriovenous malformation embolisation. 2014 , 22, 328-33		17
1133	Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle. 2014 , 12, 13		24
1132	Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. <i>European Heart Journal</i> , 2014 , 35, 716-24	9.5	174
1131	Experimental Validation of Revised Criteria for Pulmonary Hypertension Diagnosis by Uncertainty Evaluation. 2014 , 63, 592-602		3
1130	A different view on predictors of pulmonary hypertension in secundum atrial septal defect. 2014 , 176, 833-40		48
1129	Pulmonary arterial hypertension: the clinical syndrome. 2014 , 115, 115-30		221
1128	Arterial vasculopathy in systemic sclerosis: computerized tomography (CT) angiographic features of macrovascular and microvascular upper limbs arteries. 2014 , 81, 433-7		12
1127	Comprehensive Approach to Adult Congenital Heart Disease. 2014 ,		3
1126	Ion channels and transporters as therapeutic targets in the pulmonary circulation. 2014 , 144, 349-68		18
1125	Hemodynamic effect and safety of intermittent sequential pneumatic compression leg sleeves in patients with congestive heart failure. 2014 , 20, 739-746		8
1124	[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy]. 2014 , 142, 248-52		4
1123	CASE 10--2014 Eisenmenger syndrome: close the hole?. 2014 , 28, 1146-53		5
1122	Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. 2014 , 108, 287-96		115
1121	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. 2014 , 172, 561-7		24

1120	Increase of pulmonary artery wedge pressure above 15 mm Hg in patients with pre-capillary pulmonary hypertension. 2014 , 4, 161-169	2
1119	Echocardiography versus right heart catheterization in class I pulmonary hypertension. 2014 , 63, 419-422	3
1118	Iron deficiency in patients with idiopathic pulmonary arterial hypertension. 2014 , 23, 287-92	32
1117	Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. 2014 , 33, 157-62	22
1116	Doppler echocardiography inaccurately estimates right ventricular pressure in children with elevated right heart pressure. 2014 , 27, 163-71	42
1115	A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. 2014 , 133, 790-4	2
1114	Echocardiographic assessment of right ventricular contractile reserve in patients with pulmonary hypertension. 2014 , 33, 155-163	11
1113	Successful pregnancy and delivery in a patient with vasoreactive idiopathic pulmonary arterial hypertension. 2014 , 172, e87-8	2
1112	Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. 2014 , 43, 256-61	6
1111	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. 2014 , 33, 521-7	28
1110	Analyses of longitudinal and of transverse right ventricular function provide different clinical information in patients with pulmonary hypertension. 2014 , 40, 1096-103	7
1109	Interaction between pulmonary hypertension and diastolic dysfunction in an elderly heart failure population. 2014 , 20, 98-104	9
1108	Performance-enhancing effects of non-selective endothelin receptor antagonist. 2014 , 171, 294-7	
1107	Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro. 2014 , 28, 130-7	17
1106	Imaging in pulmonary hypertension: Focus on the role of echocardiography. 2014 , 107, 261-71	23
1105	Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. 2014 , 47, 175-82	25
1104	Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO ₂ . 2014 , 118, 397-403	9
1103	A systematic review of the diagnostic accuracy of cardiovascular magnetic resonance for pulmonary hypertension. 2014 , 30, 455-63	17

1102	Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension. 2014 , 63, 149-53	27
1101	Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments. 2014 , 2, 1137-1145	2
1100	Pregnancy outcomes in patients with severe pulmonary hypertension and Eisenmenger syndrome treated with sildenafil monotherapy. 2014 , 7, 40-2	6
1099	Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. 2014 , 100, 1322-8	43
1098	Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. 2014 , 7, 367-77	75
1097	Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. 2014 , 175, 268-73	11
1096	Complications cardiovasculaires du dopage. 2014 , 2014, 15-23	
1095	Pulmonary arterial hypertension and sepsis: prothrombotic profile and inflammation can changes pulmonary mechanics?. 2014 , 83, 290-1	3
1094	Adipose-derived regenerative cell therapy inhibits the progression of monocrotaline-induced pulmonary hypertension in rats. 2014 , 118, 306-12	10
1093	Increased levels of plasma CXC-Chemokine Ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension. 2014 , 43, 322-7	27
1092	Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. 2014 , 35, 369-89	53
1091	Pregnancy and pulmonary hypertension. 2014 , 28, 579-91	40
1090	Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. 2014 , 86, 90-7	13
1089	Pulmonary arterial hypertension associated with IgG4-related disease. 2014 , 53, 493-7	15
1088	Severe pulmonary hypertension in adult pulmonary Langerhans cell histiocytosis: the effect of sildenafil as a bridge to lung transplantation. 2014 , 53, 1985-90	6
1087	Integrative approach for hemodynamic monitoring. 107-119	1
1086	Invasive hemodynamic monitoring systems. 132-145	
1085	Portopulmonary hypertension and hepatopulmonary syndrome. 2014 , 20, 8072-81	46

1084	Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. 2014 , 4, e005950	30
1083	Prognostic value of pulmonary hypertension in ambulatory patients with non-ischemic dilated cardiomyopathy. 2014 , 78, 1245-53	15
1082	Visualization of complete regression of pulmonary arterial remodeling on optical coherence tomography in a patient with pulmonary arterial hypertension. 2014 , 78, 2771-3	7
1081	Nontuberculous mycobacterium diseases and chronic thromboembolic pulmonary hypertension. 2014 , 53, 2273-9	5
1080	Intensive Care in Cardiac Failure. 2014 , 503-519	
1079	Inhaled treprostinil sodium for pulmonary hypertension. 2014 , 2, 283-291	
1078	Atrial septostomy in a patient with severe pulmonary hypertension and hypoxia: A therapeutic dilemma. 2014 , 22,	
1077	Right heart morphology in elevated pulmonary artery pressure: relationship between echocardiographic and right heart catheterization data. 2014 , 69, 371-5	2
1076	Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. 2014 , 8, 21-8	10
1075	Cardiac sequelae of human immunodeficiency virus disease. 2014 , 348, 82-6	3
1074	MRI catheterization in cardiopulmonary disease. 2014 , 145, 30-36	28
1073	Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing. 2014 , 146, 1226-1236	12
1072	Echocardiography of the pulmonary circulation and right ventricular function: exploring the physiologic spectrum in 1,480 normal subjects. 2014 , 145, 1071-1078	24
1071	The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. 2014 , 145, 1230-1236	117
1070	An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. 2014 , 145, 1383-1391	50
1069	Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. 2014 , 146, 959-966	28
1068	Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. 2014 , 146, 1274-1285	162
1067	Denervaci3n renal por cat3ter como tratamiento para la hipertensi3n pulmonar: ¿esperanza o espejismo?. 2015 , 68, 551-553	3

- 1066 Pulmonary hypertension in patients with chronic myeloproliferative disorders. **2015**, 24, 400-10 29
- 1065 Kriterien für die Notwendigkeit und Dauer von Krankenhausbehandlung bei Koronarangiografien und -interventionen. **2015**, 9, 295-302 4
- 1064 Reply. **2015**, 144, 137-138
- 1063 Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. **2016**, 18, 6 92
- 1062 At high cardiac output, diesel exhaust exposure increases pulmonary vascular resistance and decreases distensibility of pulmonary resistive vessels. **2015**, 309, H2137-44 22
- 1061 Development of macitentan for the treatment of pulmonary arterial hypertension. **2015**, 1358, 68-81 4
- 1060 Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. **2015**, 27, 1309-12 16
- 1059 Cerebral oxygenation in highlanders with and without high-altitude pulmonary hypertension. **2015**, 100, 905-14 6
- 1058 Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. **2015**, 5, 547-56 44
- 1057 Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?. **2015**, 5, 424-34 24
- 1056 Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. **2015**, 2, 14065 4
- 1055 [Pulmonary hypertension in the elderly]. **2015**, 13, 8-14
- 1054 AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension. **2015**, 2015, 48
- 1053 Lung-heart clinical crosstalk in the course of COPD exacerbation. **2015**, 83, 30-8
- 1052 Epidemiological Characteristics and Prospective 6-Months Follow-up of Children with Pulmonary Arterial Hypertension. **2015**, 61, 75-82 1
- 1051 Disease-Targeted Treatment Improves Cognitive Function in Patients with Precapillary Pulmonary Hypertension. **2015**, 90, 376-83 8
- 1050 Pulmonary hypertension related to congenital heart disease: A comprehensive review. **2015**, 2015, 42
- 1049 Quality markers in cardiology: measures of outcomes and clinical practice – perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery¹. **2015**, 22, 315-324

1048	Current Treatment Strategies in Pulmonary Hypertension Associated with Left Heart Disease. 2015 , 2, 345-354	1
1047	Proyecto de cooperaci3n de un equipo de cirug3a cardiaca infantil en Etiop3a. Organizaci3n y resultados. 2015 , 22, 74-81	
1046	Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients. 2015 , 34, 28-34	15
1045	Indicadores de calidad en cardiolog3a. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y par3metros de calidad relacionados con mejores resultados en la pr3ctica cl3nica (indicadores de pr3ctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del P3a del Coraz3n): Declaraci3n de posicionamiento de	
1044	K198N polymorphism in the EDN1 gene in patients with pulmonary arterial hypertension. 2015 , 144, 348-352	1
1043	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. 2015 , 147, 1385-1394	26
1042	Left ventricular diastolic dysfunction in pulmonary hypertension predicts functional capacity and clinical worsening: a tissue phase mapping study. 2015 , 17, 116	32
1041	Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence. 2015 , 20, 69-78	5
1040	Some neonatal risk factors for adult pulmonary arterial hypertension remain unknown. 2015 , 104, 1104-8	12
1039	Reliability of Doppler-Based Measurement of Pulmonary Vascular Resistance in Congenital Heart Disease with Left-to-Right Shunt Lesions. 2015 , 32, 1009-14	5
1038	What is the evidence status of Appropriate Use Criteria (AUC)? Insight from a matching exercise with the guidelines for echocardiography. 2015 , 45, 864-9	4
1037	GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension. 2015 , 11, 233-6	1
1036	Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. 2015 , 16, 127	23
1035	Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. 2015 , 17, 231	21
1034	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. 2015 , 20, 570-6	6
1033	Is real time contrast echocardiography useful for assessment of the right ventricular morphology, function, and perfusion?. 2015 , 32, 1080-6	6
1032	Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. 2015 , 45, 1134-40	14
1031	Novel biomarkers for risk stratification in pulmonary arterial hypertension. 2015 , 1,	14

1030	Cardiovascular outcome in systemic sclerosis. 2015 , 70, 554-563	3
1029	Functional class and type of pulmonary hypertension determinate severity of cardiac autonomic dysfunction assessed by heart rate variability and turbulence. 2015 , 70, 286-96	8
1028	Melatonin as a preventive and curative therapy against pulmonary hypertension. 2015 , 59, 343-53	45
1027	Right ventricle dysfunction in pulmonary hypertension: mechanisms and modes of detection. 2015 , 21, 446-53	15
1026	The Prognostic Value of 18F-FDG Uptake Ratio Between the Right and Left Ventricles in Idiopathic Pulmonary Arterial Hypertension. 2015 , 40, 859-63	10
1025	Multifocal central serous chorioretinopathy with photoreceptor-retinal pigment epithelium diastasis in heritable pulmonary arterial hypertension. 2015 , 9, 83-7	7
1024	Renal allograft loss caused by cardiorenal syndrome: frequency and diagnosis. 2015 , 99, 1208-15	7
1023	Care of the patient with pulmonary arterial hypertension. 2015 , 34, 340-7	
1022	Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression. 2015 , 66, 504-14	9
1021	Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. 2015 , 90, 1060-4	83
1020	A binational registry of adults with pulmonary arterial hypertension complicating congenital heart disease. 2015 , 45, 944-50	9
1019	Biomechanics of Cardiac Function. 2015 , 5, 1623-44	43
1018	Imaging Studies for Pulmonary Vascular Disease. 2015 , 22, 307-321	
1017	Echocardiography in pulmonary hypertension. 2015 , 30, 574-86	24
1016	DCCN on the Web. 2015 , 34, 347	
1015	Lung transplantation for severe pulmonary hypertension--awake extracorporeal membrane oxygenation for postoperative left ventricular remodelling. 2015 , 99, 451-8	86
1014	Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. 2015 , 128, 896-901	7
1013	Chronic thromboembolic pulmonary hypertension in young woman with history of caesarian section. 2015 , 23, 232-8	2

1012	Cambios agudos en la funci3n auricular derecha post uso de iloprost inhalatorio en pacientes con hipertensi3n arterial pulmonar: estudio con t3cnicas de deformaci3n de imagen. 2015 , 34, 100-105	
1011	Metabolic Connection between Incretins and Pulmonary Hypertension. 2015 , s13,	
1010	Acute vasoreactivity test results in severe pulmonary hypertension patients with chronic obstructive pulmonary disease: our experience with 29 cases. 2015 , 10, 969-73	
1009	Evaluation of the influence of pulmonary hypertension in ultra-fast-track anesthesia technique in adult patients undergoing cardiac surgery. 2015 , 30, 449-58	1
1008	The limits of oral therapy in pulmonary arterial hypertension management. 2015 , 11, 1731-41	7
1007	[Assessment of treatment adherence among black Africans with heart failure]. 2015 , 25, 373-6	2
1006	Variants of PGIS and PPAR γ in Idiopathic Pulmonary Arterial Hypertension. 2015 , 3,	
1005	Pulmonary Hypertension in Children with Congenital Left to Right Cardiac Shunt Anomalies. 2015 , 14, 31-37	1
1004	Pulmonary Artery Relaxation was Best with Increasing GLP1 than the Metabolic Improvement in Patients with Type 2 Diabetes. 2015 , s13,	
1003	Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. 2015 , 7, 175-83	5
1002	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. 2015 , 10, 99-109	19
1001	Relationship between Right Ventricular Longitudinal Strain, Invasive Hemodynamics, and Functional Assessment in Pulmonary Arterial Hypertension. 2015 , 45, 398-407	19
1000	Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. 2015 , 10, e0126985	36
999	Mean pulmonary arterial pressures in Angus steers increase from cow-calf to feedlot-finishing phases. 2015 , 93, 3854-61	12
998	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. 2015 , 10, e0141911	51
997	Epoprostenol sodium for treatment of pulmonary arterial hypertension. 2015 , 11, 265-70	18
996	Computed tomography measurement of pulmonary artery for diagnosis of COPD and its comorbidity pulmonary hypertension. 2015 , 10, 2525-33	17
995	Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension. 2015 , 56, 86-93	10

994	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. 2015 , 2015, 929170	4
993	Progressive muscle relaxation improves anxiety and depression of pulmonary arterial hypertension patients. 2015 , 2015, 792895	15
992	Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a. 2015 , 2015, 792846	54
991	Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea. 2015 , 2015, 510105	21
990	Rescue balloon pulmonary angioplasty under veno-arterial extracorporeal membrane oxygenation in a patient with acute exacerbation of chronic thromboembolic pulmonary hypertension. 2015 , 56, 116-20	17
989	Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension. 2015 , 2015, 173970	16
988	Interventions for treating pulmonary hypertension in people with sickle cell disease or thalassaemia. 2015 ,	
987	Coronary Bypass Surgery in Patients with Pulmonary Hypertension: Assessment of Early and Long Term Results. 2015 , 21, 268-74	1
986	Diltiazem?. 2015 ,	1
985	Right Ventricular Longitudinal Strain: A Target Indicator in the Treatment of Pulmonary Arterial Hypertension. 2015 , 45, 362-3	1
984	Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. 2015 , 54, 1454-8	54
983	The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension. 2015 , 24, 1658-71	37
982	Positionspapier Schlafmedizin in der Kardiologie 2015 , 9, 140-158	19
981	Echocardiography of Chronic Right Heart Failure. 2015 , 209-248	
980	The role of wall shear stress in the assessment of right ventricle hydraulic workload. 2015 , 5, 90-100	14
979	The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension. 2015 , 13, 467-76	1
978	Pulmonary Hemodynamics and Right Heart Catheterization. 2015 , 225-264	
977	Management of Crashing Patients with Pulmonary Hypertension. 2015 , 33, 623-43	2

976	Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. 2015 , 3, 459-466	32
975	Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction. 2015 , 3, 467-474	99
974	Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. 2015 , 24, 566-72	20
973	Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. 2015 , 184, 198-207	73
972	Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. 2015 , 147, 1063-1071	78
971	Takayasu arteritis-associated pulmonary hypertension. 2015 , 42, 495-503	25
970	Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. 2015 , 45, 700-8	50
969	A lethal coexistence: Pulmonary hypertension with pregnancy. 2015 , 195, 27-8	1
968	Diagnosis and Management of Pulmonary Hypertension. 2015 ,	
967	Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2015 , 195, 19-26	32
966	Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. 2015 , 9, 351-9	
965	Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension: Seven-Year Follow-Up. 2015 , 8,	32
964	. 2015 ,	
963	HIV-associated pulmonary arterial hypertension: from bedside to the future. 2015 , 45, 515-28	25
962	Noninvasive pulmonary artery wave intensity analysis in pulmonary hypertension. 2015 , 308, H1603-11	50
961	Ventricular myocardial deformation in adults after early surgical repair of atrial septal defect. 2015 , 16, 549-57	13
960	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. 2015 , 54, 1262-9	19
959	Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). 2015 , 132, 2403-11	97

958	Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction. 2015 , 17, 79	32
957	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. 2015 , 132, 2152-61	10
956	Chronic thromboembolic pulmonary hypertension. 2015 , 44, e409-16	15
955	Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation. 2015 , 4,	11
954	Impaired Right, Left, or Biventricular Function and Resting Oxygen Saturation Are Associated With Mortality in Eisenmenger Syndrome: A Clinical and Cardiovascular Magnetic Resonance Study. 2015 , 8,	25
953	Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados (indicadores de resultados) y parámetros de calidad relacionados con mejores resultados en la práctica clínica (indicadores de práctica asistencial). INCARDIO (Indicadores de Calidad en Unidades Asistenciales del Hospital General de Caracas). Documento de posicionamiento	33
952	Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. 2015 , 8, 2013-2023	42
951	Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension. 2015 , 66, 457-67	24
950	Executive summary of the 11th HHT international scientific conference. 2015 , 18, 511-24	17
949	Assessment of N-terminal prohormone B-type natriuretic peptide as a measure of vascular and ventricular function in pediatric pulmonary arterial hypertension. 2015 , 5, 658-66	9
948	Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron. 2015 , 20, 610-7	9
947	Accuracy and reproducibility of right ventricular quantification in patients with pressure and volume overload using single-beat three-dimensional echocardiography. 2015 , 28, 363-74	40
946	Intrathecal fentanyl blockade of afferent neural feedback from skeletal muscle during exercise in heart failure patients: Influence on circulatory power and pulmonary vascular capacitance. 2015 , 201, 384-93	6
945	Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis. 2015 , 2, e000122	15
944	High altitude-induced borderline pulmonary hypertension impaired cardiorespiratory fitness in healthy young men. 2015 , 181, 382-8	19
943	Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model. 2015 , 109, 406-15	18
942	Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. 2015 , 101, 637-44	31
941	The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. 2015 , 109, 557-64	24

940	Nt-ProBNP, Anaemia and Renal function are independent predictors of hospitalization in outpatients with pulmonary artery hypertension. 2015 , 21, 46-7	1
939	An original cause of pulmonary hypertension. 2015 , 182, 4-5	
938	Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: determinants and impact on pump function. 2015 , 34, 381-9	40
937	"Porto-pulmonary hypertension: a comprehensive review". 2015 , 39, 157-67	19
936	Clinical significance of dynamic pulmonary vascular resistance in two populations at risk of pulmonary arterial hypertension. 2015 , 16, 564-70	13
935	Portopulmonary hypertension: an update. 2015 , 20, 235-42	13
934	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). 2015 , 45, 1303-13	131
933	Treating pulmonary hypertension in pediatrics. 2015 , 16, 711-26	13
932	Interleukin-6 and tumor necrosis factor- α are associated with quality of life-related symptoms in pulmonary arterial hypertension. 2015 , 12, 370-5	23
931	The utility of transoesophageal echocardiography for estimating right ventricular systolic pressure. 2015 , 70, 258-63	10
930	Principles of rehabilitation and reactivation: pulmonary hypertension. 2015 , 89, 265-73	20
929	Interdependence of right ventricular systolic function and left ventricular filling and its association with outcome for patients with pulmonary hypertension. 2015 , 31, 691-8	23
928	PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. 2015 , 45, 1314-22	113
927	Treatment of pulmonary arterial hypertension in children. 2015 , 12, 244-54	44
926	Pulmonary hypertension in well-transfused thalassemia major patients. 2015 , 54, 189-94	17
925	Evaluation of clinical presentation and outcome of patients with respiratory bronchiolitis-associated interstitial lung disease. 2015 , 21, 47-8	
924	Association of aortic stiffness to brain natriuretic peptide in children before and after device closure of patent ductus arteriosus. 2015 , 27, 23-30	1
923	An evidence-based approach to screening and diagnosis of pulmonary hypertension. 2015 , 31, 382-90	10

922	Circulating biomarkers in pulmonary arterial hypertension: update and future direction. 2015 , 34, 282-305	35
921	A global perspective on the epidemiology of pulmonary hypertension. 2015 , 31, 375-81	22
920	A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System. 2015 , 31, 367-74	12
919	Imaging of the right heart--CT and CMR. 2015 , 32 Suppl 1, S53-68	11
918	Pulmonary arterial hypertension: the key role of echocardiography. 2015 , 32 Suppl 1, S23-37	41
917	Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. 2015 , 17, 151-8	32
916	Treatment of pulmonary arterial hypertension using extemporaneous formulation of sildenafil in Mexican children. 2015 , 36, 1019-23	2
915	Clinical evaluation and management of pulmonary hypertension in the adult with congenital heart disease. 2015 , 131, 200-10	28
914	[Reply]. 2015 , 144, 137-8	
913	Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension. 2015 , 13, 193-207	7
912	FDG PET imaging for identifying pulmonary hypertension and right heart failure. 2015 , 17, 555	14
911	Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension. 2015 , 89, 41-8	24
910	Aneurysms of the pulmonary artery. 2015 , 131, 310-6	106
909	Vasculopathie artfielle dans la sclfodermie systmique. Caractfistiques micro- et macrovasculaire de l'angioscanner des artfes des membres supfieurs. 2015 , 82, 173-178	
908	Spectral Doppler of the hepatic veins in pulmonary hypertension. 2015 , 32, 170-3	5
907	The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. 2015 , 54, 528-35	36
906	Pulmonary hypertension and Hashimoto's thyroiditis: does a relationship exist?. 2015 , 48, 621-8	3
905	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. 2015 , 17, 7	63

904	Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS. 2015 , 7, 193-205	10
903	High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. 2015 , 88, 130-6	26
902	Serum Bcl-2 values in children with pulmonary hypertension. 2015 , 36, 579-83	3
901	Multimodality imaging in pulmonary hypertension. 2015 , 31, 440-59	16
900	Ventricular interdependence in pulmonary arterial hypertension: providing small pieces of a complex puzzle. 2015 , 17, 1-2	18
899	Pulmonary hypertension in antiphospholipid syndrome. 2015 , 17, 478	21
898	Why sildenafil and sildenafil citrate monohydrate crystals are not stable?. 2015 , 23, 504-14	8
897	Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. 2015 , 35, 1236-45	31
896	Advanced therapies in patients with congenital heart disease-related pulmonary arterial hypertension: results from a long-term, single center, real-world follow-up. 2015 , 10, 445-50	3
895	Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. 2015 , 5, 220-7	53
894	Pulmonary hypertension and pregnancy: the experience of a tertiary institution over 15 years. 2015 , 18, 153-60	19
893	Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. 2015 , 5, 162-70	11
892	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. 2015 , 5, 356-63	32
891	Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. 2015 , 7, 5822	11
890	Quantitative lung perfused blood volume imaging on dual-energy CT: capability for quantitative assessment of disease severity in patients with acute pulmonary thromboembolism. 2015 , 56, 284-93	6
889	The Pulmonary Circulation. 2015 , 1-20	1
888	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. 2015 , 38, 829-39	11
887	Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons. 2015 , 82, 1128-34	1

886	Sildenafil in heart transplant candidates with pulmonary hypertension. 2015 , 108, 375-84	11
885	Left and Right Ventricular Functional Dynamics Determined by Echocardiograms Before and After Lung Transplantation. 2015 , 116, 652-9	3
884	Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography. 2015 , 28, 828-43	28
883	Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension: Clinical Impact and Reversibility. 2015 , 8, 642-52	62
882	Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?. 2015 , 68, 551-3	4
881	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery: Reducing risk of heart failure patients must be in noncardiac surgery. 2015 , 62, 359-419	1
880	Impact of lung diseases on morbidity and mortality after transcatheter aortic valve implantation: insights from spirometry and body plethysmography. 2015 , 170, 837-842.e1	14
879	Accuracy and Test-Retest Reproducibility of Two-Dimensional Knowledge-Based Volumetric Reconstruction of the Right Ventricle in Pulmonary Hypertension. 2015 , 28, 989-98	13
878	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. 2015 , 34, 338-47	9
877	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. 2015 , 34, 348-55	11
876	Beta blocker for patients with pulmonary arterial hypertension: A single center experience. 2015 , 184, 528-532	8
875	Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. 2015 , 199, 170-9	78
874	Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival. 2015 , 192, 1234-46	148
873	HIPERTENSIÓN PULMONAR: IMPORTANCIA DE UN DIAGNÓSTICO PRECOZ Y TRATAMIENTO ESPECÍFICO. 2015 , 26, 344-356	
872	Pulmonary embolism and pulmonary hypertension: two issues often neglected in cardiology. <i>European Heart Journal</i> , 2015 , 36, 581-3	9.5 2
871	Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. 2016 , 17, 106-13	33
870	Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. 2015 , 76, 187-192	28
869	Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. 2015 , 29, 469-79	17

868	Epidemiology and Disease Classification of Pulmonary Hypertension. 2015 , 21-35	1
867	Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension. 2015 , 446, 272-6	4
866	Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. 2015 , 5, 364-9	23
865	Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. 2015 , 5, 296-304	26
864	Pulmonale Hypertonie bei Lungen- und Linksherzerkrankungen. 2015 , 12, 410-416	2
863	Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy. 2015 , 42, 50-4	1
862	Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009. 2015 , 5, 339-48	28
861	An Update on Pulmonary Arterial Hypertension. 2015 , 11, 551-559	5
860	Measuring vasoreactivity in pulmonary hypertension: a simple test, but do we understand it?. 2015 , 34, 306-7	2
859	Antinuclear antibody-negative systemic sclerosis. 2015 , 44, 680-6	43
858	Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome. 2015 , 8,	40
857	What's new in the treatment of portopulmonary hypertension?. 2015 , 9, 983-92	20
856	Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico. 2015 , 15, 21-26	
855	Pulmonary thromboendarterectomy in 106 patients with chronic thromboembolic pulmonary hypertension. 2015 , 51, 502-8	13
854	Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. 2015 , 34, 414-23	34
853	Dramatic improvement of clinical and hemodynamic parameters of a heart transplant candidate with sildenafil treatment. 2015 , 185, 148-9	1
852	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. 2015 , 34, 438-47	21
851	Right ventricular function and right-heart echocardiographic response to therapy predict long-term outcome in patients with pulmonary hypertension. 2015 , 31, 529-36	17

850	Portopulmonary Hypertension and Hepatopulmonary Syndrome. 2015 , 514-534	1
849	Postoperative Intensive Care Management in Adults. 2015 , 866-894	1
848	Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension. 2015 , 46, 422-30	27
847	Lungenerkrankungen in der Schwangerschaft. 2015 , 48, 101-107	
846	Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease. 2015 , 36, 1062-9	14
845	Thoracic manifestation of Eisenmenger's syndrome in adult patients: a MDCT review. 2015 , 193, 173-81	4
844	Metabolic Dysfunction in Pulmonary Arterial Hypertension. 2015 , 17, 20	33
843	Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. 2015 , 23, 278-84	27
842	Quality of life in pulmonary arterial hypertension. 2015 , 23, 275-7	2
841	Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension. 2015 , 10, 1	50
840	Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. 2015 , 45, 1603-12	92
839	Human immunodeficiency virus-associated pulmonary arterial hypertension: considerations for pulmonary vascular diseases in the developing world. 2015 , 131, 1361-70	31
838	Pulmonary vascular diseases. 2015 , 36, 235-48, viii	12
837	Pulmonary Artery Pathology. 2015 , 31-52	
836	Pulmonary Hypertension: A Nomogram Based on CT Pulmonary Angiographic Data for Prediction in Patients without Pulmonary Embolism. 2015 , 277, 236-46	16
835	"Left ventricular filling pressure(s)" - Ambiguous and misleading terminology, best abandoned. 2015 , 191, 110-3	12
834	Impact of Severe Tricuspid Regurgitation on Accuracy of Echocardiographic Pulmonary Artery Systolic Pressure Estimation. 2015 , 32, 1483-90	11
833	Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. 2015 , 193, 105-12	18

832	Abnormal right ventricular relaxation in pulmonary hypertension. 2015 , 5, 370-5	30
831	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. 2015 , 46, 283-6	6
830	Systemic sclerosis. 2015 , 1, 15002	351
829	Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. 2015 , 54, 1673-9	33
828	Management of pulmonary arterial hypertension. 2015 , 65, 1976-97	229
827	Pulmonary Hypertension in Pregnancy and Anesthetic Implications. 2015 , 5, 82-90	
826	A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. 2015 , 29, 191-204	183
825	Perioperative Management of Pregnant Women With Idiopathic Pulmonary Arterial Hypertension: An Observational Case Series Study From China. 2018 , 32, 2547-2559	14
824	The contribution of left heart disease in COPD patients with pulmonary hypertension. 2018 , 59, 160-165	3
823	Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis. 2018 , 8, 2045893217753357	1
822	Pre-operative Evaluation of Patients with Pulmonary Hypertension. 2018 , 8, 44-51	
821	Reappraisal of the reliability of Doppler echocardiographic estimations for mean pulmonary artery pressure in patients with pulmonary hypertension: a study from a tertiary centre comparing four formulae. 2018 , 8, 2045894018762270	3
820	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. 2018 , 20, 10	15
819	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. 2018 , 95, 244-250	7
818	Improving the echocardiographic assessment of pulmonary pressure using the tricuspid regurgitant signal-The "chin" vs the "beard". 2018 , 35, 1085-1096	10
817	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. 2018 , 45, 633-691	16
816	Prognostic Relevance of Liver Stiffness Assessed by Transient Elastography in Patients With Acute Decompensated Heart Failure. 2018 , 82, 1822-1829	30
815	Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect. 2018 , 44, 203-213	36

814	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. 2018 , 51,	9
813	Is there a learning effect when the 6-minute walk test is repeated in people with suspected pulmonary hypertension?. 2018 , 15, 339-346	12
812	STVNa attenuates right ventricle hypertrophy and pulmonary artery remodeling in rats induced by transverse aortic constriction. 2018 , 101, 371-378	8
811	Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. 2018 , 827, 159-166	5
810	Right atrium enlargement predicts clinically significant supraventricular arrhythmia in patients with pulmonary arterial hypertension. 2018 , 47, 237-242	12
809	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. 2018 , 107, 460-470	18
808	Peak circulatory power is a strong prognostic factor in patients with idiopathic pulmonary arterial hypertension. 2018 , 135, 29-34	6
807	Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. 2018 , 57, 480-487	21
806	Ventricular-Vascular Coupling in the Pulmonary Circulation. 2018 , 53-68	
805	Computational Study on the Cardiovascular System: Ventricular-Ventricular Interaction and Right Ventricular Failure in Pulmonary Arterial Hypertension. 2018 , 81-91	
804	Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. 2018 , 33, 403-413	3
803	Pulmonary hypertension in COPD patients at Chest Departments of Zagazig University and Kobry EL Kobba Military Hospitals in 2014. 2018 , 8, 13-17	
802	Right Ventricular Dysfunction Post-Heart Transplantation. 2018 , 193-216	2
801	Current and emerging imaging techniques in the diagnosis and assessment of pulmonary hypertension. 2018 , 12, 145-160	7
800	Right Ventricular Physiology, Adaptation and Failure in Congenital and Acquired Heart Disease. 2018 ,	0
799	Single center experience with the Potts shunt in severe pulmonary arterial hypertension. 2018 , 48, 111-115	0
798	Evaluation of the Clinical Utility of Transesophageal Echocardiography and Invasive Monitoring to Assess Right Ventricular Function During and After Pulmonary Endarterectomy. 2018 , 32, 771-778	6
797	Extrinsic compression of left main coronary artery by aneurysmal pulmonary artery in severe pulmonary hypertension: its correlates, clinical impact, and management strategies. 2018 , 19, 1302-1308	10

796	The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. 2018 , 27,	32
795	Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure. 2018 , 11, e004750	71
794	Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. 2018 , 37, 1563-1571	8
793	Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension. 2018 , 33, 1220-1228	3
792	MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF- β and IL-6/STAT3 signaling pathways. 2018 , 50, 1-11	35
791	Anthropometric Evaluation and Functional Assessment of Patients with Pulmonary Hypertension and its Relationship with Pulmonary Circulation Parameters and Functional Performance. 2018 , 37, 423-428	1
790	Lung allocation score: the Eurotransplant model versus the revised US model - a cross-sectional study. 2018 , 31, 930-937	19
789	CT derived left atrial size identifies left heart disease in suspected pulmonary hypertension: Derivation and validation of predictive thresholds. 2018 , 260, 172-177	13
788	Hipertensi \tilde{b} arterial pulmonar. 2018 , 22, 1-11	
787	Cardiovascular parameters of chest CT scan in estimating pulmonary arterial pressure in patients with pulmonary hypertension. 2018 , 12, 572-579	6
786	Clinical and hemodynamic characteristics of pulmonary hypertension associated with interstitial lung disease in China. 2018 , 12, 915-921	3
785	Pulmonary hypertension as estimated by Doppler echocardiography in adolescent and adult patients with cystic fibrosis and their relationship with clinical, lung function and sleep findings. 2018 , 12, 754-761	4
784	Pulmonary hypertension associated with combined fibrosing mediastinitis and bronchial anthracofibrosis: A retrospective analysis in a single Chinese hospital. 2018 , 12, 1134-1140	2
783	Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. 2018 , 20, 248-255	53
782	Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. 2018 , 57, 255-262	27
781	Pulmonary arterial stiffness indices assessed by intravascular ultrasound in children with early pulmonary vascular disease: prediction of advanced disease and mortality during 20-year follow-up. 2018 , 19, 216-224	13
780	Study of platelet activation, hypercoagulable state, and the association with pulmonary hypertension in children with β thalassemia. 2018 , 11, 65-74	15
779	Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. 2017 ,	14

778	Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol. 2018 , 49, 147-151	2
777	Validity of algorithm for estimating left sided filling pressures on echocardiography in a population referred for pulmonary arterial hypertension. 2017 , 7, 2045893217740471	5
776	High rate of isolated right ventricular dysfunction in patients with non-significant CT pulmonary angiography. 2018 , 36, 281-284	4
775	Pulmonary vascular resistance and proper timing of percutaneous balloon mitral valvotomy. 2018 , 34, 523-529	3
774	Left Heart Disease and Pulmonary Hypertension: Are We Seeing the Full Picture?. 2018 , 27, 301-309	6
773	Hyponatraemia and its prognosis in acute heart failure is related to right ventricular dysfunction. 2018 , 104, 1670-1677	7
772	Right ventricular speckle tracking assessment for differentiation of pressure- versus volume-overloaded right ventricle. 2018 , 38, 763-771	13
771	Right Ventricular Epicardial Vascularisation in Patients With Pulmonary Arterial Hypertension. 2018 , 27, 1428-1436	
770	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. 2018 , 37, 365-375	27
769	Primary pulmonary arterial hypertension with preserved right ventricular function leads to lower extremity venous insufficiency. 2018 , 26, 183-188	3
768	Exercise training in patients with pulmonary and systemic hypertension: A unique therapy for two different diseases. 2018 , 47, 17-24	13
767	Mechanisms underlying the impact of exercise training in pulmonary arterial hypertension. 2018 , 134, 70-78	16
766	Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary Hypertension. 2018 , 31, 34-41	42
765	Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. 2018 , 197, 509-516	84
764	Does Portopulmonary Hypertension Impede Liver Transplantation in Cirrhotic Patients? A French Multicentric Retrospective Study. 2018 , 102, 616-622	18
763	An Echocardiographic Screening Program Helps to Identify Pulmonary Hypertension in Extremely Low Birthweight Infants with and without Bronchopulmonary Dysplasia: A Single-Center Experience. 2018 , 113, 81-88	12
762	Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats. 2018 , 100, 41-50	12
761	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. 2018 , 43, 191-216	1

760	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. 2018 , 43, 217-231	1
759	Prostanoid EP agonist L-902,688 activates PPAR α and attenuates pulmonary arterial hypertension. 2018 , 314, L349-L359	14
758	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. 2018 , 7, 103-117	10
757	Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. 2018 , 34, 263-273	5
756	Prevalence and predictors associated with severe pulmonary hypertension in COPD. 2018 , 36, 277-280	16
755	Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease?. 2018 , 12, 1433-1438	14
754	Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease. 2018 , 97, e11437	8
753	Cardiorespiratory evaluation of brachycephalic syndrome in dogs. 2018 , 38, 1130-1136	3
752	Aortic stiffness index and its association with cardiovascular functions in children before and after transcatheter closure of PDA. 2018 , 70, 261-266	
751	Comparative assessment of qualitative and quantitative perfusion with dual-energy CT and planar and SPECT-CT V/Q scanning in patients with chronic thromboembolic pulmonary hypertension. 2018 , 8, 414-422	26
750	Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery. 2018 , 10, S2763-S2774	17
749	Tricuspid annular displacement measured by 2-dimensional speckle tracking echocardiography for predicting right ventricular function in pulmonary hypertension: A new approach to evaluating right ventricle dysfunction. 2018 , 97, e11710	8
748	Survival benefits of oral anticoagulants in patients with pulmonary arterial hypertension: Protocol for a systematic review and meta-analysis. 2018 , 97, e12203	
747	Bilateral semilunar perihilar opacities in a patient with pulmonary hypertension. 2018 , 6, 1919-1920	
746	Hemodynamics of the Right Heart in Health and Disease. 2018 , 497-507	
745	Pregnancy in Congenital Heart Diseases. 2018 , 03, 126-131	1
744	OBSOLETE: Hemodynamics of the Right Heart in Health and Disease. 2018 ,	
743	High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. 2018 , 32, 2739-2748	9

742	Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review. 2018 , 2018, 1015239	4
741	Exercise capacity in COPD patients with exercise-induced pulmonary hypertension. 2018 , 13, 3599-3610	3
740	A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. 2018 , 25, 1898-1909	10
739	Assessment of Right Ventricular Function in Pulmonary Hypertension with Multimodality Imaging. 2018 , 26, 189-200	14
738	Assessing the Right Ventricle. 2018 , 373-395	
737	Pulmonary Hypertension. 2018 , 397-412	
736	Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. 2018 , 24, 291-302	13
735	Potts Shunt to Be Preferred Above Atrial Septostomy in Pediatric Pulmonary Arterial Hypertension Patients: A Modeling Study. 2018 , 9, 1252	11
734	Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?. 2018 , 11, e004757	11
733	Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array. 2018 , 111, 342-349	4
732	The LKB1-AMPK- β signaling pathway triggers hypoxic pulmonary vasoconstriction downstream of mitochondria. 2018 , 11,	17
731	NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis. 2018 , 9, 843-851	2
730	Inspiratory muscle weakness contributes to exertional dyspnea in chronic thromboembolic pulmonary hypertension. 2018 , 13, e0204072	4
729	Anesthetic Considerations in the Critically Ill Gravida with Cardiac Disease. 2018 , 731-753	
728	Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. 2018 , 20, 235	17
727	Cardiac catheterization and percutaneous catheter in grown-up congenital heart diseases: single center experience at developing country. 2018 , 27, 38-43	
726	Combined Virtual/Experimental Multicomponent Solid Forms Screening of Sildenafil: New Salts, Cocrystals, and Hybrid Salt π cocrystals. 2018 , 18, 7618-7627	23
725	[Pulmonary hypertension associated with the human immunodeficiency virus in children: treatment with sildenafil. A case report]. 2018 , 116, e437-e441	2

724	Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study. 2018 , 37, 3051-3056	11
723	How I manage medical complications of β -thalassemia in adults. 2018 , 132, 1781-1791	37
722	Successful maternal outcome after vaginal delivery in a patient with Eisenmenger Syndrome. 2018 , 7, 1262	
721	Chronic Thromboembolic Pulmonary Hypertension: Evolving Therapeutic Approaches for Operable and Inoperable Disease. 2018 , 71, 2468-2486	90
720	Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. 2018 , 23, 377-383	14
719	Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. 2018 , 8, 2045894018780521	20
718	Right ventricle performances with echocardiography and Tc myocardial perfusion imaging in pulmonary arterial hypertension patients. 2018 , 243, 754-761	1
717	Prostaglandin E1 for preventing the progress of pulmonary arterial hypertension in rat model. 2018 , 22, 49	1
716	Characteristics of circular RNA expression in lung tissues from mice with hypoxia-induced pulmonary hypertension. 2018 , 42, 1353-1366	25
715	Physiotherapy practice in pulmonary hypertension: physiotherapist and patient perspectives. 2018 , 8, 2045894018783738	5
714	Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. 2018 , 2018, 3148259	13
713	Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study. 2018 , 13, e0195195	2
712	Use of Extracorporeal Membrane Oxygenation in Postpartum Management of a Patient with Pulmonary Arterial Hypertension. 2018 , 2018, 7031731	2
711	All about Pulmonary Hypertension: Echocardiography, Hemodynamics, and Treatment. 2018 , 198, 521-523	
710	Role of plasma asymmetric dimethyl-L-arginine levels in detection of pulmonary hypertension in children with CHD. 2018 , 28, 1163-1168	5
709	The level of ROCK1 and ROCK2 in patients with pulmonary hypertension in plateau area. 2018 , 8, 9356	6
708	Evaluation of the CT imaging findings in patients newly diagnosed with chronic thromboembolic pulmonary hypertension. 2018 , 13, e0201468	22
707	A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. 2017 , 23, 5191-5199	3

706	The Use of Biophysical Flow Models in the Surgical Management of Patients Affected by Chronic Thromboembolic Pulmonary Hypertension. 2018 , 9, 223	6
705	Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension. 2018 , 9, 537	12
704	Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization. 2018 , 5, 902-910	8
703	Ventricular-Assist Devices and Kidney Disease. 2018 ,	
702	The Role of Sex in the Pathophysiology of Pulmonary Hypertension. 2018 , 1065, 511-528	22
701	Clinical Presentation and Long-Term Outcomes of Systemic Sclerosis Portuguese Patients from a Single Centre Cohort: A EUSTAR Registration Initiative. 2018 , 31, 312-320	1
700	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. 2018 , 41, 1826-1839	3
699	Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension. 2018 , 9, 890	15
698	Dasatinib. 2018 , 212, 29-68	23
697	Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end-stage pulmonary hypertension with left heart disease. 2018 , 42, 1341-1352	14
696	Pulmonary Hypertension. 2018 , 597-606	
695	Pulmonary Arterial Hypertension. 2018 , 181-194	
694	Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. 2018 , 5, 755-763	7
693	Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease. 2018 , 16, 1175-1186	0
692	Hypercoagulability in Pulmonary Hypertension. 2018 , 39, 595-603	7
691	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. 2018 , 1, 21-28	8
690	Acute and Long-Term Hemodynamic Effects of MitraClip Implantation on a Preexisting Secondary Right Heart Failure. 2018 , 2018, 6817832	8
689	Risk factors for primary Sjögren syndrome-associated interstitial lung disease. 2018 , 10, 2108-2117	35

688	Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. 2018 , 272S, 53-62	32
687	Serum levels of trace minerals and heavy metals in severe COPD patients with and without pulmonary hypertension. 2018 , 13, 1803-1808	9
686	Management of Pulmonary Hypertension: Associated with Left Heart Disease. 2018 , 14, 545-551	3
685	Challenging cases in rheumatic pregnancies. 2018 , 57, v18-v25	1
684	Right Ventricular Dysfunction in Cardiac Surgery. 2018 , 847-867	
683	Fractal Analysis of Right Ventricular Trabeculae in Pulmonary Hypertension. 2018 , 288, 386-395	10
682	Impairment of Iodine-123-Metaiodobenzylguanidine (I-MIBG) Uptake in Patients with Pulmonary Artery Hypertension. 2018 , 59, 112-119	3
681	Polymorphism of Sildenafil: A New Metastable Desolvate. 2018 , 18, 3740-3746	13
680	Analysis of Outcomes in Lung Transplantation. 2019 , 33, 1455-1466	9
679	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e698-e800	248
678	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, e81-e192	279
677	Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016. 2019 , 5,	8
676	AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment. 2019 , 28, 71-79	11
675	Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. 2019 , 6, 169	5
674	Pulmonary Hypertension as a Primary Presentation for Schistosomiasis, a Case Report of Unusual Presentation. 2019 , 2019,	0
673	Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis. 2019 , 8,	4
672	Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. 2019 , 19, 573	2
671	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. 2019 , 21, 1057-1061	6

670	CMR feature tracking in cardiac asymptomatic systemic sclerosis: Clinical implications. 2019 , 14, e0221021	10
669	Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. 2019 , 39, 1767-1775	11
668	Screening for pulmonary arterial hypertension in systemic sclerosis. 2019 , 28,	21
667	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. 2019 , 39, 1883-1887	2
666	The left atrial substrate plays a significant role in the development of complex atrial tachycardia in patients with precapillary pulmonary hypertension. 2019 , 19, 157	5
665	Value of lung diffusing capacity for nitric oxide in systemic sclerosis. 2019 , 7, e14149	7
664	A Contemporary Systematic Approach to Assessing the Patient with Heart Failure with Reduced Ejection Fraction: Multimodal Noninvasive and Invasive Evaluation. 2019 , 2019, 3039740	1
663	Comparison of Pulmonary Artery Pressure Measurement With Doppler Echocardiography or With Right Heart Catheterization in Patients With Congenital Heart Disease. 2019 , 7, 421	2
662	Impact of right ventricular dyssynchrony on prognosis of patients with idiopathic pulmonary arterial hypertension. 2019 , 9, 2045894019883609	3
661	Trends in the off-label use of β blockers in pediatric patients. 2019 , 61, 1071-1080	3
660	Increased risk of pulmonary hypertension following premature birth. 2019 , 19, 288	14
659	Relationship between volume status and possibility of pulmonary hypertension in dialysis naive CKD5 patients. 2019 , 14, e0221970	4
658	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. 2019 , 4, 1112-1121	31
657	Treprostinil for the treatment of chronic thromboembolic pulmonary hypertension. 2019 , 1-7	1
656	Exercise cardiovascular magnetic resonance imaging allows differentiation of low-risk pulmonary arterial hypertension. 2019 , 38, 627-635	6
655	Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure. 2019 , 13, 148-158	1
654	Profound Increase of Lung Airway Resistance in Heart Failure: a Potential Important Contributor for Dyspnea. 2019 , 12, 271-279	1
653	Experience does matter for pulmonary endarterectomy surgery. 2019 , 157, e181	2

652	Perinatal changes in estradiol and Ang II concentrations in pregnant women with pulmonary arterial hypertension and their correlation. 2019 , 38, 163-170	
651	Circular RNAs in hypertension: challenges and clinical promise. 2019 , 42, 1653-1663	16
650	The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. 2019 , 14, 645-650	13
649	Pulmonary Hypertension Due to Left Heart Disease: an Update. 2019 , 21, 62	8
648	Pulmonary Complications of Systemic Lupus Erythematosus. 2019 , 40, 227-234	36
647	Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions. 2019 , 140, 353-365	41
646	MicroRNAs in Respiratory Diseases. 2019 , 89-131	1
645	Pulmonary Vascular Dynamics. 2019 , 9, 1081-1100	2
644	Prognostic value and diagnostic properties of the diastolic pulmonary pressure gradient in patients with pulmonary hypertension and left heart disease. 2019 , 290, 138-143	9
643	Look before you leap. 2019 , 157, e181-e182	
642	"Treat-to-close": Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry. 2019 , 291, 127-133	20
641	Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. 2019 , 6, 24	12
640	The multiple systemic artery to pulmonary artery fistulas resulting in severe irreversible pulmonary arterial hypertension in patient with previous history of pneumothorax. 2019 , 19, 80	1
639	Role of BRCA1-associated protein (BRAP) variant in childhood pulmonary arterial hypertension. 2019 , 14, e0211450	2
638	Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model. 2019 , 33, 287-295	2
637	Polysplenia Syndrome as a Risk Factor for Early Progression of Pulmonary Hypertension. 2019 , 83, 831-836	5
636	Hipertensiã pulmonar en niês. 2019 , 26, 228-235	
635	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. 2019 , 321, 1069-1080	79

634	Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. 2019 , 24, 1104-1110	29
633	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. 2019 , 53,	29
632	2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. 2019 , 118, 1584-1609	11
631	Three-Chamber Function with Cardiac CT. 2019 , 423-440	
630	Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis. 2019 , 54, 950-962	8
629	Cardiac risk prediction model for pregnant women with structural heart disease in Eastern China. 2019 , 145, 324-330	1
628	Metabolic Alterations in Cardiopulmonary Vascular Dysfunction. 2018 , 5, 120	15
627	Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. 2019 , 10, 55	7
626	A Large Animal Model of Right Ventricular Failure due to Chronic Thromboembolic Pulmonary Hypertension: A Focus on Function. 2018 , 5, 189	7
625	Chronic Thromboembolic Pulmonary Hypertension: Endovascular Treatment. 2019 , 49, 214-222	2
624	Lung Transplantation. 2019 , 773-789	
623	Reference values for the six-minute walk test in Nigerian adolescents aged 10 to 18 years. 2019 , 7, 334	
622	Design of Sublingual Nerve Electrical Stimulation Module for Sleep Respiratory Mask. 2019 ,	
621	Wave reflection in an anatomical model of the pulmonary circulation in local and global hypertensive disease. 2019 , 2019, 4973-4976	1
620	The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia. 2019 , 9, e032122	16
619	Right Ventricular Outflow Doppler Predicts Low Cardiac Index in Intermediate Risk Pulmonary Embolism. 2019 , 25, 1076029619886062	12
618	Assessing Right Ventricular Function in the Perioperative Setting, Part II: What About Catheters?. 2019 , 37, 697-712	0
617	13 Grundlegendes zu Herzerkrankungen. 2019 ,	

616 Pulmonary thromboendarterectomy. **2019**, 14, 6-13

615 Pulmonary artery involvement in Takayasu's arteritis: diagnosis before pulmonary hypertension. **2019**, 19, 225 12

614 Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. **2019**, 9, 2045894019895446 6

613 A Review of Exercise Interventions in Pulmonary Arterial Hypertension and Recommendations for Rehabilitation Programing. **2019**, 39, 138-145 9

612 The role of rehabilitation in patients with pulmonary arterial hypertension. **2019**, 25, 398-404 3

611 Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China. **2019**, 276, 224-229 12

610 Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction. **2019**, 597, 1143-1156 13

609 Pulmonary Hypertension During Pregnancy in New York State, 2003-2014. **2019**, 23, 277-284 3

608 Determining progression of scleroderma-related interstitial lung disease.. **2019**, 4, 62-70 7

607 Pulmonary Manifestations of Primary Immunodeficiency Diseases. **2019**, 1 1

606 Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. **2019**, 38, 194-202 9

605 Usefulness of High Estimated Pulmonary Artery Systolic Pressure to Predict Acute Kidney Injury After Cardiac Valve Operations. **2019**, 123, 440-445 2

604 Influence of mildly and moderately elevated pulmonary artery systolic pressure on post-renal transplantation survival and graft function. **2019**, 36, 22-27 5

603 Impact of Dialysis on the Prognosis of Patients Undergoing Transcatheter Aortic Valve Implantation. **2019**, 123, 315-322 8

602 Estimated Pulmonary Artery Systolic Pressure and Mortality in Older-Elderly Heart Failure Patients. **2019**, 67, 323-328 4

601 Residual high intrapulmonary shunt fraction limits exercise capacity in patients treated with balloon pulmonary angioplasty. **2019**, 34, 868-874 4

600 Right ventricular function in infants with bronchopulmonary dysplasia and pulmonary hypertension: a pilot study. **2019**, 9, 2045894018816063 8

599 Pulmonary Manifestations of Autoinflammatory Disorders. **2019**, 193-211 0

598 Pulmonary Hypertension. **2019**, 327-341.e9

597 Iron Homeostasis in the Lungs-A Balance between Health and Disease. **2019**, 12, 30

596 Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients. **2019**, 59, 1 16

595 Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis. **2019**, 29, 1031-1041 7

594 Quantification of biventricular strain and assessment of ventriculo-ventricular interaction in pulmonary arterial hypertension using exercise cardiac magnetic resonance imaging and myocardial feature tracking. **2019**, 49, 1427-1436 11

593 Pulmonary hypertension in left heart disease. **2019**, 15, 262-273 14

592 Can Doppler echocardiography estimate raised pulmonary capillary wedge pressure provoked by passive leg lifting in suspected heart failure?. **2019**, 39, 128-134 4

591 Nimura lecture: why are you evaluating RV function in patients with pulmonary arterial hypertension?. **2019**, 17, 1-4 2

590 Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. **2019**, 275, 158-164 7

589 Pulmonary hypertension in an adolescent with end-stage-renal disease-a diagnostic challenge: Answers. **2019**, 34, 73-74 2

588 Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. **2020**, 61, 112-117 5

587 Comparison of Right Ventricular Function Between Patients With and Without Pulmonary Hypertension Owing to Left-Sided Heart Disease: Assessment Based on Right Ventricular Pressure-Volume Curves. **2020**, 34, 143-150 3

586 Incidence, risk factors, and outcomes of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. **2020**, 25, 222-227 3

585 Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. **2020**, 157, 376-383 33

584 Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. **2020**, 72, 316-325 10

583 Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review. **2020**, 47, 888-895 9

582 Effect of Pulmonary Hypertension on Clinical Outcomes in Patients With Rheumatic Mitral Stenosis. **2020**, 109, 496-503 4

581 Retrospective cohort analysis of heart rate variability in patients with high altitude pulmonary hypertension in Tibet. **2020**, 43, 298-304 3

580	Echocardiography reporting of pulmonary hypertension and subsequent referral to a specialty clinic. 2020 , 37, 8-13	1
579	Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1 Year After First Episode of Acute Pulmonary Embolism: A Cohort Study. 2020 , 198, 59-64	2
578	Diagnostic Validity of Cardiopulmonary Exercise Testing for Screening Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease. 2020 , 40, 189-194	3
577	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. 2020 , 34, 1506-1513	4
576	Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis. 2020 , 55, 1681-1683	2
575	Evaluation of the CT imaging findings in the diagnosis of pulmonary hypertension due to chronic thromboembolism. 2020 , 14, 228-234	2
574	Catheter-Directed Pharmacologic Thrombolysis for Acute Submassive and Massive Pulmonary Emboli in Children and Adolescents-An Exploratory Report. 2020 , 21, e15-e22	5
573	A lung graph model for the radiological assessment of chronic thromboembolic pulmonary hypertension in CT. 2020 , 125, 103962	5
572	Long-term chronic intermittent hypoxia: a particular form of chronic high-altitude pulmonary hypertension. 2020 , 10, 5-12	10
571	Dynamic right ventricular function response to incremental exercise in pulmonary hypertension. 2020 , 10, 2045894020950187	3
570	Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis. 2020 , 10, 204589402095415	
569	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. 2020 , 10, 2045894020961739	5
568	Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients. 2020 , 11,	1
567	Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study. 2020 , 10, 2045894020958557	
566	Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. 2020 , 10, 2045894020962917	3
565	The outcome of pulmonary hypertension and its association with pulmonary artery dilatation. 2020 , 28, 645-655	0
564	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,	3
563	"Fit for Surgery? What's New in Preoperative Assessment of the High-Risk Patient Undergoing Pulmonary Resection". 2021 , 35, 3760-3773	0

562	Autophagy, Unfolded Protein Response and Lung Disease. 2020 , 1, 100003-100003	8
561	Bioresorbable Wireless Sensors as Temporary Implants for In Vivo Measurements of Pressure. 2020 , 30, 2003754	21
560	Impact of right ventricular function on development of significant tricuspid regurgitation in patients with chronic atrial fibrillation. 2020 , 76, 431-437	2
559	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. 2020 , 76, 1161-1168	4
558	Effects of exercise rehabilitation training on patients with pulmonary hypertension. 2020 , 10, 2045894020937129	
557	Phase Angle Evaluation of Lung Disease Patients and Its Relationship with Nutritional and Functional Parameters. 2021 , 40, 529-534	2
556	Prognostic Value of Gamma-Glutamyltransferase in Male Patients With Idiopathic Pulmonary Arterial Hypertension. 2020 , 7, 580908	1
555	Purinergic Dysfunction in Pulmonary Arterial Hypertension. 2020 , 9, e017404	6
554	The effect of oral sildenafil therapy on health-related quality of life in adults with pulmonary arterial hypertension related to uncorrected secundum atrial septal defect: a quasi experimental study. 2020 , 18, 278	1
553	A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report. 2020 , 99, e21342	1
552	CT-Based Biomarkers for Prediction of Chronic Thromboembolic Pulmonary Hypertension After an Acute Pulmonary Embolic Event. 2020 , 215, 800-806	6
551	CT-Derived Pulmonary Artery Diameters to Preselect for Echocardiography in COPD Patients Eligible for Bronchoscopic Treatments. 2020 , 99, 846-852	0
550	[Prevalence of Pulmonary Hypertension in Dialysis Patients with End-stage Renal Disease]. 2020 , 74, 210-216	1
549	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. 2020 , 75, 1397-1408	21
548	Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension. 2020 , 13, e009825	18
547	AMPK and the Need to Breathe and Feed: What's the Matter with Oxygen?. 2020 , 21,	6
546	Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension-A Genetic Study. 2020 , 21,	2
545	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. 2020 , 9,	8

544	Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension. 2020 , 49, 564-571		1
543	Assessment of ventilation-perfusion scans in patients with chronic thromboembolic pulmonary hypertension before and after surgery and correlation with clinical parameters. 2020 , 66, 147-152		2
542	The Left Heart, Systemic Circulation, and Bronchopulmonary Dysplasia: Relevance to Pathophysiology and Therapeutics. 2020 , 225, 13-22.e2		5
541	Right ventricular function parameters in pulmonary hypertension: echocardiography vs. cardiac magnetic resonance. 2020 , 20, 259		7
540	Effects of Different Types of Exercise Training on Pulmonary Arterial Hypertension: A Systematic Review. 2020 , 9,		8
539	Pregnancy outcomes in patients with pulmonary arterial hypertension: A retrospective study. 2020 , 99, e20285		9
538	Long-term outcome with focus on pulmonary hypertension in Obesity Hypoventilation Syndrome. 2020 , 14, 940-947		2
537	Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. <i>European Heart Journal</i> , 2020 , 41, 2785-2795	9.5	42
536	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. 2020 , 75, 935-945		10
535	Postpartum Pulmonary Hypertension Masquerading as Submassive Pulmonary Embolism: A Case Report and a Literature Review. 2020 , 2020, 8899562		
534	Atrial Septal Defect. 2020 , 38, 317-324		11
533	Right-to-Left Shunt Through Iatrogenic Atrial Septal Defect After MitraClip Procedure. 2020 , 13, 1544-1553		3
532	Evaluation and management of pulmonary hypertension in the emergency department setting. 2020 , 38, 1237-1244		
531	Correlation Between Arterial and Left Ventricle Diastolic Stiffness in Hypertensive Patients. 2020 , 441, 012166		
530	ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. 2020 , 34, 549-573		62
529	Data-driven stochastic optimization approaches to determine decision thresholds for risk estimation models. 2020 , 52, 1098-1121		0
528	Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. 2020 , 17, 439-461		11
527	Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study. 2020 , 15, e0229173		8

526	Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance. 2020 , 164, 105900	2
525	Genetic Predisposition to High-Altitude Pulmonary Edema. 2020 , 21, 28-36	9
524	The Prognostic Importance of TAPSE in Early and in Stable Cardiovascular Diseases. 2020 , 7,	2
523	Chronisch thromboembolische pulmonale Hypertonie. 2020 , 34, 79-86	
522	Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization. 2020 , 28, 100513	
521	Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia. 2020 , 2020, 7526508	4
520	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. 2020 , 9,	3
519	Associations between functional tricuspid regurgitation and long-term outcomes for patients with pulmonary hypertension. 2020 , 36, 1261-1269	1
518	Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension. 2020 , 11, 145	8
517	Clinical factors affecting left ventricular end-diastolic pressure in patients with acute ST-segment elevation myocardial infarction. 2020 , 9, 1834-1840	1
516	Diagnostic and predictive values of plasma connective tissue growth factor in children with pulmonary hypertension associated with CHD. 2020 , 30, 533-538	3
515	Serum human epididymis protein 4 level as a predictor of clinical worsening in idiopathic pulmonary arterial hypertension: a pilot study. 2020 , 20, 175	2
514	Significance of Pulmonary Vascular Resistance and Diastolic Pressure Gradient on the New Definition of Combined Post-Capillary Pulmonary Hypertension. 2020 , 61, 301-307	2
513	Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries. 2012 , 7, 249-259	20
512	Novel angiogenesis strategy to ameliorate pulmonary hypertension. 2021 , 161, e417-e434	4
511	Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. 2021 , 9, 33-38	26
510	Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease. 2021 , 40, 205-211	1
509	Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry. 2021 , 51, 355-365	7

508	Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension. 2021 , 29, 170-178	2
507	Evaluation of maternal and fetal outcomes in pregnancy complicated with pulmonary arterial hypertension. 2021 , 10, 1404-1410	5
506	Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 2021 , 35, 235-259	7
505	Longitudinal changes in risk status in pulmonary arterial hypertension. 2021 , 8, 680-690	1
504	BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival. 2021 , 21, 125-131	
503	Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension. 2021 , 14, 162-172	8
502	Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China. 2021 , 26, 196-203	8
501	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. 2021 , 56, 243-256	3
500	Can microsomal RNA be a biomarker in pulmonary hypertension secondary to bronchopulmonary dysplasia?. 2021 , 34, 1401-1406	3
499	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. 2021 , 22, 111-118	8
498	Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. 2021 , 15, 1753466621995040	0
497	Long-Term Complications: Portopulmonary Hypertension. 2021 , 247-254	
496	Sex difference in pulmonary hypertension in the evaluation by exercise echocardiography. 2021 , 11, 2045894020988453	0
495	The prevalence and clinical outcome of supraventricular tachycardia in different etiologies of pulmonary hypertension. 2021 , 16, e0245752	3
494	Vital capacity and valvular dysfunction could serve as non-invasive predictors to screen for exercise pulmonary hypertension in the elderly based on a new diagnostic score. 2021 , 13, 68-78	
493	Experimental Models. 2021 , 27-52	
492	Endothelial progenitor cells in pulmonary diseases, repair and regeneration. 2021 , 119-134	
491	Echocardiographic features of pre- and postcapillary pulmonary hypertension with a focus on the right ventricle in dogs. 41,	

- 490 Medicinal Plants Used in the Treatment of Pulmonary Hypertension. **2021**, 317-339
- 489 Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. **2021**, 452-462
- 488 Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: a retrospective single-center study in China. **2021**, 11, 1047-1057 1
- 487 Clinical Practice Guidelines for Biliary Atresia. **2021**, 341-350 0
- 486 Right-Heart Reverse Remodeling During Treatment for Pulmonary Hypertension. **2021**, 291-299
- 485 Transcatheter pulmonary denervation in patients with left heart failure with reduced ejection fraction and combined precapillary and postcapillary pulmonary hypertension: A prospective single center experience. **2021**, 98, 588-594 1
- 484 Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. **2021**, 10, 1515-1524 0
- 483 Natural course of tricuspid regurgitation and prognostic implications. **2021**, 8, 2
- 482 Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model. **2021**, 66, 101985
- 481 In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. **2021**, 16, 1221-1229 3
- 480 Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension. **2021**, 42, 125-131 0
- 479 Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. **2021**, 42, 59-70 3
- 478 Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement. **2021**, 98, E758-E767 1
- 477 Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension. **2021**, 49, 3000605211002379 2
- 476 Role of functional echocardiographic parameters in the diagnosis of bronchopulmonary dysplasia-associated pulmonary hypertension. **2021**, 2
- 475 Congenital Heart Disease-Associated Pulmonary Hypertension. **2021**, 42, 9-18 3
- 474 An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. **2021**, 12, 1720 9
- 473 Multicentre prospective observational study exploring the predictive value of functional echocardiographic indices for early identification of preterm neonates at risk of developing chronic pulmonary hypertension secondary to chronic neonatal lung disease. **2021**, 11, e044924 1

472	Pulmonary artery obstruction index, pulmonary artery diameter and right ventricle strain as prognostic CT findings in patient with acute pulmonary embolism. 2021 ,	
471	Early risk prediction in idiopathic connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. 2021 , 7,	2
470	Detection of severe pulmonary hypertension based on computed tomography pulmonary angiography. 2021 , 37, 2577-2588	0
469	Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease. 2021 , 180, 2889-2895	2
468	A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. 2021 , 11, 2045894021995055	0
467	Morphological Analysis of the Right Ventricular Endocardial Wall in Pulmonary Hypertension. 2021 , 143,	
466	Evaluation of left ventricular function by vector flow mapping in females with systemic lupus erythematosus. 2021 , 40, 4049-4060	0
465	Does Duke Activity Status Index help predicting functional exercise capacity and long-term prognosis in patients with pulmonary hypertension?. 2021 , 181, 106375	1
464	Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension. 2021 , 13, 2746-2757	
463	Echocardiographic Prognosis Relevance of Attenuated Right Heart Remodeling in Idiopathic Pulmonary Arterial Hypertension. 2021 , 8, 650848	1
462	Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. 2021 ,	0
461	Is it time for a paradigm shift: Should double-lung transplant be considered the treatment of choice for idiopathic pulmonary arterial hypertension and giant pulmonary aneurysm?. 2021 , 36, 2996-2999	3
460	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. 2021 , 18, 981-988	3
459	Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES). 2021 , 11, 20458940211024206	0
458	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. 2021 , 10, e020633	4
457	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. 2021 , 51, 495-512	3
456	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. 2021 , 204, 842-854	13
455	Riding the Ferrous Wheel of Iron Supplementation in Pulmonary Arterial Hypertension. 2021 , 18, 946-948	0

454	Impact of circGSAP in Peripheral Blood Mononuclear Cells on Idiopathic Pulmonary Arterial Hypertension. 2021 , 203, 1579-1583	6
453	Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?. 2021 , 8, 679487	1
452	Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension. 2021 , 3, 872-879	1
451	Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. 2021 , 48, 1830-1838	0
450	Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension. 2021 , 335, 105-110	4
449	Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension. 2021 , 8, 699904	0
448	An echocardiographic evaluation to determine the immediate and short-term changes in biventricular systolic and diastolic functions after PDA device closure-an observational analytical prospective study (echo- PDA study). 2021 , 73, 617-621	0
447	Predictive Modeling of Secondary Pulmonary Hypertension in Left Ventricular Diastolic Dysfunction. 2021 , 12, 666915	2
446	Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. 2021 , 21, 251	1
445	Potential of C-X-C motif chemokine ligand 1/8/10/12 as diagnostic and prognostic biomarkers in idiopathic pulmonary arterial hypertension. 2021 , 15, 1302-1309	0
444	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. 2021 , 73, 1731-1737	5
443	Pulmonary Arterial Hypertension as a Fatal Complication of Neurofibromatosis Type 1 in a Neonate: A Diagnostic Dilemma. 2021 , 13, e17137	
442	Treatment of pulmonary arterial hypertension in children. 2021 , 11, 1144-1159	1
441	Anti-Inflammatory Effect of Allicin Associated with Fibrosis in Pulmonary Arterial Hypertension. 2021 , 22,	3
440	Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure. 2021 , 19, 202	2
439	Estimation of pulmonary artery pressure with transesophageal echocardiography: An observer-blinded test accuracy study. 2021 , 100, e26988	
438	Echocardiographic Assessment of the Transitional Circulation. 2021 , 964-991	
437	The prediction of right atrial pressure using electrocardiogram: a novel approach. 2021 ,	1

436	Proposition of quantitative parameters for pre- and early post-operative assessment in pulmonary thromboendarterectomy - An Indian prospective study. 2021 , 2184923211042183	
435	Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension. 2021 , 11, 20458940211041500	0
434	Physical Examination for the Detection of Pulmonary Hypertension: A Systematic Review. 2021 , 13, e18020	
433	Oxygen Therapy in Children. 2022 , 321-329	
432	Group 2 Pulmonary Hypertension: Clinical Features and Treatment. 2022 , 665-677	
431	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.. 2021 , 11, 1255-1268	0
430	Pulmonary and Critical Care Medicine. 2021 , 325-338	
429	Predicting mortality during long-term follow-up in pulmonary arterial hypertension. 2021 , 7,	3
428	Epidemiology of Pediatric Pulmonary Hypertension. 2014 , 2123-2137	2
427	Pulmonary Hypertension in Congenital Heart Disease. 2014 , 553-572	2
426	Pulmonary Arterial Hypertension and Oxidative Stress. 2014 , 259-325	1
425	Pathophysiology and Pharmacotherapy of Adult Congenital Heart Disease. 2015 , 1269-1291	1
424	Herz-Kreislauf-Erkrankungen. 2011 , 289-324	2
423	Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. 2013 , 218, 381-408	10
422	Calcium-channel blockers in pulmonary arterial hypertension. 2013 , 218, 161-75	5
421	Prostacyclins. 2013 , 218, 177-98	4
420	Dasatinib. 2014 , 201, 27-65	46
419	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. 2015 , 85, 215-24	6

418	RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. 2017 , 810, 92-99	13
417	Detection of mechanical complications related to the potential risk of sudden cardiac death in patients with pulmonary arterial hypertension by computed tomography. 2017 , 243, 460-465	10
416	Machine Learning of the Cardiac Phenome and Skin Transcriptome to Categorize Heart Disease in Systemic Sclerosis.	1
415	Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?. 2013 , 43, 599-603	10
414	Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low -Arrestin Recruitment and Desensitization Potential. 2017 , 362, 186-199	19
413	Pulmonary arterial hypertension associated with neurofibromatosis type 1. 2010 , 2010,	2
412	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. 2011 , 121, 2888-97	70
411	Epidemiology of pulmonary hypertension in the elderly. 2017 , 14, 11-16	6
410	The incidence and severity of pulmonary hypertension in obstructive sleep apnea with hypothyroidism. 2013 , 19, 883-7	5
409	Can Echocardiography, Especially Tricuspid Annular Plane Systolic Excursion Measurement, Predict Pulmonary Hypertension and Improve Prognosis in Patients on Long-Term Dialysis?. 2015 , 21, 4015-22	6
408	Caregiver's burden in pulmonary arterial hypertension: a clinical review. 2016 , 12, 386-392	9
407	The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. 2010 , 5, e9526	37
406	Clinical presentation of acute pulmonary embolism: survey of 800 cases. 2012 , 7, e30891	57
405	Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound. 2012 , 7, e33331	33
404	Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. 2012 , 7, e38519	35
403	Temperature variations around medication cassette and carry bag in routine use of epoprostenol administration in healthy volunteers. 2012 , 7, e52216	4
402	Circulating miRNAs as potential marker for pulmonary hypertension. 2013 , 8, e64396	93
401	Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. 2013 , 8, e65114	29

400	Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. 2013 , 8, e72013	45
399	Single intraperitoneal injection of monocrotaline as a novel large animal model of chronic pulmonary hypertension in Tibet minipigs. 2013 , 8, e78965	8
398	Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension. 2013 , 8, e82628	15
397	N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency. 2014 , 9, e94263	10
396	Skeletal muscle abnormalities in pulmonary arterial hypertension. 2014 , 9, e114101	32
395	Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. 2014 , 9, e115219	14
394	Echocardiographic predictors of mortality in patients with pulmonary hypertension and cardiopulmonary comorbidities. 2015 , 10, e0119277	13
393	Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertension. 2015 , 10, e0120657	7
392	Hemodynamic changes of the middle hepatic vein in patients with pulmonary hypertension using echocardiography. 2015 , 10, e0121408	6
391	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. 2015 , 10, e0130072	41
390	Prognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis. 2015 , 10, e0136024	20
389	Pulmonary Arterial Capacitance Predicts Cardiac Events in Pulmonary Hypertension Due to Left Heart Disease. 2016 , 11, e0165603	8
388	Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. 2016 , 11, e0168706	9
387	Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping. 2017 , 12, e0169238	15
386	Oxidative profiling of the failing right heart in rats with pulmonary hypertension. 2017 , 12, e0176887	18
385	Magnetic resonance imaging in pediatric pulmonary hypertension. 2015 , 42, 209-15	4
384	Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clinical outcome and survival in pulmonary hypertension Groups (SIMURG). 2017 , 18, 242-250	8
383	B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis. 2018 , 37, 406-414	4

382	Echocardiographic assessment of the tricuspid and pulmonary valves: a practical guideline from the British Society of Echocardiography. 2020 , 7, G95-G122	6
381	Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease. 2020 , 2, R17-R34	12
380	Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. 2011 , 52, 323-6	6
379	[Current issues in pulmonary hypertension]. 2012 , 153, 603-6	1
378	Pulmonary hypertension as a risk assessment factor for unfavorable outcome in patients with COVID-19. 2020 , 25, 4136	4
377	[Physical rehabilitation of patients with pulmonary hypertension]. 2019 , 96, 51-60	1
376	[The concurrence of kidney and liver dysfunctions in decompensated heart failure]. 2016 , 88, 40-44	1
375	[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]. 2017 , 89, 100-103	2
374	Influence of Left Ventricular Diastolic Function on Exercise-induced Pulmonary Hypertension in Patients with Systemic Sclerosis. 2015 , 6, 131-139	1
373	Levamisole, Aminorex, and Pulmonary Arterial Hypertension: A Review. 2015 , 3,	2
372	Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension. 2017 , 8, 54106-54114	2
371	Antithrombotic therapy in patients with pulmonary arterial hypertension. 2019 , 25, 25-33	2
370	Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors. 2016 , 9, 474-484	2
369	An Update on Therapies for Pediatric Pulmonary Arterial Hypertension 2011. 2011 , 10, 109-114	1
368	Contraceptive Options for the Patient with Pulmonary Arterial Hypertension. 2011 , 10, 167-172	1
367	The Role of Warfarin Anticoagulation in Pulmonary Hypertension. 2012 , 11, 15-16	1
366	Pulmonary Hypertension in Patients With Chronic Kidney Disease: Noninvasive Strategies for Patient Phenotyping and Risk Assessment. 2013 , 12, 76-81	2
365	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. 2013 , 12, 127-134	1

364	Classification of Pulmonary Hypertension. 2014 , 13, 17-20	1
363	Pulmonary Hypertension Due to Valvular Heart Disease: Aortic and Mitral. 2015 , 14, 95-101	1
362	HIV-Associated Pulmonary Hypertension: A Global Perspective. 2017 , 15, 138-143	4
361	Center-based Care for Pulmonary Hypertension: A European Perspective. 2018 , 16, 170-174	3
360	What Can be Learned in 6 Minutes? 6-Minute Walk Test Primer and Role in Pulmonary Arterial Hypertension. 2010 , 9, 107-111	4
359	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. 2019 , 26, 2844-2864	11
358	Heart failure in sub-Saharan Africa. 2013 , 9, 157-73	57
357	Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function. 2019 , 15, 3-11	2
356	The Mobile-Based 6-Minute Walk Test: Usability Study and Algorithm Development and Validation. 2020 , 8, e13756	22
355	The relationship between platelet-to-lymphocyte ratio and pulmonary embolism severity in acute pulmonary embolism. 2019 , 38, 4-9	10
354	Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations. 2015 , 4, Doc03	3
353	The predictive value of echocardiography for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism in Korea. 2017 , 32, 85-94	13
352	Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. 2015 , 30, 232-41	19
351	Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. 2015 , 7, 309-19	20
350	Tuberculosis associated pulmonary hypertension: The revelation of a clinical observation. 2016 , 33, 135-9	9
349	Evaluation of Serum Vitamin D Levels in Patients with Systemic Sclerosis and Healthy Controls: Results of a Pilot Study. 2018 , 9, 250-255	13
348	Incidence of chronic thromboembolic pulmonary hypertension in Thammasat University Hospital. 2018 , 35, 373-378	5
347	Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. 2015 , 47, 937-42	13

346	Efficacy of Isovolumic Acceleration in Assessing Right Ventricular Function in Pulmonary Hypertension. 2014 , 05, 674-680	1
345	Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension. 2014 , 10, 518-25	84
344	Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. 2013 , 9, 269-76	54
343	Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. 2014 , 9, 1042-9	50
342	Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. 2013 , 9 Suppl R, R149-54	1
341	Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. 2014 , 6, 825-9	4
340	Transoesophageal echocardiography during liver transplantation. 2015 , 7, 2432-48	23
339	Long term combination treatment for severe idiopathic pulmonary arterial hypertension. 2010 , 2, 68-70	3
338	Pulmonary hypertension in hereditary haemorrhagic telangiectasia. 2015 , 7, 230-7	28
337	Frequency of pulmonary hypertension in transthoracic echocardiography screening is not increased in Takayasu arteritis: Experience from a single center in Turkey. 2018 , 5, 249-253	3
336	The Incidence and Related Risk Factors of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. 2016 , 17, 53-58	1
335	Assessment of Thyroid Function in Idiopathic Pulmonary Hypertension. 2016 , 5, e29361	8
334	Shortness of Breath and Lower Limb Edema in a 54-Year-Old Woman, Is There Any Cure?. 2016 , 5, e30549	2
333	Comparison of Tadalafil and Sildenafil in Controlling Neonatal Persistent Pulmonary Hypertension. 2016 , In Press,	3
332	Effect of Peripheral Heart Action on Body Composition and Blood Pressure in Women with High Blood Pressure. 2018 , In Press,	3
331	Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension. 2010 , 21, 334-7	9
330	Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study. 2017 , 28, 370-376	2
329	MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension. 2015 , 30, 380-5	10

328	Neuroprotective effects of dynamic bubble trap use in patients undergoing pulmonary endarterectomy: a two-arm randomized controlled trial. 2021 , 13, 5807-5817	0
327	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. 2021 ,	6
326	Mortality trends in pulmonary arterial hypertension in canada: a temporal analysis of survival per ESC/ERS Guideline Era. 2021 ,	6
325	A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines. 2021 , 8,	0
324	Cardiovascular Diseases That Have Emerged From the Darkness. 2021 , 10, e021095	3
323	Liver abnormalities in pulmonary arterial hypertension. 2021 , 11, 20458940211054304	1
322	[Functional characterization of patients with isolated post-capillary or combined post-capillary and pre-capillary pulmonary hypertension]. 2021 , 146, e88-e94	0
321	Incidence and predictors of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism: An echocardiography guided approach. 2021 , 73, 746-750	1
320	The predictive role of cardiac magnetic resonance imaging in determining thalassemia patients with intermediately to highly probable pulmonary hypertension. 2021 , 38, 1769-1777	
319	Modalities Used to Help Prolong Survival in Patients With Advanced PAH. 2010 , 9, 61-62	
318	Surgical outcome of severe pulmonary arterial hypertension secondary to left-to-right shunt lesions. 2010 , 53, 195	
317	Angiology: Diseases of the Blood Vessels. 2010 , 305-333	
316	Hypertension artfielle pulmonaire. 2010 , 287-293	
315	Pulmonary Arterial Hypertension. 2010 , 153-163	
314	Leitsymptom Beinödeme. 2011 , 195-205	
313	Pulmonale Hypertonie. 2011 , 309-334	
312	Is There a Role for Acute Vasoreactivity Testing Outside of Patients With Pulmonary Arterial Hypertension?. 2011 , 10, 15-16	
311	Les atteintes pulmonaires de la sclérodemie. 2011 , 195, 79-92	

- 310 Leitsymptom Dyspnoe, Leistungsschwäche. **2011**, 87-194
- 309 [Treatment of idiopathic pulmonary arterial hypertension]. **2011**, 131, 1285-8 1
- 308 Chronická plicní hypertenze. Doporučení diagnostického a léčebného postupu českých kardiologů společnosti, 2010. **2011**, 53, 169-182 3
- 307 Two years of cooperation between Regional Cardiology Centre and the Centre for Pulmonary Hypertension: results. **2011**, 53, 486-489
- 306 Current Clinical Needs. **2012**, 149-161
- 305 Lungenoperationen, Bronchoskopie, Tracheaoperationen. **2012**, 357-417 1
- 304 2. Guanylate Cyclase Enhancer. **2012**, 43, 311-315
- 303 Pulmonary Hypertension/Eisenmenger Syndrome. **2012**, 2413-2423
- 302 Pulmonary Hypertension. **2012**, 389-397
- 301 Screening for Pulmonary Arterial Hypertension. **2012**, 11, 78-83 1
- 300 Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (Including Eisenmenger Syndrome). 168-175
- 299 Primary Pulmonary Arterial Hypertension in Children. 164-167
- 298 Contemporary treatment of pulmonary arterial hypertension: the North-West Registry data analysis. **2012**, 11, 79-84
- 297 Thromboembolic Disease and Pulmonary Hypertension. **2013**, 415-433
- 296 Pulmonale hypertensie en het Eisenmenger-syndroom. **2013**, 75-82
- 295 [Ventricular septal defects in adults: 15 years of surgical experience in a single Colombian cardiovascular center]. **2013**, 83, 24-30
- 294 Drugs for Pulmonary Arterial Hypertension. **2013**, 72, 260-261
- 293 Legoch'naya arterial'naya gipertenziya: na puti ot ratsional'noy diagnostiki k vyboru effektivnoy lekarstvennoy terapii. **2013**, 10, 57-69 1

292 Pulmonary Hypertension. **2014**, 97-114

291 Monitoring and prognosis of pulmonary arterial hypertension. **2013**, 98-111

290 Echocardiography in the ICU. **2014**, 879-899

289 The right heart. **2013**, 191-217

288 Pulmonary hypertension (2008 classification).

287 Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment. **2013**, 10, 70-75

3

286 Heart Failure and Pulmonary Hypertension in Women. **2014**, 155-173

285 The Essential Role of Imaging in the Evaluation of Patients With Pulmonary Arterial Hypertension in Association With Congenital Heart Disease. **2013**, 11, 171-182

284 Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. **2013**, 11, 183-188

283 Leitsymptom Beinödeme. **2014**, 223-233

282 A Treatment Algorithm for Pulmonary Arterial Hypertension. **2014**, 13, 31-37

281 Ask the Expert: How Might Adherence to the Treatment Recommendations of the 2013 Fifth World Symposium on Pulmonary Hypertension Improve Long-Term Outcomes?. **2014**, 13, 38-39

280 Pulmonary Venous Hypertension. **2014**, 1-14

279 Pulmonary Hypertension Associated with Congenital Heart Disease, Eisenmenger Syndrome. **2014**, 117-124

278 Chapter 13:Treatments for Pulmonary Arterial Hypertension. **2014**, 369-397

277 Portopulmonary Hypertension in Patients Undergoing Liver Transplantation: A Case Report. **2014**, 05, 53-56

276 The Right Heart in Chronic Thromboembolic Pulmonary Hypertension. **2014**, 243-257

275 Aging and Right Ventricular Failure from Pulmonary Hypertension: Effect of Right Ventricular and Pulmonary Artery Remodeling. **2014**, 291-304

- 274 Congenital heart disease and inherited cardiac disorders. **2014**, 273-290
- 273 Pulmonale Hypertonie. **2014**, 1423-1427
- 272 Experimental Models. **2014**, 45-67
- 271 Acute heart failure. **2014**, 271-288.e5
- 270 Pulmonary Arterial Hypertension in Intensive Care Unit. **2014**, 37-58
- 269 Arrhythmias in Right Heart Failure due to Pulmonary Hypertension. **2014**, 277-290
- 268 Pulmonale Hypertonie (PAH) und akute Rechtsherzdekompensation. **2014**, 497-505
- 267 Echocardiography in Sleep Apnea Patients: A Long Way to Go. **2014**, 2,
- 266 Leitsymptom Dyspnoe, Leistungsschwäche. **2014**, 111-222
- 265 Nitric Oxide Therapeutics in Pulmonary Vascular Disease. **2014**, 13, 134-137
- 264 Pulmonary hypertension in idiopathic pulmonary fibrosis. **2014**, 8, 23-31
- 263 A thalassaemia intermedia case with concomitant left atrial thrombus. **2014**, 2014,
- 262 Heart and APS. **2015**, 127-150
- 261 Evaluation of Right Ventricular Systolic Function by Echocardiography in Pulmonary Hypertension Associated With Congenital Heart Disease: a Cross Sectional Study. **2014**, 2,
- 260 Pulmonary Hypertension in Orphan Lung Diseases. **2015**, 529-539
- 259 The development of a screening questionnaire to improve the early detection of pulmonary arterial hypertension. **2014**, 11, 62-67
- 258 Encyclopedia of Trauma Care. **2015**, 1365-1371
- 257 Selected Disorders of the Cardiovascular System. **2015**, 1-21

256 Pathophysiology and Treatment of Pulmonary Arterial Hypertension. **2015**, 949-974

255 Pulmonale Hypertonie bei Kindern und Jugendlichen. **2015**, 1-8

254 Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. **2015**, 1-38

253 [Pulmonary hypertension associated with congenital heart disease and Eisenmenger syndrome]. **2015**, 85, 32-49 4

252 A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension. **2015**, 10, 102-107

251 [Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan]. **2015**, 87, 64-71 1

250 Research Reviews: Vasoreactivity in PAH. **2015**, 14, 19-20

249 [Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases]. **2015**, 87, 24-32 1

248 Pulmonary Venous Hypertension. **2015**, 4157-4168

247 Sport bei Patienten mit angeborenen Herzfehlern (inklusive rechtsventrikuläre Vitien). **2015**, 257-266

246 The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone—**2015**, 31, 157-183

245 Pulmonary Hypertension. **2015**, 10, 9-11

244 Pulmonary Vascular Capacitance as a Predictor of Vasoreactivity in Idiopathic Pulmonary Arterial Hypertension Tested by Adenosine. **2015**, 4, e28945 0

243 [Pulmonary arterial hypertension associated to human immunodeficiency virus]. **2015**, 85, 118-23

242 Clinical case: combination therapy with iloprost and sildenafil in the treatment of idiopathic pulmonary hypertension. **2015**, 12, 66-70

241 Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension. **2016**, 16, 491-496 2

240 Correlation between Automated Quantification of Lung Perfusion Blood Volume (PBV) and Pulmonary Artery Pressure. **2016**, 06, 105-112 0

239 The Right Heart. **2016**, 145-168

- 238 The benefit of using a low dose calcium channel blocker in a patient with idiopathic pulmonary hypertension. **2016**, 35, 60-64
- 237 Support Care for the Pulmonary Hypertension Patient. **2016**, 327-343
- 236 Lung transplantation for pulmonary hypertension. **2016**, 213-222
- 235 [Risk factors for pulmonary hypertension at the predialysis stage of chronic kidney disease]. **2016**, 88, 33-39
- 234 Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. **2016**, 29-61
- 233 Pulmonale Hypertonie. **2016**, 313-329
- 232 Unable to Access the Pulmonary Artery. **2016**, 71-80
- 231 Congenital coronary artery fistulas complicated with pulmonary hypertension: Analysis of 211 cases. **2016**, 8, 596-605 3
- 230 Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. **2016**, 1183-1219
- 229 Survival of the Infants with Bronchopulmonary Dysplasia and Congenital Heart Disease. **2016**, 23, 190
- 228 Biomarkers for Cardiovascular Diseases. **2016**, 2, 94-98
- 227 Assessing Disease State in the Pulmonary Vasculature in Clinical Practice and Research. **2016**, 219-229
- 226 The Cardiopulmonary Hemodynamic Evaluation of Pulmonary Hypertension. **2016**, 173-198
- 225 Echocardiographic Measurement of Pulmonary Arterial Pressure in Patients with Sarcoidosis. **2016**, 06, 7-13
- 224 Findings Associated with Pulmonary Hypertension: CT Angiography Based Study. **2016**, 06, 191-201
- 223 Pneumologie. **2016**, 423-487
- 222 The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. **2016**, 13, 34-38
- 221 Coronary Artery Bypass Surgery in Left Main Disease with Idiopathic Artery Pulmonary Hypertension. Role of PGE Therapy. **2016**, 2, 024-027

220 Pulmonary Hypertension in Sickle Cell Disease Patients: Correlation of TRV Jet with Serum NT-Pro BNP Concentration. **2016**, 1, 5-10

219 Pulmonary and Critical Care Medicine. **2017**, 325-337

218 Biomarkers in Systemic Sclerosis. **2017**, 245-260

217 Managing Children with Bronchopulmonary Dysplasia. **2016**, 13, 319-333

2

216 Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy. **2017**, 691-700

215 Correlation between high-resolution computed tomography of the chest and pulmonary functions in idiopathic pulmonary fibrosis. **2016**, 10, 330-336

1

214 Imaging Assessment of Functional Tricuspid Regurgitation. **2017**, 167-179

213 Clinical Trial Design in Systemic Sclerosis. **2017**, 623-635

212 Cardiac Catheterization. **2017**, 215-226

1

211 Management of Fontan Patients. **2017**, 329-340

210 Case 5/2017 - A 28-Year-Old Woman with Cor Pulmonale Due to Pulmonary Hypertension Secondary to Chronic Pulmonary Thromboembolism. **2017**, 109, 370-375

209 Derivation and Validation of Formula relating Pulmonary Acceleration Time and Mean Pulmonary Artery Pressure in Indian Population. **2017**, 5, 3-11

208 Three Element Windkessel Model to Non-Invasively Assess PAH Patients: One Year Follow-up. **2017**, 151-154

207 Cardiac Effect of Interstitial Lung Disease Correlated with Spirometry and Six Minute Walk Test. **2017**, 11, OC14-OC17

4

206 Kardiale Umfelddiagnostik bei Gefäßoperationen und Gefäßinterventionen. **2017**, 1-21

205 Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines?. **2017**, 15, 182-183

204 Acute Right Heart Failure. **2017**, 209-271

203 Pulmonary Hypertension in Left Heart Disease. **2017**, 341-369

- 202 Interstitial Lung Disease-Associated Pulmonary Hypertension in the Connective Tissue Disorders. **2017**, 165-180
- 201 Pulmonary hypertension complicated with asbestos-related disease in a patient with severe renal impairment. **2017**, 50, 527-534
- 200 Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort. **2017**, 16, 14-19
- 199 Prognostication in PAH \square HD. **2017**, 315-328
- 198 [Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension]. **2017**, 87, 172-174 1
- 197 Inherited Pulmonary Arterial Hypertension. **2018**, 741-753
- 196 Thoraxchirurgie. **2018**, 1005-1023 0
- 195 OBSOLETE: Pulmonary Arterial Hypertension. **2018**,
- 194 Eisenmenger \square Syndrome. **2018**, 185-187
- 193 Increased microvolt T-wave alternans in children and adolescents with Eisenmenger syndrome. **2018**, 19, 303-310 0
- 192 Understanding Cardiovascular Hemodynamics. **2018**, 15-32 1
- 191 Heart Sound Analysis for Blood Pressure Estimation. **2018**, 1006-1016
- 190 Principles of pharmacological correction of pulmonary arterial hypertension. **2018**, 4, 59-76 1
- 189 AN EPIDEMIOLOGICAL STUDY OF PULMONARY HYPERTENSION BY ECHOCARDIOGRAPHY IN TERTIARY CARE INSTITUTE, TAMILNADU, SOUTH INDIA. **2018**, 7, 3950-3953
- 188 THE COMPLEXITY OF DIAGNOSING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. **2018**, 63, 167-171
- 187 Heart Sound Analysis for Blood Pressure Estimation. **2019**, 98-109 0
- 186 Pneumologie. **2019**, 457-525
- 185 PH Grand Rounds: Eisenmenger Syndrome: When Less Is More. **2019**, 18, 33-36

184	Relationship Between Preoperative Diastolic Transpulmonary Gradient With Pulmonary Vascular Resistance and 1-Year and Overall Mortality Rates Among Patients Undergoing Cardiac Transplant. 2019 , 17, 231-235	1
183	Chronic postembolic pulmonary embolism: the role of radionuclide imaging. 2019 , 18, 17-23	
182	Postoperative pulmonary complications in contemporary cohort of patients with pulmonary hypertension. 2019 , 19, 392-399	3
181	Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension - Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE). 2019 , 1, 303-311	1
180	Perioperative anesthetic considerations in patients with pulmonary hypertension undergoing non-cardiac and non-obstetric surgeries. 2019 , 2, 31-39	1
179	Ask the Expert: What Is the Exercise Prescription That You Provide to Your Patients?. 2019 , 18, 68-69	
178	Pulmoner hipertansiyonlu hastalarda comet analizi ile deęerlendirilen artmıDNA hasarđ	
177	Direct medical costs of hospitalized patients with idiopathic pulmonary fibrosis in China.	
176	Radiological and hemodynamic parameters in patients with suspected ventricular aneurysm and interventricular septal perforation after acute myocardial infarction: A comparison of non-invasive and invasive diagnostic modalities. 2020 , 20, 961-967	
175	Respiratory Variations in Aortic Blood Flow to Predict Volume Responsiveness in Ventilated Children With Leukemia and Neutropenic Septic Shock. 2020 , 21, e247-e252	0
174	Cardiovascular complications of cystic fibrosis. 2020 , 108-117	
173	PeakPCO combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension. 2021 , 11, 20458940211059713	
172	Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2021 , 23, 442-454	
171	Pulmonary arterial hypertension associated with congenital heart disease: classification and pathophysiology. 2020 , 4,	1
170	Doppler-defined pulmonary hypertension in ðthalassemia major in Kurdistan, Iraq. 2020 , 15, e0243648	
169	The preventive and therapeutic effects of AAV1-KLF4-shRNA in cigarette smoke-induced pulmonary hypertension. 2021 , 25, 1238-1251	1
168	Usefulness of mean pulmonary artery pressure for predicting outcomes of transcatheter closure of atrial septal defect with pulmonary arterial hypertension. 2020 , 16, e1029-e1035	0
167	[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. 2020 , 92, 80-85	5

166	Relationship between transesophageal echocardiography-derived pulmonary artery systolic pressure measurements and early morbidity in patients undergoing coronary artery bypass grafting. 2020 , 23, 453-459	
165	Leitsymptom Beinödeme. 2020 , 231-241	
164	Effect of Obesity on Pulmonary Vascular Hemodynamics. 2020 , 30, 75-81	
163	Selected Disorders of the Cardiovascular System. 2020 , 1-22	
162	Kardiale Umfelddiagnostik bei Gefäßoperationen und Gefäßinterventionen. 2020 , 209-229	
161	Pulmonary Hypertension. 2020 , 365-378	
160	Ductal closure in infants under 6 kg including premature infants using Amplatzer duct occluder type two additional sizes: a single-centre experience in South Africa. 2020 , 31, 33-39	2
159	Predictive modeling of secondary pulmonary hypertension in left ventricular diastolic dysfunction.	0
158	Sex and gender in pulmonary arterial hypertension. 2021 , 30,	2
157	Conformance Checking Methodology Across Discharge Summaries and Standard Treatment Guidelines. 2020 , 1, 1-19	0
156	Multiple Choice Questions with explanations. 1-544	
155	Question 110. 225-227	
154	Question 258. 535-536	
153	Anti-inflammatory and immunosuppressive agents in PAH. 2013 , 218, 437-76	12
152	Hypoxia in utero increases the risk of pulmonary hypertension in rat offspring and is associated with vasopressin type-2 receptor upregulation. 2020 , 22, 4173-4182	1
151	Multi-detector CT assessment in pulmonary hypertension: techniques, systematic approach to interpretation and key findings. 2015 , 5, 423-32	12
150	Pulmonary arterial hypertension: an unusual cause of portal hypertension. 2012 , 8, 408-10	1
149	Tricuspid regurgitation improvement in relation to the amount of pulmonary artery pressure reduction. 2010 , 5, 132-6	3

148	Tricuspid regurgitation improvement in relation to the amount of pulmonary artery pressure reduction. 2010 , 5, 209-10	
147	Prognostic factors in pulmonary hypertension. 2012 , 7, 30-7	6
146	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. 2012 , 30, S30-7	42
145	Effect of prostaglandin E1 inhalation on pulmonary hypertension following corrective surgery for congenital heart disease. 2013 , 18, 13-6	2
144	Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. 2013 , 18, e37-9	11
143	Pulmonary arterial hypertension and pregnancy. 2013 , 18, 73-6	9
142	A review of ongoing trials in exercise based rehabilitation for pulmonary arterial hypertension. 2013 , 137, 900-6	8
141	New Echocardiographic Tehniques in Pulmonary Arterial Hypertension vs. Right Heart Catheterization - A Pilot Study. 2013 , 8, 116-23	5
140	Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension. 2014 , 4, 341-9	7
139	Complete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case report. 2014 , 9, 198-203	1
138	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. 2015 , 67, 169-85	5
137	Diagnostic performance of cardiac magnetic resonance for the detection of acute cardiac allograft rejection: a systematic review and meta-analysis. 2015 , 7, 252-63	7
136	Platelet abnormalities in chronic thromboembolic pulmonary hypertension. 2015 , 8, 9700-7	9
135	Iranian Pulmonary Arterial Hypertension Registry. 2015 , 14, 115-20	4
134	Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1. 2015 , 8, 10743-51	5
133	Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension. 2015 , 8, 15302-7	9
132	Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study. 2014 , 30, 236-44	2
131	Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease. 2015 , 31, 325-36	7

130	Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View. 2015 , 31, 507-15	6
129	The Challenges in Managing Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. 2015 , 31, 516-7	1
128	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. 2014 , 30, 401-44	11
127	Surgical strategies for patients with congenital heart disease and severe pulmonary hypertension in low/middle-income countries. 2015 , 7, 31-7	4
126	Nerve distribution of canine pulmonary arteries and potential clinical implications. 2016 , 8, 365-74	4
125	Pulmonary Hypertension in Children - a Practical Approach. 2015 , 10, 237-242	
124	Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective. 2018 , 21, 116-122	11
123	[Evaluation of Pulmonary Hypertension with CMR: Pulmonary Hypertension ?Patients and Healthy Volunteers Control Study]. 2016 , 19, 293-8	0
122	[The assessment of right ventricular function and pulmonary artery hemodynamics in patients with pulmonary hypertension by 1.5T MRI]. 2012 , 15, 471-5	0
121	Impact of preoperative pulmonary arterial hypertension on early and late outcomes in patients undergoing valve surgery for rheumatic heart disease. 2018 , 62, 963-971	1
120	Idiopathic Pulmonary Arterial Hypertension Was Diagnosed Initially by the Computed Tomographic Angiogram. 2018 , 8, 72-75	
119	Thromboendarterectomy in a patient with Systemic Lupus and antiphospholipid Syndrome, lessons learned from a complex disease interaction. 2020 , 2020, e202015	
118	Patient-Specific Computational Analysis of Hemodynamics in Adult Pulmonary Hypertension. 2021 , 49, 3465	0
117	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. 2021 ,	0
116	Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. 2021 , 21, 365	0
115	New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid. 2021 , 100, 22-22	1
114	The effect of azithromycin for management of HIV-associated chronic lung disease on right heart function: Results from the BREATHE trial. 2021 , 37, 100920	
113	Heart Rate Recovery at 1 Min after Exercise Is a Marker of Disease Severity and Prognosis in Chronic Thromboembolic Pulmonary Hypertension.. 2021 , 1-10	1

112 Chronisches Cor pulmonale/pulmonale Hypertonie. **2015**, 1-18

111 Pulmonale Hypertonie: Funktion des rechten Herzens beeinflusst Prognose.

110 CLINICAL AND HEMODYNAMIC PROFILE AND NEUROHORMONAL INDICATORS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION, DEPENDING ON VASOREACTIVITY RESERVE OF PULMONARY ARTERIES. **2016**, 12-20

109 Management of pulmonary hypertension in secondary antiphospholipid syndrome. **2020**, 2020, e202015

108 Echocardiographic abnormalities in children and adolescents living with human immunodeficiency virus on highly active antiretroviral treatment. **2020**, 31, 236-240

107 Selected Disorders of the Cardiovascular System. **2022**, 1145-1166

106 The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy.. **2022**, 11,

1

105 The Right Heart. **2022**, 161-177

104 PHD2 deletion in endothelial or arterial smooth muscle cells reveals vascular cell type-specific responses in pulmonary hypertension and fibrosis.. **2022**, 1

0

103 Pulmonale Hypertonie. **2022**, 419-438

102 Mortality in β -thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization.. **2022**,

0

101 Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.. **2022**, 12, e12001

0

100 Pulmonary hypertension is associated with an increased incidence of NAFLD.. **2022**,

1

99 Echocardiographic Estimated Pulmonary Systolic Pressure and Outcome After Noncardiac-Obstetrics Surgery in Postcapillary Pulmonary Hypertensive Patients.. **2022**,

98 Pilot study on the value of echocardiography combined with lung ultrasound to evaluate COVID-19 pneumonia.. **2022**, 20, 2

97 Outcome of Surgery for Chronic Thromboembolic Pulmonary Disease without Pulmonary Hypertension.. **2022**,

0

96 Excimer laser coronary atherectomy (ELCA) can be a powerful weapon in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). **2022**, 160, 110779

95 POINT: Did the World Symposium on Pulmonary Hypertension Get It Right in Redefining Abnormal Pulmonary Arterial Pressure? Yes.. **2022**, 161, 311-312

0

94	Obstructive sleep apnea is associated with depressed myocardial mechanoenergetics.. 2021 ,	1
93	The Role of Pulmonary Artery Wedge Pressure on the Incidence of Atrial Fibrillation and Atrial Tachycardias in Patients With Isolated Pre-capillary Pulmonary Hypertens. 2021 , 70,	
92	The Forgotten Circulation and Transpulmonary Pressure Gradients. 2022 , 51-66	
91	Leitsymptom Beinödeme. 2022 , 243-254	
90	Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls.. 2022 , 18, 27-42	
89	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension.. 2022 , 13, 821468	1
88	Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry.. 2022 ,	2
87	Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.. 2022 , 1	1
86	Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study.. 2022 ,	
85	Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise - a systematic review.. 2022 ,	0
84	Giant high-pressure pulmonary artery aneurysm (PAA) in a patient with COPD and chronic pulmonary embolism (PE).. 2022 , 15,	
83	Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 years of evidence from the REHAP registry.. 2022 ,	0
82	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.. 2022 , 1	0
81	Association Between the Presence of Pulmonary Hypertension Before Cardiovascular Surgery and the Nephroprotective Effect of Carperitide: A Retrospective Cohort Study.. 2022 , 14, e22891	
80	Mechanics modeling of electrodes for wireless and bioresorbable capacitive pressure sensors. 1-19	1
79	The Glycobiology of Pulmonary Arterial Hypertension.. 2022 , 12,	2
78	Maladaptive Pulmonary Vascular Responses to Chronic Sustained and Chronic Intermittent Hypoxia in Rat.. 2021 , 11,	1
77	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study.. <i>European Heart Journal</i> , 2022 ,	9.5 2

76 Pulmonary hypertension. 158-170

75 Data_Sheet_1.pdf. 2020,

74 Data_Sheet_1.docx. 2018,

73 Image_1.tif. 2018,

72 Image_2.tif. 2018,

71 Image_3.tif. 2018,

70 Image_4.tif. 2018,

69 Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension.. 2022,

68 Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. 2022, 38, e2021032

67 Impact of preoperative pulmonary arterial hypertension on early and late outcomes in patients undergoing valve surgery for rheumatic heart disease. 2018, 62, 963 3

66 Noninvasive diagnosis of pulmonary hypertension with hyperpolarised Xe magnetic resonance imaging and spectroscopy.. 2022, 8,

65 Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?. 2022, 81, 100893

64 Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. 2022, 9, 0

63 EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. 2022, 11, 677 1

62 Echocardiographic Assessment of Right Ventricular Function in Pediatric Heart Disease: A Practical Clinical Approach. 2022, 0

61 Cardiomyopathies. 2016, 285-387

60 KBEKLERDE AKCER YKSEK TANZYONUNUN NEDENLERİTANI VE SAĞALTIM YÖNTEMLERİ

59 Time-Velocity Integral of Left Ventricular Outflow Tract Predicts Worse Long-Term Survival in Pulmonary Arterial Hypertension. 2022, 2, 235-243

58	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). 2022 , 6-70	
57	Pulmonary artery obstruction index, pulmonary artery diameter and right ventricle strain as prognostic CT findings in patient with acute pulmonary embolism. 2022 ,	
56	Noninvasive Estimation of Mean Pulmonary Artery Pressure Using MRI, Computer Models, and Machine Learning. 2022 , 14-27	0
55	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. 2022 , 9, 151-160	1
54	AMPK deficiency in smooth muscles causes persistent pulmonary hypertension after birth and premature death.	
53	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. 2022 , 9,	
52	Obstructive sleep apnea is associated with specific gut microbiota species and functions in the population-based Swedish CardioPulmonary bioImage Study (SCAPIS).	
51	Antiphospholipid Syndrome in Patients with Venous Thromboembolism.	0
50	Diseases of small and medium-sized blood vessels. 2022 , 307-351	1
49	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). 2022 , 6-70	
48	Manifestations of Pulmonary Disease in Adults with Congenital Heart Disease. 2022 , 55, 85-95	
47	Exercise Rehabilitation Training in Patients with Pulmonary Hypertension: A Review. 2022 ,	0
46	Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association.	2
45	A patient-specific image-based approach to estimate pulmonary artery stiffness based on vessel constitutive model. 2022 , 103851	
44	The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review. 2022 , 12, 1198	0
43	Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis. 2022 , 24,	0
42	MEDICAL TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. 2014 , 113-118	
41	APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION. 2015 , 42-49	2

- 40 CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION. **2015**, 40-47
- 39 Non-opportunistic Infections. **2021**, 377-379
- 38 Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6R α . **2022**, 12, ○
- 37 AMPK deficiency in smooth muscles causes persistent pulmonary hypertension of the new-born and premature death. **2022**, 13, ○
- 36 Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study. **2022**, 9, 1217
- 35 Frequency and Predictors for Chronic Thromboembolic Pulmonary Hypertension after a first Unprovoked Pulmonary Embolism: results from PADIS studies. ○
- 34 The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression. **2022**, 19, 10303
- 33 Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. **2022**, 76, 102144
- 32 Exercise for Systemic and Pulmonary Arterial Hypertension: Killing Two Birds with One Stone. **2022**, 175-190 ○
- 31 Nanovesicles for the delivery of cardiovascular drugs. **2022**, 341-369 ○
- 30 HİPERTANSİYON TANISI ALAN HASTALARDA ANGIOTENSİNOJEN (AGT) GEN TARAMASI VE NUTRİGENETİK YAKLAŞIMLAR. ○
- 29 Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. **2022**, ○
- 28 Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. 9, ○
- 27 EACVI survey on the multi-modality imaging assessment of the right heart. ○
- 26 Palliative Care Early in the Care Continuum among Patients with Serious Respiratory Illness: An Official ATS/AAHPM/HPNA/SWHPN Policy Statement. **2022**, 206, e44-e69 1
- 25 The Predictability of Echocardiography in Children with Primary Pulmonary Hypertension and Its Comparison with Cardiac Catheterization Parameters. **2022**, 24, ○
- 24 Diagnostic and prognostic value of ventilatory power in pulmonary hypertension. **2022**, 23, ○
- 23 Pulmonary rehabilitation of chronic pulmonary diseases (the review of clinical trials, national and international recommendations). **2022**, 13, 65-78 ○

- 22 Comprehensive assessments of pulmonary circulation in children with pulmonary hypertension associated with congenital heart disease. 10, ○
- 21 Funktionelle Charakterisierung von Patienten mit isoliert postkapillärer oder kombiniert post- und präkapillärer pulmonaler Hypertonie. **2022**, 76, 689-696 ○
- 20 Recent Advances in the Treatment of Pulmonary Arterial Hypertension. **2022**, 15, 1277 3
- 19 COMPARATIVE CLINICAL CHARACTERISTICS OF PATIENTS WITH VARIOUS FORMS OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE, ACCORDING TO THE CLINICAL CLASSIFICATION. **2019**, 108-121 ○
- 18 Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis. 13, ○
- 17 Quantitative evaluation of pulmonary hypertension using 4D flow MRI: a retrospective study. ○
- 16 Management of pregnant patients with pulmonary arterial hypertension. 9, ○
- 15 Incorporation of noninvasive assessments in risk prediction for pulmonary arterial hypertension. ○
- 14 Pulmonary hypertension associated with left-sided heart disease. **2017**, 147, w14395 ○
- 13 Clinical and Predictive Value of Computed Tomography Angiography in High-Altitude Pulmonary Hypertension. **2022**, 2, 803-815 ○
- 12 Diagnosis and management of pulmonary arterial hypertension. **2022**, 18, 220168 ○
- 11 Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: a retrospective, observational cohort study in France. **2022**, 100987 ○
- 10 Characteristics, long-term survival and risk assessment of pediatric pulmonary arterial hypertension in China: Insights from a national multicenter prospective registry. **2022**, ○
- 9 Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions. **2022**, 18, 220217 ○
- 8 Updated definition of exercise pulmonary hypertension. **2022**, 18, 220232 ○
- 7 A new risk score for the assessment of outcomes for Chinese patients with peripartum cardiomyopathy. **2023**, 60, 81-86 ○
- 6 Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension. **2023**, 24, 3979 ○
- 5 Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry. **2023**, ○

- 4 OSA Was Associated With the Human Gut Microbiota Composition and Functional Potential in the Population-Based Swedish CardioPulmonary bioImage Study. **2023**, ○
- 3 Routine Rehabilitation as a Treatment Component for Patients With Pulmonary Arterial or Chronic Thromboembolic Pulmonary Hypertensions. Publish Ahead of Print, ○
- 2 Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag. ○
- 1 Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension. ○